Heart UK

The Peter Attia Drive

Expert insight on health, performance, longevity, critical thinking, and pursuing excellence. Dr. Peter Attia (Stanford/Hopkins/NIH-trained MD) talks with leaders in their fields.

Peter Attia, MD

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Lloyd B. Klickstein is a physician-scientist who has spent more than 20 years at the intersection of drug discovery, healthy aging, and preventive medicine. Drawing on his experience in academic medicine, translational research, and biotechnology, Lloyd walks through the full arc of modern drug development. He explains how scientists identify an unmet medical need and decide which diseases and therapeutic targets are worth pursuing. From there, he takes us through the process of engineering a drug, testing it in animals, and navigating clinical trials and regulatory approval. Using bimagrumab as a case study, Lloyd explains the rationale for targeting myostatin and activin signaling to increase muscle mass and strength and describes how the antibody was engineered and screened. He then walks through what was learned from early clinical trials. Unexpected effects on fat mass and type 2 diabetes helped reshape bimagrumab's development as a potential treatment for obesity, including its use in combination with semaglutide. Along the way, Peter and Lloyd explore the differences among drug modalities, including biologics and small-molecule therapeutics. They discuss the roles of patents and capital allocation in drug development, along with the requirements for IND submission and GMP manufacturing. They also examine why developing a new drug takes so long and costs so much, and why identifying failures early is critical. At the end of the episode, the conversation turns to mTOR inhibition and geroprotection, as well as Lloyd's current work on a novel pharmacologic approach to cancer prevention. This episode provides a rare behind-the-scenes look at how new medicines are actually created and the scientific, regulatory, and economic decisions that determine which ideas ultimately make it to patients. We discuss:  Lloyd's path from academic medicine to translational drug development [3:15]; Drug modalities, patents, and the economics of innovation [11:30]; Choosing sarcopenia as a target for drug development, and confronting the problem of measuring falls [23:00]; The rationale for bimagrumab: improving muscle mass and strength by targeting myostatin and activin signaling (and why follistatin failed) [36:45]; Engineering and screening the bimagrumab antibody, and the cost of developing a new drug [43:45]; From candidate antibodies to animal proof of concept (impressive muscle hypertrophy) [54:15]; Toxicology, capital allocation, and the path to an IND [1:02:45]; IND requirements, GMP manufacturing, and gray market peptides [1:14:45]; First in-human study design, patient selection, and protection of healthy volunteers [1:22:00]; Phase 1 dosing, pharmacodynamics, and global trial strategy [1:33:45]; Phase 2 lessons on muscle mass, function, and nutrition [1:43:30]; Bimagrumab's effects on fat mass and type 2 diabetes [1:50:45]; The BELIEVE trial of bimagrumab plus semaglutide [1:59:30]; Selective mTORC1 inhibition and the challenge of testing geroprotection [2:11:45]; A new pharmacologic approach to cancer prevention [2:15:45]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#409 ‒ Inside modern drug development: the science, economics, and regulatory hurdles behind bringing new medicines to patients | Lloyd Klickstein, M.D., Ph.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter takes a deep dive into thyroid health and explains why diagnosing and managing thyroid dysfunction is unusually complex. He begins with the basic biology of the thyroid gland and three commonly measured hormones—free T4, free T3, and TSH. He explains how T4 is converted to the active hormone T3 and the important functions T3 performs throughout the body. He also explains what reverse T3 is and when it may be useful to measure it. Peter then breaks down thyroid blood tests and their limitations and provides a practical framework for evaluating suspected thyroid dysfunction. He explains why symptoms alone are insufficient for diagnosis and reviews the criteria for diagnosing hypothyroidism, along with conditions that can mimic it. He also explores how hypothyroidism can be both underdiagnosed and overtreated and how to navigate subclinical hypothyroidism. Peter discusses treatment with T4 and T3, including why some patients continue to experience symptoms despite standard T4 replacement. He also explains how thyroid medications should be taken to optimize absorption. Additional topics include Hashimoto's disease, thyroid considerations during pregnancy, hyperthyroidism, the risks of excess iodine, and supplements marketed to support thyroid function. Finally, Peter offers guidance for patients who continue to feel unwell despite apparently normal thyroid tests. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #89 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  Why thyroid management is unusually complex and what the thyroid does [2:00]; Why symptoms are insufficient for diagnosis and the risks of underdiagnosis and overtreatment [9:00]; Regulation of the thyroid axis and conversion of T4 to T3 [13:30]; Reverse T3 and the metabolic effects of T3 [20:00]; Thyroid blood tests, assay limitations, and who should be tested [22:45]; Causes and mimics of hypothyroidism and the criteria for diagnosis [29:00]; Navigating subclinical hypothyroidism [34:30]; Treating hypothyroidism with T4 and T3 [37:00]; Hashimoto's disease, pregnancy, and associated autoimmune risks [42:45]; Proper timing and administration of thyroid medication [43:45]; Causes, symptoms, diagnosis, and treatment of hyperthyroidism [45:15]; Iodine excess, the risks of thyroid-support supplements, and evidence for dietary interventions [53:45]; A practical framework for evaluating and treating patients who suspect thyroid dysfunction [59:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#408 ‒ AMA #89: Thyroid health: interpreting symptoms, diagnosing and treating dysfunction, and navigating the gray zone

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Michael Davidson is a world-renowned cardiologist, lipidologist, and the founding CEO of NewAmsterdam Pharma. He begins this episode by sharing how his family history shaped his interest in lipidology and primary prevention. He explains why prevention should focus on causal drivers of disease rather than near-term risk and examines the causal relationship between LDL and atherosclerotic cardiovascular disease. Michael then traces the complicated history of CETP inhibitors—from the original rationale that raising HDL would reduce cardiovascular risk to the failures of torcetrapib, dalcetrapib, and evacetrapib—and explains how lessons from these trials ultimately led to the development of obicetrapib. He reviews the phase 2 and phase 3 trials of obicetrapib, its effects on LDL-C, apoB, LDL particle number, and Lp(a), the ongoing cardiovascular outcomes trial, and where the drug could fit alongside statins and other lipid-lowering therapies. Peter and Michael discuss the relationship between statins and diabetes risk, then turn to the potential role of obicetrapib in Alzheimer's disease prevention, exploring the genetics of APOE4 and CETP, cholesterol metabolism within the brain, and emerging biomarker data. Finally, Peter and Michael explore the benefits of omega-3 fatty acids and the challenge of delivering DHA to the brain, as well as ongoing work on klotho in preparation for clinical trials. They discuss the potential for AI to transform clinical trials and the scientific and financial challenges of developing new therapies for cardiovascular and neurodegenerative disease. We discuss:  Michael's path to lipidology, and his passion for primary prevention [3:30]; Reframing prevention around causal drivers rather than time horizon [9:30]; What CETP inhibition does, the evolutionary biology of CETP, the HDL-raising rationale, and Pfizer's torcetrapib failure [15:00]; Why raising HDL is thought to be beneficial, a quick review of the functions of HDL, and how this connects to torcetrapib [24:00]; The graveyard of CETP inhibitors: Roche's dalcetrapib, Lilly's evacetrapib, and Merck's REVEAL trial [27:15]; The causality of LDL in cardiovascular disease [34:30]; Reviving obicetrapib at NewAmsterdam, and confirming the benefit is LDL lowering: the TULIP data, the abandoned statin-intolerance path, and the Mendelian randomization verdict on HDL [37:30]; Phase 2 and phase 3 trials of obicetrapib—ROSE, BROOKLYN, BROADWAY, and TANDEM—and the PREVAIL outcomes trial, with the European and US approval paths [44:45]; Discordance among LDL-C, LDL-P, and apoB with CETP inhibition, and obicetrapib's Lp(a)-lowering effect [50:30]; Where obicetrapib fits in the lipid-lowering toolkit, the case against high-dose statins, and the problem of drug pricing [57:30]; The case for obicetrapib in Alzheimer's: the APOE4 and CETP genetics, the animal models, and funding Alzheimer's research [1:03:45]; Brain cholesterol metabolism and the APOE4 mechanism: the blood-brain barrier, astrocyte cholesterol efflux, the amyloid-tau cascade, the role of HDL, and why statins don't cause Alzheimer's disease [1:08:00]; The biomarker evidence: the CSF pilot study, Alzheimer's as a disease of middle age, the pharma graveyard problem, and the p-tau 217 results from BROADWAY [1:17:45]; Whether obicetrapib translates into clinical benefit for Alzheimer's disease: the risk of fooling yourself, the persistence of the amyloid dogma, ARIA in APOE4 homozygotes, and the next prevention trial [1:28:00]; Fish oil, EPA, and DHA: the cardiovascular trials and the challenge of delivering DHA to the brain [1:32:00]; Two open problems: using AI to reform clinical trials, and the statin–diabetes signal [1:41:15]; What it takes to develop a drug, the biotech investment landscape, and the klotho program [1:48:15]; Closing reflections: what to do if you carry APOE4, balancing motivation against over-testing, and the need for multiple therapies [1:55:15]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#407 ‒ Preventing cardiovascular and Alzheimer's disease: lowering LDL early, APOE4, and promising new therapies | Michael Davidson, M.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter delves into the critical subject of blood pressure, which is one of the three primary causes of atherosclerosis, along with high apoB and smoking. He begins by unraveling the nature of high blood pressure, its prevalence, and why it often goes undiagnosed. Peter describes in detail the proper way to accurately measure blood pressure and what determines a diagnosis. Next, Peter discusses the actionable steps one can take in response to high blood pressure, shedding light on the extent to which factors like weight loss, exercise, and nutrition can make an impact. He also explores the pharmacological options available and offers valuable insights on how to approach them. We discuss:  Blood pressure and other risk factors for cardiovascular disease [2:30]; Defining blood pressure and the purpose and meaning of a blood pressure measurement [5:45]; The implications of high blood pressure and the importance of maintaining an optimal level [10:30]; The importance of accurate measurements of blood pressure and how Peter approaches the care of patients at the very top range of "normal" [21:45]; The prevalence of high blood pressure—a hidden epidemic? [24:30]; The consequences of high blood pressure on cardiovascular health, brain health, kidneys, and more [24:45]; Low blood pressure: symptoms and consequences [35:30]; How to properly measure blood pressure [37:45]; Daily variance in blood pressure and the transient changes in blood pressure during exercise [48:00]; Primary hypertension vs. secondary hypertension: what to look for [51:45]; Lifestyle factors impacting blood pressure: weight loss, exercise, and sodium [57:45]; Impact of insulin resistance and type 2 diabetes on blood pressure [1:04:45]; How sleep impacts blood pressure [1:06:45]; Pharmacologic options for managing blood pressure [1:08:00]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

Blood pressure: how to measure, manage, and treat high blood pressure (AMA #48 rebroadcast)

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Brian Grosberg is a world-renowned headache specialist who joins Peter to provide a master class on the diagnosis and treatment of headache disorders. In this episode, Brian explains the distinction between primary and secondary headaches and breaks down the defining features of the "big three" primary headache types (migraine, cluster, and tension headache)—highlighting how often they are misdiagnosed and how they are treated. He explores the epidemiology of headaches, describing migraine as an invisible disease affecting about 12% of the population, disproportionately affecting women, while cluster headaches more often affect men. He discusses the major gap between demand for headache care and available specialists, and he offers advice on when to see a physician. Brian dives into the multifactorial nature and pathophysiology of migraine, including genetic and hormonal influences, neurovascular changes, and inflammatory signaling, and connects these mechanisms to modern therapies. Throughout the conversation, he emphasizes the individualized nature of headache disorders and the importance of a detailed headache diary. Brian shares practical strategies for treating headaches including lifestyle changes, medications, and neuromodulation devices. We discuss:  Brian's interest in headaches and how Peter met Brian [2:15]; Differentiating the types of headaches: primary versus secondary headache and tension versus migraine headache [7:30]; The epidemiology and burden of migraine, its disproportionate affect on women, and the shortage of headache specialists [20:00]; Genetic susceptibility to migraine and the role of hormones [24:45]; Migraine triggers, the impact of hormones, and the importance of a headache diary [31:15]; The phases of a migraine: premonitory symptoms, aura, the headache itself, and the postdrome [38:15]; Tension headaches: symptoms, causes, and prevalence [41:45]; Cluster headaches: extreme pain, distinctive symptoms, and frequent misdiagnosis as a sinus infection or allergies [43:15]; Lifestyle interventions to prevent headaches [51:15]; Pharmacological treatments to prevent headaches [1:05:00]; What's known about the pathophysiology of migraines: neurovascular changes, release of neuropeptides, and inflammatory response [1:14:45]; CGRP antagonists for the treatment of migraines: large monoclonal antibodies and gepants [1:20:15]; Use of calcium channel blockers and Botox to treat cluster headache and migraine [1:28:30]; Drugs for the acute treatment of migraines [1:32:30]; Treatment of migraines with electrical stimulation devices [1:40:00]; Use of THC or cannabis to treat headaches [1:44:00]; What Brian wants people to know about headaches [1:45:45]; Brian's advice on when to see a doctor about headaches and how to prepare for that visit [1:49:15]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#406 ‒ Migraine, cluster headache, and tension headache: symptoms, causes, prevention, and treatment | Brian Grosberg, M.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter takes a deep dive into the liver and its central role in metabolic health. He explains why the liver can serve as a "canary in the coal mine" for metabolic dysfunction and explores how insulin resistance, visceral fat, alcohol consumption, genetics, and hormones contribute to liver disease, along with how increasing muscle mass can benefit liver health. Peter provides a framework for understanding the progression of liver disease, highlighting which stages are reversible and why early detection matters. He explains why normal liver enzymes can provide false reassurance, which labs he uses to assess liver health, and the tools available for detecting fibrosis and more advanced disease. Peter then breaks down the interventions that can meaningfully improve liver health once risk or disease is identified, ranging from diet and exercise to GLP-1–based therapies and other medications. Finally, he examines popular claims around liver "detoxification" and supplements, separating what is supported by evidence from what is unlikely to meaningfully improve liver health. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #88 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  Why the liver is the "canary in the coal mine" for metabolic dysfunction, and an overview of what the liver does [2:00]; The relationship between the liver and blood sugar control [6:30]; A framework for understanding how metabolic disease affects the liver [9:15]; Chronic caloric surplus and insulin resistance as drivers of liver disease [11:00]; Liver diseases that result from metabolic dysfunction and the difference between steatosis and fibrosis [15:15]; How visceral fat affects liver health [20:00]; The importance of lifestyle interventions for liver and metabolic health: resistance training, not drinking calories, and the impact of fructose [22:00]; Why alcohol-associated liver disease is more common than we give it credit for [26:30]; Genetic and hormonal risks for liver disease [31:45]; Labs that objectively measure liver health and the FIB-4 score [35:30]; FibroScan: non-invasive imaging of the liver [44:30]; The resiliency of the liver: an organ that can heal itself [47:00]; Fibrosis staging and its impact on mortality and cancer risk [49:15]; Interventions for someone with MASLD: weight loss and GLP-1s [52:00]; Other medications used to treat metabolic liver disease [57:00]; The role of exercise in treating metabolic liver disease: caloric deficit and building muscle [59:45]; The myth of liver detoxes and cleanses, and a few supplements that may benefit the liver [1:01:15]; A practical summary: how to assess your risk and the levers that reverse the disease [1:08:00]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#405 ‒ AMA #88: Metabolic liver health: how to assess risk, catch dysfunction early, and prevent or reverse liver disease

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter sits down with Dr. Linus Abrams, a psychiatrist with nearly 35 years of clinical experience specializing in mood disorders and psychopharmacology, to explore how our understanding of mental health is evolving beyond the traditional neurotransmitter model. After decades in practice, Linus began questioning many of the assumptions underlying modern psychiatry, leading him to investigate how hormones, metabolism, inflammation, circadian biology, and the endocrine system shape mood and cognition. Together, Peter and Linus examine why psychiatric care should aim not only to reduce symptoms but also to restore the full human experience. They discuss how psychiatric medications work, where they fall short, and why distinguishing bipolar disorder from unipolar depression is essential for effective treatment. The conversation also explores the growing mental health burden of social isolationn associated with digital devices and social media, along with the biological factors—nutrition, exercise, sleep, and chronic stress—that influence resilience and distress tolerance. Linus explains the powerful roles of estrogen, progesterone, testosterone, and thyroid hormone in regulating mood and cognition across the lifespan. Finally, Peter and Linus review the promise and limitations of ketamine and psychedelic therapies, and why the future of psychiatry may lie in integrating neuroscience, endocrinology, and whole-body physiology to better understand, diagnose, and treat mental illness. We discuss:  Linus's passion for understanding his patients and going beyond traditional psychiatry [2:45]; A short primer on the different classes of drugs used in psychiatry [12:45]; Evaluation of a patient with bipolar disorder [26:00]; An evolutionary perspective on depression [33:30]; Changes in the modern world triggering mental health problems [41:00]; An evolutionary perspective on insomnia [48:15]; Peter's window analogy to understand distress tolerance and irritability [49:45]; The impact of foundational biological factors on psychiatry: nutrition, exercise, sleep, and endocrinology [52:30]; The effect of estradiol on neurotransmitters in the brain [58:15]; Options for increasing testosterone in men, and why clomiphene is inferior to exogenous testosterone [1:11:00]; The rapid drop in progesterone is linked to both premenstrual dysphoric disorder (PMDD) and postpartum depression [1:14:30]; Treatment of postpartum depression [1:18:00]; Hypothyroidism presenting as depression: how Linus makes the diagnosis and what he uses for treatment [1:26:00]; The link between hyperarousal and chronically elevated cortisol [1:39:30]; A case where the menopause transition uncovers bipolar disorder [1:44:15]; Ketamine as a tool to treat recalcitrant depression, and concerns about its recreational use [1:49:15]; Case study: an Alzheimer's patient who improved after psilocybin, and why Linus is cautious about drawing conclusions from it [1:55:15]; Peter's experience with psychedelics, and the myth that estrogen is bad for men [2:00:30]; The therapeutic potential of psychedelics in psychiatry [2:11:00]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#404 ‒ Mental health beyond neurotransmitters: the role of hormones in psychiatry, why symptom reduction isn't enough, and the future of psychedelic therapies | Linus Abrams, M.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter returns to the topic of peptides, offering a clear and accessible guide to a field surrounded by both genuine scientific promise and widespread misinformation. Peptides are increasingly marketed for everything from injury recovery and muscle growth to longevity and improved appearance, often with claims that extend far beyond the available evidence. Rather than promoting or dismissing peptides as a category, Peter presents a practical framework for evaluating any peptide: what it is, how it is supposed to work, and where the science is strong, weak, or simply absent. He then applies this framework to a specific example before examining the risks of gray-market products, concerns about sourcing and quality, and where the field may be headed—ultimately helping listeners distinguish legitimate therapies from hope that has been packaged and sold without sufficient evidence. We discuss:  What peptides are and why they must be evaluated individually [3:15]; A five-question framework for evaluating peptides and other drugs [5:30]; A three-tier system for classifying the scientific evidence behind peptides [10:00]; Evaluating BPC-157: unclear mechanisms, absent human evidence, and unknown risks [14:00]; Why BPC-157's expanding claims do not indicate a broad mechanism [20:45]; CJC-1295: biological activity versus meaningful clinical benefit [23:30]; Why testimonials about peptide benefits cannot establish the effectiveness of peptides [27:30]; The placebo effect, and the importance of controlled trials for evaluating peptides [31:00]; What FDA approval provides when evaluating peptide safety and effectiveness [34:45]; Why prescriptions from doctors, compounding pharmacies, and third-party testing do not validate unapproved peptides [38:30]; Approved peptides sold on the gray market: why evidence for an approved peptide does not automatically extend to gray-market versions [40:45]; Addressing the claim that pharmaceutical companies ignore effective natural peptides because they cannot be patented [43:00]; The promise of peptide science, and the risks of the gray-market wellness industry [46:30]; Why peptide claims must be falsifiable and why evidence should precede widespread use rather than be expected to catch up later [49:00]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#403 ‒ Peptides: separating scientific promise from marketing hype

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Jim Otvos is a biophysical chemist who pioneered the use of nuclear magnetic resonance (NMR) spectroscopy to measure lipoprotein particles and developed the first FDA-cleared method for directly quantifying LDL particle number (LDL-P), a technology that has since expanded to provide broader insights into metabolic health, inflammation, insulin resistance, and mortality risk. In this episode, Jim recounts the unlikely story of transforming a flawed cancer test into a new way of measuring lipoproteins, explains what standard cholesterol tests can miss and why LDL-P and apoB can inform treatment decisions beyond LDL cholesterol alone, and dispels the misconception that large, "fluffy" LDL particles are benign. He also explores how NMR can reveal insulin resistance before blood sugar rises, GlycA as a marker of chronic low-grade inflammation, and the metabolic vulnerability index (MVX) as a potential measure of frailty, resilience, and mortality risk across the lifespan. Finally, Jim explains why NMR diagnostics remain underused despite the wealth of information they can extract from a single blood test. We discuss:  How investigating a flawed 1986 cancer test led to the development of NMR (nuclear magnetic resonance) lipoprotein testing [3:30]; How standard lipid panels measure cholesterol and triglycerides, and why LDL cholesterol is estimated rather than directly measured [15:15]; How NMR spectroscopy measures lipoprotein particle size and concentration [20:30]; Why LDL particle number matters more than particle size, and why large, "fluffy" LDL is not benign [28:45]; Discordance between LDL cholesterol and LDL particle number: which measure better reflects cardiovascular risk? [36:30]; How metabolic syndrome and lipid-lowering treatment contribute to the discordance between LDL-C and LDL-P, and the value of particle number for managing risk [45:30]; Using the NMR-derived LP-IR score to detect insulin resistance and predict type 2 diabetes before glucose rises [51:15]; The development, commercialization, and uncertain future of the Vantera NMR Analyzer and NMR-based diagnostics [1:04:45]; The analytical efficiency of NMR testing and the data-driven development of the Metabolic Vulnerability Index (MVX) [1:16:00]; GlycA as an NMR-derived marker of systemic inflammation: its discovery, biological basis, and advantages over hs-CRP [1:25:45]; Developing the Metabolic Vulnerability Index (MVX): biomarkers of inflammation, malnutrition, muscle wasting, and mortality risk [1:34:00]; What MVX can tell us about longevity and mortality [1:44:15]; How MVX may reveal metabolic frailty and predict premature mortality decades in advance in young, healthy adults [1:50:30]; Potential applications of MVX for predicting treatment response, surgical resilience, and clinical trial outcomes, and the barriers to broader use [2:00:00]; ApoB versus LDL-P: their clinical similarities, the additional information provided by NMR, and barriers to broader adoption [2:07:30]; Interpreting the effects of the CETP inhibitor, obicetrapib, on LDL-P, apoB, and small HDL particles [2:13:00]; The future of NMR diagnostics and MVX: translating scientific potential into broader clinical use [2:20:45]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#402 ‒ NMR blood analysis: how heart disease risk, insulin resistance, inflammation, and mortality risk can be assessed from a single blood sample | Jim Otvos, Ph.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this episode of The Drive, Peter explores how seemingly obscure basic science discoveries have laid the foundation for some of the most important medical breakthroughs of the past half century. Rather than focusing on the clinical applications of modern therapies, he traces the fascinating stories behind the scientists, experiments, and unexpected discoveries that ultimately led to transformative drug classes, revealing how groundbreaking advances often emerge from research with no obvious clinical goal. Through these historical case studies, Peter provides a new perspective on the unpredictable path of medical innovation and makes the case for why investing in basic scientific research remains essential for driving the next generation of life-changing therapies. We discuss:  The discovery of green fluorescent protein (GFP): how curiosity about glowing jellyfish transformed modern biology [2:30]; Why basic research and nature's biological innovations are the foundation of medical progress [10:45]; The discovery of statins: how fungi provided the blueprint for cholesterol-lowering drugs [15:15]; From snake venom to ACE inhibitors: the discovery of a cornerstone therapy for cardiovascular disease [21:00]; From Yellowstone hot springs to PCR: how Thermus aquaticus transformed modern biology and medicine [28:00]; The discovery of CRISPR: from salt flats to gene editing and genetic medicine [37:15]; The discovery of GLP-1 receptor agonists: from Gila monster venom to a new era in metabolic medicine [47:30]; Why curiosity-driven basic research is essential for the future of medical innovation [54:15]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#401 ‒ How curiosity transforms medicine: extraordinary discoveries that changed modern healthcare

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter explores the evidence behind environmental pollution and its impact on long-term health, separating well-supported risks from less substantiated claims while providing a practical framework for deciding which exposures deserve attention. He explains what environmental pollution encompasses, where it fits within the broader hierarchy of longevity interventions, and why studying its health effects is uniquely challenging. Peter examines the evidence linking air pollution to disease and shares actionable strategies for improving indoor and outdoor air quality. He also discusses how noise and light pollution can influence sleep, cardiovascular health, and overall well-being, offering practical ways to reduce their effects in daily life. Finally, Peter takes an evidence-based look at electromagnetic fields (EMFs) and 5G technology, evaluating the current science and whether concerns about these exposures are supported by the available data. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #87 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  Defining environmental pollution and its role in longevity [1:45]; Why the topic of environmental pollution is both polarizing and difficult to study [6:00]; Where environmental exposures fit within the hierarchy of health priorities, and a framework for evaluating which environmental risks are worth addressing [13:15]; Understanding air pollution: the major pollutants and why PM2.5 is a key marker of health risk [16:00]; Indoor air pollution: why indoor air quality often matters most for reducing personal air pollution exposure [21:45]; How air pollution is measured and how the Air Quality Index (AQI) translates pollution data into practical guidance [25:00]; The health effects of air pollution: evidence linking exposure to respiratory and cardiovascular disease [27:00]; How air pollution causes disease: biological mechanisms linking pollution to respiratory and cardiovascular health [29:15]; Who is most susceptible to the health effects of air pollution? [31:45]; Understanding air pollution thresholds and the differences between WHO and EPA air quality guidelines [34:15]; Comparing acute air pollution events with chronic exposure and cumulative health risk [36:15]; Best strategies for mitigating air pollution exposure [38:00]; Noise pollution: effects on hearing, sleep, and cardiovascular health [44:30]; Measuring noise exposure and understanding the thresholds for hearing loss and chronic health effects [48:00]; Practical strategies to reduce noise exposure and protect your hearing [54:15]; Light pollution: defining light pollution and the importance of timing for circadian health [58:15]; The health effects of artificial light at night and the evidence behind blue light and blue light-blocking glasses [1:00:00]; Practical strategies for optimizing light exposure to support circadian rhythms and sleep [1:04:00]; Concerns about EMF and 5G exposure: understanding electromagnetic fields and the distinction between ionizing and non-ionizing radiation [1:06:30]; Evaluating the evidence linking radiofrequency electromagnetic fields to cancer risk [1:10:15]; Evaluating the evidence for electromagnetic hypersensitivity and EMF-related symptoms [1:14:00]; Practical recommendations for managing everyday EMF and 5G exposure and avoiding unnecessary interventions [1:15:30]; Prioritizing environmental exposures based on their impact on health and longevity [1:18:00]; The highest-ROI strategies for reducing environmental pollution exposure and protecting long-term health [1:19:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#400 ‒ AMA #87: Environmental pollution and longevity: air pollution, noise, light, EMFs, and practical strategies to mitigate health risks

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Gayatri Devi is a nationally recognized neurologist specializing in memory disorders, including Alzheimer's disease and related dementias. In this episode, Gayatri explains how to think about dementia as a spectrum—including Alzheimer's disease, vascular dementia, Lewy body dementia, and mixed presentations—while exploring the evolving biology of amyloid, tau, and neuroinflammation and why brain pathology does not always correlate with symptoms. She discusses her approach to detecting subtle cognitive decline in high-functioning individuals, the role of biomarkers and APOE4 testing in asymptomatic patients, the benefits and risks of anti-amyloid therapies such as lecanemab and donanemab, and strategies for minimizing treatment-related complications. Gayatri also examines why some patients may stabilize or even improve with individualized care, the overlap among different dementia syndromes, and the relationship between menopause, estrogen, and cognition—including her concept of menopause-related cognitive impairment. Finally, she discusses how advances in early detection, AI-assisted monitoring, targeted therapies, and precision medicine are reshaping the future of dementia care. We discuss:  Gayatri's training and clinical focus, why dementia is a spectrum disease, and how personalized treatment is changing Alzheimer's care [3:45]; How Alzheimer's disease fits within the broader spectrum of dementia: diagnosis, biomarkers, and early pathophysiology [7:15]; The emerging role of neuroinflammation and viral infections in Alzheimer's disease [13:30]; Gayatri's comprehensive approach to evaluating cognitive decline in high-functioning patients [17:45]; Why forgetting names is usually normal and when word-finding problems become concerning [29:00]; Why women are at higher risk for Alzheimer's disease and how menopause influences cognition [33:45]; The promise and limitations of blood-based biomarkers for diagnosing Alzheimer's disease [40:15]; When preclinical Alzheimer's screening is appropriate and how to interpret positive biomarker results [45:00]; Case study: early Alzheimer's prevention in a highly-functional woman in her 50s with two copies of APOE4 [47:15]; Anti-amyloid therapies: balancing clinical benefit with ARIA risk using slow titration [51:45]; The aducanumab controversy, why it was discontinued, and why Gayatri would still choose it [1:00:00]; How anti-amyloid therapies cause ARIA, strategies for detecting and managing these complications, and how future therapies may improve safety and accessibility [1:03:30]; Two patient examples of exceptional responses to anti-amyloid therapy [1:12:30]; A multimodal approach to Alzheimer's treatment: combination therapy, MRI-guided TMS, GLP-1 receptor agonists, and more [1:15:00]; Vascular dementia, Lewy body dementia, and the overlap with Alzheimer's disease [1:21:00]; Lewy body dementia and Parkinson's disease: distinguishing two alpha-synuclein disorders [1:26:45]; Risk factors for Lewy body dementia and what remains unknown [1:36:15]; Treating menopause-related cognitive impairment: hormone therapy, brain rehabilitation, and balancing breast cancer risk [1:38:45]; How biomarkers changed Gayatri's perspective on the potential for Alzheimer's patients to improve [1:47:15]; The future of Alzheimer's care: AI, precision medicine, and personalized treatment [1:49:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#399 ‒ The evolution of Alzheimer's disease and dementia care: how early detection, personalized treatment, new therapies, and a multimodal approach are changing the landscape | Gayatri Devi, M.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter dives deep into the topic of muscle mass and strength, examining their essential roles in both lifespan and healthspan. Drawing from over 30 hours of prior discussions with experts including Layne Norton, Andy Galpin, and Mike Israetel, this episode distills the most important insights into one comprehensive and up-to-date conversation. Peter explores why muscle matters for longevity, metabolic health, and injury prevention, and clarifies the differences between muscle mass and strength, including which is more vital for aging well. He breaks down practical strategies for building muscle safely and effectively, including progressive overload, training intensity, rep ranges, and the importance of explosive power. Peter also covers key nutrition strategies—like protein intake, timing, and creatine supplementation—and offers practical advice for everyone from beginners to seasoned lifters on building and maintaining muscle safely and sustainably. We discuss:  Peter's humorous experience talking nutrition with a second grader [3:00]; Overview of topics, episode structure, and reasoning for focus on muscle mass and strength [6:30]; Defining key terms: muscle mass, strength, hypertrophy, power, and more [8:45]; The importance of muscular strength, muscle mass, and cardiorespiratory fitness for longevity [11:00]; Grip strength as a simple yet powerful predictor of all-cause mortality [17:15]; Is muscle strength causal or just a marker of health? [20:30]; Why VO2 max, strength, and muscle mass are powerful health markers: a reflection of long-term consistent effort [23:00]; How muscle mass and strength enhance healthspan by supporting metabolic health, inflammation control, recovery from illness, mobility, and fall prevention [24:15]; How muscle mass and strength decline with age, and why it's essential to act early to slow decline and preserve function later in life [31:00]; The foundational principles of building muscle strength and size through resistance training [36:00]; How to apply "progressive overload" for long-term strength and muscle gains [40:00]; The difference between concentric and eccentric muscle contractions and how each impacts strength, hypertrophy, and injury prevention [45:15]; The differences between muscle fiber types, and how aging disproportionately affects fast-twitch fibers responsible for power [50:45]; How to effectively train for power [52:30]; Training intensity: the benefits and safety of using the "reps in reserve" method [53:30]; How to balance compound and isolation exercises in a workout routine, and why compound lifts are foundational [56:15]; Can bodyweight exercises build muscle as effectively as weight training? [58:15]; How women can effectively build strength and muscle: key considerations [59:45]; Effective methods for tracking progress in strength [1:01:45]; Effective methods for tracking progress in muscle mass, and how to interpret results from a DEXA scan [1:05:00]; How to balance workout frequency with recovery for optimal results [1:07:15]; How to recognize signs of overtraining and when to consider taking rest days [1:10:45]; Avoiding injury: how beginners or returning lifters can start resistance training safely [1:15:45]; Protein: recommended intake, quality sources, timing of consumption, and more [1:18:00]; How fasting and calorie restriction affect muscle mass and what can be done to minimize muscle loss [1:24:45]; Key nutritional factors beyond protein that support muscle growth: hydration, creatine, and recovery [1:28:15]; The impact of hormones, sleep, stress, and consistency on muscle building and recovery [1:29:15]; How to structure an effective workout routine for a younger person who is new to resistance training [1:32:00]; How to modify beginner resistance training programs for older individuals to prioritize safety and gradual progress [1:36:00]; Should beginners start with machines or free weights when resistance training? [1:37:00]; How experienced lifters should modify their training to support healthspan and performance in later life [1:38:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

Building strength and muscle mass: how to optimize training, nutrition, and more for longevity (AMA #71 rebroadcast)

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter explores the effects of GLP-1 receptor agonists—including drugs such as Ozempic, Wegovy, and Zepbound—with a particular focus on their impact on muscle. He examines how much lean mass people actually lose during treatment and how those changes compare to weight loss achieved through other methods, while explaining why measurements of lean mass on DEXA scans can sometimes be misleading. Peter discusses the effects of these medications on bone mass, fracture risk, strength, and physical function, highlighting why functional outcomes may be more important than body composition metrics alone. He also explores how GLP-1–based therapies affect different fat depots throughout the body, identifies who may be most vulnerable to muscle loss, and outlines practical strategies for preserving muscle and bone health while using these medications. Finally, Peter reviews early insights into retatrutide, a next-generation weight-loss therapy, including what current evidence suggests about its effects on weight loss and muscle mass. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #86 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  The evolution of GLP-1 receptor agonists from diabetes drugs to breakthrough weight-loss therapies [1:45]; Early concerns about lean mass loss with GLP-1 receptor agonists and the limitations of clinical trial data [3:45]; How newer research has changed the understanding of lean mass loss on GLP-1 receptor agonists and why DEXA measurements can misrepresent muscle loss [6:15]; Comparing lean mass loss across semaglutide, tirzepatide, and traditional weight-loss interventions [10:30]; Comparing lean mass loss from GLP-1 receptor agonists with bariatric surgery, and whether these drugs cause muscle loss beyond normal expectations from substantial weight loss [13:15]; The limited evidence regarding the timing of lean mass loss during GLP-1 therapy and the implications for exercise and nutrition strategies [16:00]; Body composition changes after stopping GLP-1 receptor agonists: weight regain, fat regain, and lean mass recovery [17:45]; Why lean mass measurements are an imperfect proxy for muscle health and function [21:45]; The effects of GLP-1 receptor agonists on bone mineral density, fracture risk, and the importance of resistance training [23:00]; Do GLP-1 receptor agonists directly cause muscle loss or simply mimic the effects of calorie restriction? [26:00]; Why strength and physical function often improve despite lean mass loss on GLP-1 receptor agonists [28:00]; Who is most at risk for lean mass loss during GLP-1–induced weight loss? [34:45]; Intramuscular fat (IMAT), DEXA limitations, and the challenge of measuring true muscle loss [37:00]; Preserving muscle while losing weight: resistance training, protein intake, and emerging research on preserving muscle during GLP-1–induced weight loss [39:00]; Resistance-training principles for preserving lean mass during GLP-1–induced weight loss [43:45]; Managing side effects and prioritizing protein intake while training on GLP-1 receptor agonists [46:15]; Retatrutide: early evidence on its effects on weight loss, lean mass, and muscle function, as well as the limitations of the data being collected in ongoing clinical trials [48:00]; The risks of using gray-market retatrutide before FDA approval [52:15]; Key takeaways [54:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#398 ‒ AMA #86: GLP-1 RAs and muscle loss: new data, better questions, and how to preserve muscle during weight loss

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter  View our full terms of use Renato Tomioka is a leading expert in reproductive medicine and gynecologic surgery whose unique skills allow him to diagnose and treat some of the most impactful yet frequently overlooked conditions affecting women's health. In this episode, Renato explores endometriosis and adenomyosis, explaining what these conditions are, why they often go undiagnosed for years despite affecting millions of women worldwide, and how advances in MRI and specialized ultrasound are transforming diagnosis beyond traditional surgical laparoscopy. He discusses the decision-making process behind hormonal therapy versus surgery, how treatment strategies change when fertility preservation is a priority, and where IVF fits into the care pathway for women with endometriosis, adenomyosis, or age-related fertility decline. Renato also examines the profound effects of female age on egg quality and quantity, including the accelerating rise in chromosomal abnormalities after age 35, highlights common mistakes in both surgical and fertility management, and shares promising developments on the horizon for treating these conditions and preserving fertility. Follow Dr. Tomioka's work: Instagram: @dr.renatotomioka; Website: Renato Tomioka, M.D., Ph.D. We discuss:  0:00:00 - Intro 0:00:11 - Endometriosis: definition, prevalence, infertility risk, and theories of disease development 0:09:03 - The biology of endometriosis: estrogen dependence, progesterone resistance, and tumor-like growth mechanisms 0:13:25 - Adenomyosis explained: how it differs from endometriosis, why it develops, and its impact on reproductive health 0:18:52 - Recognizing endometriosis and adenomyosis: the "6 Ds" of endometriosis and key differences in clinical presentation 0:22:09 - Uterine fibroids: classification, symptoms, and the importance of fibroid location for bleeding and fertility 0:24:09 - Understanding endometriosis pain: lesion-driven pain, nerve involvement, central sensitization, and the importance of early treatment 0:28:26 - Endometriosis in young women: rising prevalence, delayed diagnosis, and barriers to care 0:33:11 - Modern diagnosis of endometriosis: specialized ultrasound, MRI, and the decline of diagnostic laparoscopy 0:45:52 - Clinical case example #1: Managing endometriosis in a young woman seeking pain relief while preserving future fertility 0:54:10 - Clinical case example #2: Comparing treatment strategies for symptom control versus fertility 1:01:24 - Endometriosis and fertility: the roles of age, embryo quality, IVF, and surgery 1:11:50 - Clinical case example #3: Managing adenomyosis after failed IVF transfers to improve implantation and pregnancy outcomes 1:20:51 - The funding gap in endometriosis research: disease burden, economic impact, and growing awareness 1:22:01 - Clinical case example #4: Surgical decision-making in endometriosis—balancing pain relief, fertility preservation, and common treatment pitfalls 1:27:43 - Common misconceptions about fertility: maternal age, embryo aneuploidy, the inefficiency of human reproduction, and the limits of IVF 1:34:23 - Elective egg freezing: timing, success rates, the fertility funnel, and the tradeoffs of fertility preservation 1:45:49 - Emerging fertility technologies: mitochondrial replacement, ovarian tissue preservation, stem-cell-derived eggs, and current limitations 1:55:10 - The future of endometriosis treatment: new guidelines, biologic therapies, and unanswered questions about IVF 1:58:30 - Why earlier diagnosis matters: reducing years of suffering from endometriosis and adenomyosis  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#397 ‒ Endometriosis and adenomyosis: diagnosis, fertility, reproductive aging, and emerging treatments | Renato Tomioka, M.D., Ph.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter explores the critical topic of breast cancer screening, examining why thousands of women continue to die from breast cancer each year despite the availability of effective screening tools. He explains the strengths and limitations of current screening strategies, reviews the recommendations from major medical organizations, and discusses why screening guidance can often seem confusing or contradictory. Peter outlines a practical framework for understanding breast cancer risk and personalizing screening decisions, including when to begin screening, how frequently to screen, and which imaging modalities may be most appropriate based on an individual's risk profile. Throughout the episode, he emphasizes that while population-based guidelines provide an important foundation, optimizing outcomes requires a more personalized approach aimed at helping women make informed screening decisions that can improve the chances of early detection and successful treatment. We discuss:  Why women still die from breast cancer: the benefits of screening, the problem of under-screening, and the need for risk-based screening strategies [1:45]; Current screening recommendations, why they differ between organizations, and the importance of personalized screening decisions [6:30]; A framework for personalizing screening [8:45]; Assessing baseline breast cancer risk: genetics, family history, breast density, lifestyle factors, and the role of risk calculators in personalized screening [9:30]; Balancing cancer detection and false positives: how breast cancer risk influences screening intensity and imaging choices [17:45]; Mammography as the foundation of breast cancer screening: detecting ductal carcinoma in situ (DCIS) and the advantages of 3D versus 2D mammography [21:00]; MRI for high-risk women: the benefits of supplemental screening, abbreviated MRI, and the emerging role of contrast-enhanced mammography [23:00]; The role of ultrasound: supplemental cancer detection, diagnostic evaluation, and limitations compared with mammography and MRI [26:00]; Choosing the right breast cancer screening strategy: imaging modality selection, screening hierarchies, and the importance of imaging center quality [28:00]; How often should you screen for breast cancer? [30:15]; At what age should you start screening? [37:30]; Breast cancer in younger women: aggressive tumor biology, BRCA-related risk, breast density, and individualized decisions about when to begin screening [41:45]; Inflammatory breast cancer, the limitations of screening mammography for symptomatic disease, and the importance of promptly evaluating new breast symptoms in both women and men [44:45]; From risk assessment to personalized screening: a practical framework for reducing breast cancer mortality through earlier and more effective detection [46:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#396 ‒ Breast cancer screening: understanding risk, deciding when to start and how often to screen, and choosing the right imaging strategy

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Tom Dayspring is a world-renowned lipidologist and one of the most thoughtful teachers in the field of lipid metabolism. In this episode, Tom returns to The Drive for a deep dive into the relationship between lipids and brain health, beginning with the fundamentals of cholesterol transport before exploring why the brain's cholesterol system operates almost entirely independently from the rest of the body. Tom examines the roles of apoB, apoA-I, and especially apoE in cholesterol homeostasis, discusses how APOE genotype influences Alzheimer's disease risk, and unpacks the complex links between cholesterol metabolism, amyloid, and tau pathology. He also reviews what is currently known—and still uncertain—about the effects of statins, ezetimibe, omega-3 fatty acids, and emerging CETP inhibitors on brain health and neurodegenerative disease risk. Although highly technical, this conversation provides an essential framework for understanding the nuanced relationship between lipid-lowering therapies, cardiovascular disease prevention, and neurodegenerative diseases in an area often clouded by misinformation. We discuss:  The fundamentals of cholesterol transport in the body, and how peripheral cholesterol metabolism differs from cholesterol handling in the brain [2:45]; How cholesterol is transported through plasma and stored within cells, and why lowering LDL cholesterol does not deplete the body or brain of cholesterol [11:45]; How apoB particles drive atherosclerosis, why lowering lipids matters, and the factors that influence individual cardiovascular risk [20:00]; How the brain produces and transports its own cholesterol using apoE lipoproteins independently of circulating cholesterol and apoB-containing lipoproteins [29:00]; How apoB structure influences LDL receptor binding and LDL clearance [39:00]; How neurons acquire cholesterol from apoE-containing lipoproteins and why desmosterol serves as a unique marker of cholesterol synthesis in the brain [41:45]; The difference between the APOE gene and the apoE protein, the major APOE genotypes found in humans, and how APOE4 influences Alzheimer's disease risk [48:45]; HDL function beyond cholesterol: immune function, protein cargo, and communication with the brain [53:30]; How APOE4-associated defects in brain cholesterol transport may promote Alzheimer's disease: amyloid production, neuronal cholesterol homeostasis, and cholesterol clearance [58:00]; Statins and brain health: reviewing the evidence of the potential impact of statins on cognition and Alzheimer's disease risk [1:09:00]; Desmosterol and 24S-hydroxycholesterol as biomarkers of brain cholesterol metabolism and statin effects [1:17:15]; Possible cognitive benefits of ezetimibe beyond lowering apoB [1:19:30]; EPA, DHA, and the evidence for omega-3 fatty acids in brain health [1:23:15]; Obicetrapib: an emerging CETP inhibitor with potential implications for both cardiovascular and brain health [1:31:00]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#395 - Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer's disease risk, and the effects of lipid-lowering therapies on brain health | Tom Dayspring, M.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter dives into the pharmacology of sleep, exploring where sleep medications fit within the broader framework of achieving healthy, restorative sleep. He explains why sleep is a biological imperative, why behavioral and environmental interventions must remain the foundation of good sleep, and how medications can serve as useful tools when carefully matched to a person's specific sleep problem. Peter examines the major classes of prescription sleep medications, including how they work, their effects on sleep architecture, their duration of action, side effects, and risks of tolerance and dependence. He also discusses the dangers of using sleep drugs without a clear understanding of the underlying problem being treated, the role of medications as short-term bridges during periods of acute stress, pain, or anxiety, and the promise that newer drugs like DORAs may hold for Alzheimer's prevention in high-risk individuals. Finally, Peter reviews the evidence for select off-label medications and supplements commonly used for sleep. We discuss:  The biological foundations of sleep, the major drivers of sleep dysfunction, and the role sleep medications can play when appropriately matched to specific sleep problems [1:00]; Sleep hygiene, circadian alignment, and the medical causes of insomnia: building the foundation for effective sleep treatment [7:15]; Understanding insomnia: hyperarousal, CBT-I, paradoxical insomnia, and why different sleep problems require different treatments [12:45]; The difference between sedation and physiologic sleep: sleep architecture, restorative sleep stages, and matching medications to specific sleep problems [17:00]; Benzodiazepines for insomnia: mechanisms, effects on sleep architecture, and the risks of long-term use [18:45]; Z-drugs for insomnia: how Ambien, Sonata, and Lunesta work, and the ongoing risks of sleep medications targeting GABA systems [23:00]; Dual orexin receptor antagonists (DORAs) and the future of sleep medicine: orexin signaling, sleep architecture, and the emerging connection between sleep and Alzheimer's disease [27:15]; Melatonin for circadian timing: how timing signals differ from sedatives in the treatment of sleep disorders [36:30]; Trazodone for insomnia: preserving deep sleep while minimizing the risks of traditional sedative-hypnotics [42:00]; First-generation antihistamines for sleep: short-term sedation, anticholinergic risks, and concerns about long-term cognitive health [44:00]; Sleep supplements and the evidence behind them: glycine, magnesium, ashwagandha, phosphatidylserine, and more [45:45]; Takeaways: supplement quality, individualized sleep treatment, and the importance of matching interventions to the biology of insomnia [52:00]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#394 ‒ Sleep pharmacology: the role of medications in healthy sleep, the promise of emerging therapies, and the evidence for common sleep supplements

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter explores how to think critically about medications and supplements by focusing not on whether an intervention is inherently "good" or "bad," but on whether it makes sense for a specific person with a specific problem. He explains why clearly defining the problem matters more than choosing the intervention itself, how the intended purpose of a medication or supplement should influence the standard of evidence required, and why mechanistic reasoning alone is rarely enough to justify taking something. Peter also examines how baseline risk shapes the true benefit of an intervention, why relative risk statistics can be misleading without proper context, and how to weigh not only side effects, but also cost, inconvenience, and opportunity cost when deciding whether something is worth taking. Additionally, he discusses practical ways to evaluate whether a supplement is actually having a meaningful effect, how to think about discontinuing therapies, why supplements deserve far more skepticism than they often receive, and the small group of over-the-counter supplements he believes may offer a reasonable risk-reward trade-off. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #85 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  How to properly define health problems before considering medications or supplements [1:45]; How the intended purpose of an intervention should determine evidence standards and risk tolerance [5:00]; Understanding the hierarchy of evidence for medications and supplements and avoiding the mistake of treating weak evidence as clinical proof [9:00]; Why mechanistic explanations can be misleading when evaluating longevity interventions [13:15]; How baseline risk—and the distinction between relative and absolute risk reduction—changes the real-world benefit of medications and supplements [18:15]; Thinking beyond side effects: the many forms of downside associated with medications and supplements [22:45]; Why medications and supplements require different standards of trust and evidence [26:00]; How to structure meaningful self-experiments with medications and supplements to determine if it's they're working [30:30]; How to monitor the effects of medications and supplements without fooling yourself [32:30]; How to periodically reevaluate and potentially discontinue medications and supplements [35:15]; The biggest risks and failure modes of over-the-counter supplements: efficacy, poor quality control, contamination, interactions, toxicity, and marketing-driven overuse [38:30]; Why the US supplement regulatory system creates unreliable products [41:45]; A practical framework for evaluating medications and supplements [46:30]; Over-the-counter supplements with the best balance of evidence and low downside risk [48:00]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#393 ‒ AMA #85: A guide to medications and supplements: determining what to take, what to skip, and how to know if they're working for you

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter explores the complex and often misunderstood world of genetic testing, building a practical framework for understanding what these tests can and cannot actually tell us about health and disease. He explains why some genetic findings can be genuinely life-changing while many others offer information that is far more probabilistic than deterministic, and why directly measuring the phenotype is often more valuable than inferring risk from DNA alone. Peter examines where genetics can provide meaningful insight across the major disease categories and where its predictive power is far more limited than many people assume. He also discusses how to think critically about different types of genetic tests, how to interpret results in the proper context, and how to avoid the common trap of accumulating more genetic information without gaining greater clarity or actionable insight. We discuss:  Genetic testing: understanding what it can reveal, where it falls short, and how to think about its clinical value [1:45]; The Human Genome Project: why decoding DNA did not immediately unlock the mysteries of disease [4:15]; The limitations of genetic testing: probabilistic risk, interpretive uncertainty, and the importance of phenotype [9:30]; Questions to ask when considering genetic testing [15:45]; Genetic testing in cardiovascular and metabolic disease: when genotype adds value beyond phenotype [17:00]; Genetic testing for inherited cardiac conditions: identifying hidden risk beyond routine screening [21:45]; Genetic testing for cancer risk: inherited syndromes, clinical utility, and the limits of consumer testing [24:00]; Genetic testing for neurodegenerative disease: risk prediction, planning, and the challenge of limited actionability [28:45]; Functional medicine genetic testing: the gap between biological plausibility and clinical evidence, and the supplement protocols that aren't supported by evidence [32:45]; Pharmacogenetics: using genetic testing to guide medication selection and safety [38:45]; A framework for evaluating genetic tests according to effect size and clinical actionability [41:45]; The major types of genetic tests, and how each should be matched to the clinical question being asked [43:30]; Interpreting genetic test results: choosing the right testing laboratory and understanding what the findings actually mean [49:45]; Framework summary: why genetic testing is most valuable when it is guided by a clear question, matched with the appropriate test, and capable of meaningfully influencing decisions [56:45]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#392 - Genetic testing: when it's valuable, how to choose the right test, and what to do with the results

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter takes a deep dive into colorectal cancer (CRC) screening, explaining why it is one of the most preventable cancers and why getting screening right can have life-saving implications. He walks through how colorectal cancer develops and why it is uniquely well-suited to early detection and prevention, with a particular emphasis on the dual role of colonoscopy as both a diagnostic and therapeutic tool. Peter also examines the concerning rise in early-onset CRC among younger adults, highlighting why awareness and timely screening matter more than ever. The episode provides a practical guide to preparing for and evaluating the quality of a colonoscopy, including how to think about appropriate screening intervals and the real risks and tradeoffs involved. Finally, Peter explores the expanding landscape of non-invasive screening options, offering clear insight into what these alternatives can and cannot do so listeners can make informed decisions about their care at any age. We discuss:  CRC statistics and goals for this episode [1:00]; Colorectal cancer development: polyp progression, risk types, and the window for prevention [4:00]; Why colorectal cancer is uniquely screenable: direct visualization and the dual role of colonoscopy [6:30]; Colonoscopy effectiveness: prevention through polyp removal and interpreting the NordICC trial data [8:15]; Rising colorectal cancer in younger adults: trends, possible causes, and the case for earlier screening [12:15]; Colonoscopy preparation: why bowel prep matters and how newer options improve the experience [16:45]; Colonoscopy quality, polyp miss rates, and personalized screening intervals [20:00]; Colonoscopy risks versus colorectal cancer risk: understanding the true risk-benefit tradeoff [29:30]; Non-invasive screening options for CRC: benefits, limitations, and their role alongside colonoscopy [37:00]; Colorectal cancer prevention principles: why screening matters and the role of colonoscopy [39:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#391 ‒ Colorectal cancer screening: importance of early screening, colonoscopy as a screening and preventive tool, and how to build a personalized strategy

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter answers listener questions across a wide range of topics, focusing on how to think through real-world trade-offs and apply scientific evidence in practice. He explores how to build and interpret a meaningful family health history, how individual risk tolerance influences decisions around testing and treatment, and why heart disease remains poorly prevented despite available tools. He also examines whether it's possible to carry excess body fat while remaining metabolically healthy, outlines the minimum effective dose for strength training for those with limited time, and discusses the habits and interventions most likely to reduce dementia risk. Additional topics include what evidence would need to emerge for him to reconsider his current stance on NAD-boosting supplements, and when hydration and electrolyte strategies are truly beneficial versus unnecessary. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #84 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  Topics overview [1:15]; Using family history to assess disease risk: why it matters more than genetic testing and how to analyze it effectively [2:30]; Peter's views that differ from conventional medicine: approaches to cardiovascular risk, cancer screening, nutrition, and more [10:30]; Risk tolerance in health decisions: weighing action versus inaction and avoiding low-benefit, high-risk interventions [16:00]; Why cardiovascular disease persists: delayed treatment, insufficient thresholds, and missed opportunities for early intervention [22:00]; Whether someone can be overweight yet metabolically healthy, and how fat distribution influences metabolic risk [26:45]; Strength training with limited time: how to maximize results with intensity and efficiency [30:00]; Designing a sustainable exercise routine: balancing volume, recovery, and enjoyment over time [34:45]; Reducing dementia risk: prioritizing exercise, sleep, and cardiometabolic health based on individual gaps [38:00]; Peter's current skepticism toward NAD-related supplements and what evidence would be needed to change his view [40:45]; Hydration and electrolytes: factors that impact needs and when supplementation might be necessary [43:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#390 ‒ AMA #84: Family health history, preventing heart disease, metabolic health, strength training efficiency, dementia risk reduction, NAD supplements, and hydration

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter explores one of the most foundational topics underlying nearly everything discussed on the podcast: how to think scientifically. Framed as an introspective deep dive, he examines why scientific thinking is inherently difficult for humans, the cognitive biases and tendencies that make it challenging to separate belief from evidence, and why these challenges are even more consequential in today's environment saturated with misinformation. He also offers a framework for improving our ability to evaluate claims, question assumptions, and identify a personal panel of experts, providing listeners with practical tools to become more disciplined and effective thinkers. We discuss:  Topics to be covered and goals for this episode [2:00]; Scientific thinking: hypotheses, uncertainty, and the process of ruling out explanations [3:45]; How scientific knowledge differs from mathematical proof: useful approximations, evolving evidence, and acting under uncertainty [8:00]; Why scientific thinking is difficult: evolution, social instincts, and the need for deliberate practice [13:30]; Systems and tools designed to correct human bias [18:15]; How to think scientifically pt. 1: Notice when you're feeling certain [20:30]; How to think scientifically pt. 2: Judge the process, not just the conclusion [23:00]; How to think scientifically pt. 3: Notice when identity is shaping your beliefs [28:15]; How to think scientifically pt. 4: Don't confuse criticism with understanding [33:45]; How to think scientifically pt. 5: Outsource your thinking carefully [36:15]; Evaluating who to trust: incentives, consensus, and red flags in scientific credibility [45:15]; Science as a self-correcting system: why updating with evidence is a strength, not a weakness [49:00]; The key principles of scientific thinking, and a practical framework for evaluating claims and improving judgment [50:45]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#389 - Thinking scientifically: why it's hard, why it matters, and a practical toolkit

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter takes a deep dive into prostate cancer screening, explaining why advanced and metastatic diagnoses continue to rise despite the availability of screening tools, and what can be done to reverse this trend. He breaks down what PSA actually measures and why it is far more informative when tracked over time rather than interpreted as a single value, and he explores how tools like MRI, PSA density, PSA velocity, and improved biopsy techniques can both reduce unnecessary procedures and improve the detection of aggressive cancers. Peter also discusses the role of active surveillance in avoiding overtreatment for low-risk cases, examines the flawed evidence that has historically been used to argue against PSA screening, and highlights how medications like finasteride can suppress PSA levels and potentially mask warning signs if not properly accounted for. Ultimately, he makes a compelling case for the importance of regular PSA testing as a key strategy in the effort to eliminate prostate cancer mortality. We discuss:  The failure of current prostate cancer screening guidelines, and the rise in advanced disease despite available tools [2:30]; PSA screening fundamentals: benefits, harms, and the guideline shift driven by overdiagnosis concerns [5:30]; The impact of reduced PSA screening: rising rates of late-stage prostate cancer and worsening population-level outcomes [12:00]; How modern screening practices use PSA trends, MRI, and new imaging advances to improve accuracy and reduce unnecessary procedures [15:00]; Advances in prostate biopsy: transperineal approach improves safety and cancer detection [23:00]; Reducing overtreatment: Gleason scoring and active surveillance in modern prostate cancer care [25:30]; Reevaluating PSA screening guidelines: how flaws in the PLCO trial undermine the evidence used to argue against PSA screening [29:45]; Prostate cancer screening today: improved tools, flawed guidelines, and preventable mortality [33:45]; How finasteride and similar drugs suppress PSA levels and can lead to missed or delayed prostate cancer diagnoses if not properly accounted for [38:00]; The optimistic future of prostate cancer: modern screening advances and the potential to reduce mortality [43:15]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#388 — Prostate cancer screening: why current PSA guidelines are failing men and how modern tools improve early detection and save lives

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter explores the topic of gray-market peptides, one of the most requested and most confusing topics he's covered on The Drive. Peptides sit at the intersection of biological plausibility, clinical promise, and aggressive commercialization, and are often marketed as cutting-edge therapies for everything from muscle repair and longevity to cosmetic enhancement. Rather than promoting or dismissing peptides wholesale, Peter lays out a clear, repeatable framework for evaluating any peptide or drug—covering mechanism, intended effects, safety, dosing, and alternatives. He distinguishes FDA-approved peptide therapeutics from the loosely regulated "peptides" common in biohacking culture; examines the strengths and limitations of animal and human evidence; unpacks manufacturing, gray-market sales, "research use only" labeling, and third-party testing; addresses oral peptides and absorption challenges; and explains how patents and incentives shape which compounds advance through clinical pipelines. The discussion concludes with a sober look at what would need to change for peptides to become broadly usable therapies, where legitimate peptide therapeutics may expand next, and which areas of medicine stand to benefit most right now. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #83 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  Setting the framework for evaluating peptides, and explaining the goal of this discussion [3:15]; What peptides are: basic definitions, biological roles, and therapeutic foundations [5:30]; A framework for evaluating peptides: mechanism, evidence, safety, and regulatory context [10:00]; Peptide case study—SS-31: mechanism of action, approved use in Barth syndrome, and other claimed effects [18:15]; Does the mechanistic rationale for SS-31 translate into measurable benefits? [22:15]; SS-31 continued: safety considerations, gray market risks, the balance of risk versus reward, and why it belongs in bucket #3 [26:00]; Peptide case study—melanotan-II: claimed effects, mechanism of action, safety, and side effects [30:45]; Melanotan-II continued: weighing the potential risks versus benefits and why it belongs in bucket #2 [36:30]; Peptide case study—CJC-1295: growth hormone–stimulating mechanism, claimed effects, and limited human data [40:15]; CJC-1295 continued: dosing uncertainty, risk-reward analysis, lack of long-term safety data, limited approved options, and why it belongs in bucket #2 [49:30]; Peptide case study—BPC 157: uncertain origins, broad claims, and weak mechanistic evidence [57:45]; BPC 157 continued: review of human evidence, lack of replication of animal data, safety considerations, risk-reward analysis, and why it belongs in bucket #1 [1:03:15]; Other popular "gray market" peptides and why they mostly fail when under scrutiny [1:11:15]; How the evidence on peptides compares to rapamycin, and why the lack of data is the biggest concern [1:20:00]; Understanding peptide regulation: FDA approval, supplement oversight, and the risks of gray-market compounds [1:23:00]; Inside the gray market: how peptides are sold, regulated, and why testing cannot guarantee safety [1:26:45]; Limitations of oral peptides, and examples of peptides in bucket #4 [1:31:45]; The future of peptides: real therapeutic potential versus hype in the wellness market [1:35:00]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#387 - AMA #83: Peptides—evaluating the science, safety, and hype in a rapidly growing field

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter takes a deep dive into the science and application of aging clocks, unpacking what they are, the differences between chronological age, biological age, and the pace of aging, and what epigenetic clocks may actually be measuring. He explores key research in the field, including a randomized controlled trial that tested simple lifestyle interventions against several commonly used aging clocks, as well as a study using brain MRI to assess the pace of aging and its relationship to dementia risk and mortality. Throughout the episode, Peter highlights the promises and pitfalls of these tools, ultimately focusing on the field's central question: whether improving an aging clock score truly translates into meaningful clinical outcomes. We discuss:  Why aging clocks are being used as proxies for long-term health outcomes and the uncertainty surrounding their clinical value [2:00]; How aging clocks use DNA methylation to predict age and how they compare to traditional mortality prediction models [5:00]; The shift from aging clocks that predict chronological age to newer models that aim to measure biological age, lifespan differences, and the pace of aging [11:45]; The limitations of second-generation aging clocks: biological and measurement noise affecting reliability and interpretation [14:45]; Why aging clocks are exciting tools—compression, speed, and individual feedback [17:15]; The DO-HEALTH randomized trial: the study design and how different aging clocks were used to measure biological age and the pace of aging [22:00]; The DO-HEALTH study results: findings, takeaways, and open questions [27:45]; The DunedinPACNI study: how the model was developed and what it may add to the field [35:00]; The promise and limitations of aging clocks in measuring meaningful biological aging and predicting health outcomes [48:00]; Why aging clocks are not yet reliable as consumer tools and why traditional health metrics still matter most [52:00]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#386 - Aging clocks—what they measure, how they work, and their clinical and real-world relevance

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter answers listener questions across a wide range of topics, focusing on practical decision-making and real-world application. He explores how health priorities and strategies should evolve across different decades of life, which chronic diseases are most challenging to manage and how to think about risk hierarchies, and which emerging interventions—beyond exercise—show the most promise for dementia prevention. Peter also breaks down the utility of wearables and explains how to use and interpret DEXA scans effectively. He discusses the challenges of behavior change and how to make healthy habits stick, along with training strategies for balance, stability, and injury resilience, drawing lessons from his own setbacks. Additional topics include high-protein diets and mTOR, how to weigh mechanisms versus outcomes, how to evaluate diet sodas and non-nutritive sweeteners in context, and a range of listener questions covering health fads, emotional health, and sleep routines. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #82 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  Overview of episode topics, emphasizing the goal of providing actionable, real-world health guidance  [1:30]; How health priorities and training strategies should evolve from early adulthood through older age [2:45]; Comparing the four major chronic diseases: which are most preventable, most uncertain, and most concerning [8:00]; Emerging strategies for dementia prevention: biomarkers, early detection, and new pharmacologic approaches [15:00]; How to use wearable data effectively: when it's helpful, when it's not, and how to avoid over-reliance [19:00]; DEXA scans: timing, interpretation, and limitations in body composition and bone density tracking [23:00]; Best practices for building sustainable health habits [30:15]; How to train your balance and stability [33:30]; How to recover from injuries and use setbacks to build strength and resilience [36:15]; High protein intake and the impact on mTOR: evaluating mechanisms versus real-world evidence on longevity [38:30]; Diet soda and artificial sweeteners: evaluating risks, benefits, and the importance of context [47:00]; How to balance enjoying life today with making choices that support long-term health and longevity [51:45]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#385 - AMA #82: Applying the tools of longevity in the real world: disease prevention, DEXA scans, artificial sweeteners, injury recovery, stability training, habit formation, protein intake and mTOR activation, and more

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this special episode, Peter takes a deep dive into obicetrapib, an investigational drug that has captured his attention and renewed interest in an entire class of therapies known as CETP inhibitors. He explains what obicetrapib is and how it works, revisits the history of CETP inhibitors and why earlier versions of these drugs failed—sometimes dramatically—and breaks down the key clinical trials designed to evaluate their impact on cardiovascular risk. Peter examines how obicetrapib influences major lipid biomarkers, including LDL cholesterol and lipoprotein(a) [Lp(a)], and discusses emerging evidence from a study that explored the drug's effects on Alzheimer's-related blood biomarkers. He also highlights intriguing findings in individuals carrying the APOE4 allele and reflects on what these early results may mean for both cardiovascular disease prevention and potential implications for Alzheimer's risk, as well as how he is thinking about this therapy in the context of caring for his own patients. We discuss:  Introducing obicetrapib: CETP inhibitor history, lipid biology, and early Alzheimer's biomarker signals in APOE4 carriers [2:15]; CETP biology explained: lipoproteins, reverse cholesterol transport, and how CETP inhibition alters HDL and LDL particles [5:15]; The early CETP inhibitor story: why raising HDL cholesterol alone failed to deliver cardiovascular protection [13:45]; The rise and fall of early CETP inhibitors: torcetrapib, dalcetrapib, evacetrapib, and anacetrapib [18:30]; Why obicetrapib may succeed where earlier CETP inhibitors failed [23:30]; The BROADWAY trial: obicetrapib's effects on LDL, ApoB, Lp(a), and residual cardiovascular risk [26:00]; Brain lipid metabolism and APOE4: how CETP inhibition may influence cholesterol transport in Alzheimer's disease [30:45]; Findings from the substudy of the BROADWAY trial which looked at changes in biomarkers of Alzheimer's disease [40:00]; Interpreting the BROADWAY Alzheimer's biomarker results: limitations, cautious optimism, and the need for a dedicated prevention trial [46:45]; Why Peter is optimistic about obicetrapib: cardiovascular benefits, Lp(a) reduction, and the path toward approval [50:00]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#384 - Special episode — Obicetrapib: The CETP inhibitor with cardiovascular benefits and potential Alzheimer's prevention

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Layne Norton is a nutrition scientist and accomplished power athlete,who returns to The Drive for a conversation that departs from the show's usual format. In this episode, Layne presents the evidence-based case that seed oils are not uniquely harmful under isocaloric conditions, while Peter steelmans the strongest versions of the opposing argument that seed oils are inherently harmful. They examine how scientific bias and evidence are evaluated, revisit the historical randomized controlled trials that shaped the seed oil controversy, and explore the mechanistic biology underlying LDL oxidation and atherosclerosis. Along the way, Layne unpacks the chemistry and processing of modern seed oils, assesses evolutionary and ancestral nutrition arguments, clarifies the relationship between seed oils, ultra-processed foods, and contemporary dietary patterns, and situates these questions within the larger context of lifestyle factors that drive cardiometabolic health. Layne concludes by offering practical considerations around dietary fats, cooking oils, and real-world food choices. We discuss:  The idea behind this episode, biases, and evidence-based thinking [5:15]; The four core arguments behind claims that seed oils are harmful [12:30]; The Minnesota Coronary Experiment (MCE) [14:30]; The differences among saturated, monounsaturated, polyunsaturated, and trans fats, and why those differences matter for cardiovascular disease [18:30]; Missing trans fat data as a confounder in the Minnesota Coronary Experiment, other limitations of that study, and the challenge detecting meaningful differences in hard outcomes through nutrition research [24:00]; The Sydney Diet Heart Study (SDHS): an attempt to address the "duration problem" by enrolling a much higher-risk population [28:30]; Debating whether evidence from randomized trials supports the idea that seed oils are uniquely harmful once major confounders are removed [34:00]; The Rose Corn Oil trial: an often-cited study used to argue against polyunsaturated fats [36:30]; Three studies where replacing saturated fat with polyunsaturated fat produced different results than earlier trials [41:30]; Layne's explanation for why the evidence is pointing towards cardiovascular risk reduction when substituting polyunsaturated fat for saturated fat [47:30]; What Mendelian randomization says about the causal role of LDL cholesterol in ASCVD [56:45]; The compounding effects of life-long exposure to high LDL cholesterol [1:06:45]; Does the linoleic acid (omega-6) content of seed oils cause inflammation? [1:13:45]; Does the linoleic acid (omega-6) content of seed oils increase oxidized LDL? [1:19:30]; Layne's analogy to explain why lower LDL particle number outweighs higher per-particle oxidation risk when comparing polyunsaturated fats to saturated fats [1:26:15]; The role of oxidized LDL in CVD: exploring differences in a diet high in polyunsaturated fat (seed oils) versus high in saturated fat [1:28:00]; Examining whether industrial processing and solvent extraction of seed oils—especially residual hexane—could plausibly cause long-term harm [1:34:00]; The evolutionary and "ancestral diet" argument against seed oils [1:40:45]; Weighing concerns about industrial processing of seed oils against the totality of metabolic and cardiovascular evidence [1:47:30]; Practical considerations around dietary fats, cooking oils, and real-world food choices [1:50:00]; Comparing the health impact of seed oils with that of caloric intake and activity levels, and how to prioritize interventions [2:00:15]; More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#380 ‒ The seed oil debate: are they uniquely harmful relative to other dietary fats? | Layne Norton, Ph.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter brings together his most up-to-date thinking on cardiorespiratory fitness into a single, practical guide designed to help listeners structure training for maximal impact on healthspan, lifespan, and long-term independence. He explains why cardiorespiratory fitness is one of the strongest modifiable predictors of longevity, clarifies what zone 2 training actually represents and how it differs from higher-intensity work, and addresses persistent confusion around exercise volume, intensity, and time constraints. The discussion covers how to measure and track progress in zone 2, VO₂ max targets and age-adjusted goals, planning for the marginal decade, and how to balance zone 2 with higher-intensity training across different weekly volumes. Peter also outlines how cardio training should be tailored for beginners, experienced trainees, and older adults, with special considerations for women and guidance on avoiding the most common cardio-training mistakes. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #79 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  Rational for discussing cardiorespiratory fitness, zone 2, and VO₂ max despite having covered the topic extensively [2:30]; Why cardiorespiratory fitness and VO₂ max are powerful and modifiable predictors of all-cause mortality compared with other health metrics [7:30]; How age-related declines in VO₂ max constrain healthspan and everyday physical function [12:30]; The cardiorespiratory fitness triangle: how different training intensities contribute to building the aerobic base, the aerobic peak, and overall aerobic capacity [14:15]; The cellular mechanics of cardiorespiratory fitness: mitochondria, lactate, muscle fiber recruitment, and intensity thresholds [18:45]; The debate over whether zone 2 training has unique benefits or whether higher-intensity exercise alone is sufficient [27:15]; Balancing intensity and sustainability as training volume increases, and the important role of zone 2 training [32:15]; How to identify your zone 2 training intensity [34:45]; How to measure and track improvements in zone 2 fitness [40:00]; How to accurately measure VO₂ max: lab testing, field tests, and the limits of wearables [45:15]; How to set meaningful VO₂ max targets based on age, sex, long-term decline, and desired physical capabilities later in life [51:15]; How to structure and execute a zone 2 workout [59:45]; How strictly should zone 2 be maintained during a workout? [1:04:00]; How to design a VO₂ max training session: interval length, intensity, recovery, and progression strategies [1:07:00]; Why heart rate is not a reliable metric for titrating VO₂ max interval intensity [1:12:00]; Practical ways to monitor VO₂ max improvements [1:13:30]; How to balance zone 2 and VO₂ max training [1:15:30]; How to structure training for someone limited to 150 minutes per week of total exercise [1:19:00]; How to allocate 150 minutes per week of dedicated cardiorespiratory training between zone 2 and VO₂ max work [1:23:00]; How to structure training for someone with substantial available time who wants to maximize cardiorespiratory fitness [1:24:30]; Why spreading aerobic training across the week beats compressing volume into one session [1:26:15]; How beginners and metabolically unhealthy individuals should start cardiorespiratory training safely [1:28:00]; How "training age" determines the intensity and workload needed to continue improving cardiorespiratory fitness [1:31:15]; Why zone 2 training still matters for women (including postmenopausal women) [1:32:45]; How cardiorespiratory training should adapt with aging [1:35:45]; The most common mistakes people make when training cardiorespiratory fitness and how to avoid them [1:37:45]; How to break through a VO₂ max plateau [1:40:45]; The main takeaways about cardiorespiratory fitness and longevity [1:41:30]; Peter's carve out: oral hygiene and Peter's two-toothbrush system [1:43:00]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#379 - AMA #79: A guide to cardiorespiratory training at any fitness level to improve healthspan, lifespan, and long-term independence

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Abbie Smith-Ryan is a leading researcher in exercise physiology whose work focuses on how training and nutrition influence body composition, metabolism, cardiovascular health, and women's health across the lifespan, with particular attention on perimenopause and post-menopause. In this episode, Abbie explains how early exercise and play help build the foundation for bone health, muscle development, and cardiorespiratory fitness in girls, as well as how puberty and menstruation shape athletic performance, motivation, and recovery. She also explores how women can tailor training and nutrition across the menstrual cycle through smart fueling, hydration, and inflammation management; examines the evidence behind supplements such as creatine, omega-3s, and magnesium; and unpacks the metabolic and body composition changes that accompany the transition into perimenopause and menopause. Finally, she covers practical exercise programming for busy women, training and nutrition considerations during pregnancy and postpartum, and the evolving role of hormone therapy alongside lifestyle-based, evidence-driven approaches that help women better advocate for their health. We discuss:  Abbie's background in distance running and her interest in studying women's health around exercise [3:00]; The role of early-life exercise in building lifelong bone, muscle, and cardiovascular health in girls [4:00]; Training principles for premenstrual girls, the risks of early specialization and delayed puberty from intense training, and how youth sport participation can shape bone and spinal health [7:15]; Nutrition as fuel in young female athletes: supporting training, growth, and performance [11:00]; Training and recovery across the menstrual cycle: recovery, nutrition, supplements, and practical strategies for performance support [16:00]; The benefits of creatine supplementation and importance of protein intake across the menstrual cycle [27:15]; How women should approach training intensity and volume across the menstrual cycle [33:00]; How to identify and monitor the perimenopausal transition and why this phase represents a critical window for exercise and nutrition interventions [37:15]; Case study: time-efficient exercise program for a busy, perimenopausal woman [42:00]; Why improving body composition is a better goal than weight loss, and how to set realistic fat-loss targets in midlife women [53:30]; How to preserve muscle and bone while using GLP-1 medications: resistance training, protein intake, and more [58:15]; Designing a three-hour-per-week training plan for sustainable body recomposition [1:03:30]; Abbie's insights from her 20+ years of self-tracking: nutrient timing, injury prevention, excessive training, bone health, and more [1:07:15]; How pregnancy and the postpartum period affect body composition, and how consistent exercise and intentional nutrition can prevent a permanent shift in body fat or muscle mass [1:13:30]; Changes in muscle quality and metabolic flexibility during perimenopause and menopause, and how exercise may counteract hormonally driven sarcopenia [1:21:45]; The biggest open questions about women's health: combining menopause hormone therapy with exercise, GLP-1 drugs, minimizing injury risk, and more [1:32:00]; How the training response differs between men and women, and the importance of type IIa muscle fibers [1:39:15]; Training advice for the hypothetical 70-year-old woman who has never exercised deliberately [1:47:00]; Misinformation about exercise and nutrition for women, injury risk, supplement hype, and the need for more nuanced messaging around hormones, recovery, and midlife training [1:53:30]; Benefits of hormone therapy in midlife women and its interaction with exercise and lifestyle interventions [2:00:15]; Peter's overall take on how women should approach exercise volume and intensity at various life phases and time constraints [2:03:00]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#378 ‒ Women's health and performance: how training, nutrition, and hormones interact across life stages | Abbie Smith-Ryan, Ph.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter James Clear is the author of the New York Times bestseller Atomic Habits. His extensive research into human behavior has helped him identify key components of habit formation and develop the "Four Laws of Behavioral Change." In this episode, James provides insights into how both good and bad habits are formed, including the influence of genetics, environment, social circles, and more. He points to changes one can make to cultivate more perseverance and discipline and describes the profound impact habits can have when tying them into one's self-identity. Finally, James breaks down his "Four Laws of Behavioral Change" and how to use them to create new habits, undo bad habits, and make meaningful changes in one's life. We discuss:  Why James became deeply interested in habits [1:45]; Viewing habits through an evolutionary lens [6:00]; The power of immediate feedback for behavior change, and why we tend to repeat bad habits [9:15]; The role of genetics and innate predispositions in determining one's work ethic and success in a given discipline [14:30]; How finding one's passion can cultivate perseverance and discipline [23:15]; Advantages of creating systems and not just setting goals [29:15]; The power of habits combined with self-identity to induce change [36:30]; How a big environmental change or life event can bring on radical behavioral change [50:30]; The influence of one's social environment on their habits [54:15]; How and why habits are formed [1:00:30]; How to make or break a habit with the "Four Laws of Behavior Change" [1:09:30]; Practical tips for successful behavioral change—the best strategies when starting out [1:16:15]; Self-forgiveness and getting back on track immediately after slipping up [1:30:30]; Law #1: Make it obvious—Strategies for identifying and creating cues to make and break habits [1:39:45]; Law #2: Make it attractive—examples of ways to make a new behavior more attractive [1:47:45]; Law #3: Make it easy—the 2-minute rule [1:58:45]; Law #4: Make it satisfying—rewards and reinforcement [2:03:30]; Advice for helping others to make behavioral changes [2:06:00]; More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

Building & Changing Habits | James Clear (#183 rebroadcast)

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this special episode of The Drive, Peter presents a curated "best of" conversation with bestselling author and previous guest Arthur Brooks, organized around four core themes: happiness itself, the forces that undermine it, the tools and practices that help cultivate it, and the courage required to live and love well. The episode brings together the most meaningful moments from two past interviews into a single, focused discussion that distills Brooks' most insightful ideas and offers practical takeaways for building a life that's both successful and deeply happy. We discuss:  Happiness vs. happy feelings, and how happiness and unhappiness can coexist [2:15]; The six fundamental emotions [5:30]; The three main "macronutrients" of happiness [15:00]; Enjoyment: one of the three macronutrients of happiness [22:45]; Satisfaction: one of the three macronutrients of happiness [30:45]; Sense of purpose: one of the three macronutrients of happiness [38:45]; Fame: one of the traps that hijack our happiness [46:30]; Success addiction, workaholism, and their detriment to happiness [49:15]; The reverse bucket list: one of Arthur's tools and practices he recommends for moving past the traps that hijack our happiness [59:15]; Metacognition: one of Arthur's tools and practices he recommends for moving past the traps that hijack our happiness [1:01:00]; Taking charge of your happiness: discipline, transcendent experiences, and other deliberate actions for "happier-ness" [1:11:30]; Tracking happiness: the biomarkers and micronutrients behind the macronutrients of happiness [1:22:45]; The value of minimizing the self and looking outward [1:30:45]; How Arthur surprised himself with his ability to improve his happiness [1:34:45]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#377 ‒ Special episode: Understanding true happiness and the tools to cultivate a meaningful life—insights from past interviews with Arthur Brooks

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter tackles a wide-ranging set of listener questions spanning lifespan interventions, exercise, cardiovascular risk reduction, time-restricted eating, blood pressure management, hormone therapy, diagnostics, and more. Peter reveals the single most important lever for extending healthspan and lifespan, and explains how he motivates midlife patients using the Centenarian Decathlon framework. He discusses the importance of addressing high apoB and cholesterol even in metabolically healthy individuals with calcium scores of zero, how to manage high blood pressure, and how to accurately evaluate metabolic health beyond HbA1c. Additional topics include time-restricted eating, practical considerations around ultra-processed foods, nuanced approaches to HRT for women and TRT for men, and why early and expanded screening for chronic disease—colonoscopy, PSA, coronary imaging, low-dose CT—can be lifesaving. He also offers insights into treating prediabetes, crafting exercise programs for those short on time, and safely incorporating high-intensity training in older adults. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #78 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  Introducing a wide-ranging AMA: practical perspectives on lifespan interventions, metabolic health, diet, hormones, diagnostics, and more [2:45]; Why exercise is the most powerful single intervention for lifespan and healthspan [4:15]; How Peter motivates midlife patients to prioritize exercise [6:00]; Why lifespan and healthspan should not be treated as competing priorities and how choosing sustainable interventions benefits both [9:30]; Why high apoB deserves treatment even in a metabolically healthy patient with a CAC score of zero [14:00]; Managing hypertension: ideal targets for blood pressure, lifestyle levers, and why early pharmacology matters [18:15]; Assessing metabolic health beyond HbA1c: fasting insulin, triglycerides, lactate, zone 2, and more [23:30]; How to avoid common self-sabotaging patterns by choosing sustainable habits over extreme health interventions [26:00]; Time-restricted eating: minimal effect beyond calorie control, implications for protein intake, and practical considerations for implementing it [28:00]; Ultra-processed foods: definitions, real-world risks, and practical guidelines for smarter consumption [30:30]; How women should prepare for menopause and think about hormone replacement therapy: early planning, symptom awareness, and guidance on HRT [36:45]; Testosterone replacement for aging men: indications, benefits, and safe clinical management [39:45]; Why Peter recommends earlier and more aggressive screening tests than guidelines suggest: colonoscopies, coronary imaging, PSA, Lp(a), and low-dose CT scans, and more [43:30]; Full-body MRI screening: benefits, limitations, potential false positives, and the importance of physician oversight [47:15]; Prediabetes: individualized treatment strategies using tailored combinations of nutrition, sleep, and training interventions [51:00]; Time-efficient training plans for people with only 30 minutes per day to exercise [53:00]; How to safely introduce high-intensity exercise for older adults [55:00]; Timed dead hangs and ripping phone books: a playful look at Peter's early attempts to impress his wife [57:15]; Peter's carve out: The Four Kings documentary about a golden era of boxing [1:01:15]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#376 - AMA #78: Longevity interventions, exercise, diagnostic screening, and managing high apoB, hypertension, metabolic health, and more

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Dom D'Agostino is a neuroscientist and professor at the forefront of metabolic therapies, including ketogenic diets, exogenous ketones, and hyperbaric oxygen. In this episode, Dom breaks down nutritional versus supplemental ketosis, defines meaningful ketone thresholds, and outlines practical ways to achieve ketosis. He explains how a ketogenic diet can support metabolic health and weight loss, and advises on how to maintain adequate protein and avoid common mistakes. Dom surveys the growing landscape of exogenous ketones—from salts and esters to 1,3-butanediol—and effective pairings like caffeine, MCT oil, and alpha-GPC. He highlights the role of ketogenic therapy in cancer (particularly glioblastoma) and its promise for neurodegenerative diseases. The conversation also covers recommended hyperbaric oxygen protocols for brain injuries and cognitive function, situations where fasting or ketones offer cognitive and anti-inflammatory benefits, and touches on the carnivore diet as a ketogenic variant with potential relevance for autoimmune and metabolic conditions. We discuss:  Dom and Peter's shared interest in ketosis, and Dom's scientific journey [2:30]; Dom's work for the Navy on oxygen toxicity [7:00]; Nutritional ketosis defined: physiology, biomarkers, and how fasting and diet generate therapeutic ketones [15:00]; The historical roots of ketogenic diets in epilepsy treatment, and evidence showing ketones reduce seizure activity and strengthen brain resilience [19:00]; Dom's personal experience on the ketogenic diet: tracking macros, getting enough protein, and monitoring ketone levels [24:15]; Using a ketogenic diet for weight loss: Dom's guidance on protein, fiber, calorie tracking, lipid monitoring, and more [31:00]; Protein on ketogenic diets: Dom's rationale for higher intake and muscle preservation [38:00]; Incorporating carbohydrates into keto: timing, high-fiber foods, and other considerations [41:30]; The carnivore diet: whether this diet induces ketosis, how it functions metabolically, and why it may help individuals with autoimmune conditions [44:15]; Early exogenous ketones: how 1,3-butanediol works, its liver toxicity risk, and why ketone esters replaced it [48:15]; The progression of exogenous ketones: why BHB monoesters and ketone salts emerged as better alternatives to 1,3-butanediol for ketone supplementation [59:30]; Ketone salts: easing the transition into ketosis, dosing, and how they compare to ketone esters [1:04:00]; The differences between D- and L-β-hydroxybutyrate, and how racemic mixtures may elevate ketones longer and offer unique biological effects [1:09:30]; How ketosis may boost NAD, and why NAD supplements have fallen short so far [1:16:30]; Emerging evidence for using a ketogenic diet to treat anorexia and other psychiatric disorders [1:20:30]; Potential cognitive and performance benefits of ketone supplementation, and why pushing ketones too high can be dangerous [1:23:45]; Applications for ketone esters, and why ketone salts or MCT-blended formulations may be safer and more practical for most people [1:29:15]; The role of a ketogenic diet in treating cancer [1:34:45]; The potential of a ketogenic diet for treating Alzheimer's disease [1:45:45]; Tools for cognitive enhancement: ketones, alpha-GPC, MCT, caffeine, strategic fasting, and more [1:53:45]; Hyperbaric oxygen therapy for concussion, TBI, PTSD, and cognitive function, including protocols and dosing approaches [1:55:30]; Peter's takeaways, recommended products, and additional resources to learn more [2:03:00]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#375 - Ketogenic diet, ketosis & hyperbaric oxygen: metabolic therapies for weight loss, cognition, Alzheimer's & more | Dom D'Agostino, Ph.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Carole Hooven is a human evolutionary biologist whose research centers on testosterone, sex differences, and behavior. In this episode, she explores how prenatal testosterone orchestrates male development in the body and brain, how early hormonal surges shape lifelong behavioral tendencies, and what rare natural experiments—such as 5-alpha-reductase deficiency—reveal about the biology of sex differentiation. She discusses distinct male and female aggression styles through an evolutionary lens, how modern environments interact with ancient competitive drives, and the implications of attempting to suppress them. The conversation also covers testosterone across the lifespan, the role of hormone therapy in both men and women, and Carole's own experience after surgical menopause, culminating in a broader discussion of masculinity, cultural narratives, and the consequences of denying biological sex differences. We discuss:  How Carole became interested in exploring the biological and evolutionary roots of sex differences and the role of testosterone [2:30]; How testosterone and other hormones influence sex differences in aggression and behavior across species [9:45]; How chromosomes, the SRY gene, and early hormones direct embryonic sexual differentiation [12:15]; A stark contrast of male social bonding compared to females, and evolutionary parallels in chimpanzees [19:30]; How hormones like DHT shape sexual differentiation, and how 5⍺-reductase deficiency reveals the distinct roles of these hormones [22:45]; How sex chromosomes and prenatal testosterone shape early brain development and explain sex differences in childhood behavior [31:30]; How gamete differences shape reproductive strategies, energetic costs, and sex-specific behavior [42:30]; How evolutionary biology shapes sex differences in play, aggression, and conflict resolution (and how modern environments and cultural messaging can disrupt those patterns) [49:00]; Why males commit disproportionately more violent crime, and how cultural and environmental forces shape aggression [1:01:00]; Why females evolved different behavioral strategies: nurturing, risk aversion, and the cultural norms that override biology [1:04:00]; Whether male aggression is still necessary in modern society, why the underlying biological drives persist, and how modern society redirects these drives [1:06:30]; How testosterone levels naturally shift to support fatherhood and caregiving [1:13:30]; How testosterone shapes male mating strategies, and why long-term pair-bonding persists even when reproduction is no longer at stake [1:18:30]; The distinct roles of estrogen in male development, mood, libido, and muscle [1:25:00]; How evolution, health, lifestyle, and androgen receptor biology shape modern testosterone replacement therapy (TRT) [1:34:15]; Carole's experience with hormone replacement therapy (HRT), and the risks associated with TRT in younger men [1:45:15]; How Carole rebuilt after controversy: leaving academia and recommitting to scientific honesty [1:51:30,]; Carole's next book: examining masculinity, cultural narratives, and the cost of denying biological sex differences [1:57:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#374 - The evolutionary biology of testosterone: how it shapes male development and sex-based behavioral differences, | Carole Hooven, Ph.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Walter Green is a remarkable philanthropist, mentor, author of This Is the Moment!, and founder of the impactful "Say It Now" movement. In this episode, Walter delves into the unique insights gained from his challenging upbringing, discusses embracing mortality, and highlights the mindset of "finishing strong." He shares insights on intentionality, thinking in reverse, saying "no," prioritizing relationships, and the essence of focusing on others. The conversation focuses on the "Say It Now" movement, which stresses the importance of expressing sentiments to loved ones well before the end of life. We discuss:  How Peter and Walter met through Ric Elias [3:30]; The unique perspectives and life lessons provided by Walter's challenging childhood [6:00]; Walter's harrowing experience with a sudden mental breakdown and his subsequent recovery with the help of therapy [12:15]; A diverse professional journey ending in great success [19:15]; The birth of a movement: celebrating friendships through public tributes and expressing gratitude to those who have shaped your life's journey [23:30]; Intentionality, thinking in reverse, saying "no", and other guiding principles for Walter [30:45]; Walter's global journey of gratitude on his 70th birthday, visiting friends, and creating memorable experiences [40:15]; The profound impact of acknowledging and expressing gratitude for the people who contribute to our lives [47:15]; The key elements for creating meaningful connections and cultivating deep, authentic friendships [53:15]; The "Say It Now" movement: the inspiration behind the remarkably impactful initiative [59:15]; What "finishing strong" means to Walter [1:08:15]; Finding peace at the end of life through expressing gratitude and finding purpose in serving others [1:16:45]; Resources to learn about "Say It Now" [1:27:00]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

The impact of gratitude, serving others, embracing mortality, and living intentionally | Walter Green (#288 rebroadcast)

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Antonio Bianco is a world-renowned physician-scientist and expert in thyroid physiology and metabolism. In this episode, Antonio explores the complex biology of thyroid hormone production, conversion, and regulation—highlighting how deiodinase enzymes modulate hormone activity at the tissue level and why that matters for interpreting lab results. He discusses the shortcomings of relying solely on TSH as a marker of thyroid function, the ongoing debate around combination therapy with T3 and T4 versus standard T4 treatment, and how genetics, tissue sensitivity, and individual variability influence thyroid hormone metabolism. The conversation also examines how hypothyroidism affects energy, mood, cognition, and longevity; why some patients remain symptomatic despite "normal" labs; and how future research could reshape treatment paradigms. We discuss:  How the thyroid produces, stores, and activates hormones like T4 and T3 to finely regulate thyroid activity [2:45]; How fasting alters thyroid hormones to conserve energy [12:45]; Action of the deiodinases: how D1, D2, and D3 enzymes control the activation and inactivation of thyroid hormones [19:15]; The normal function of thyroid hormone and the roles of the hypothalamus, pituitary gland, and deiodinases in maintaining hormonal balance [23:30]; Why understanding thyroid physiology is essential for proper diagnosis and treatment of hypothyroidism [33:45]; Testing for thyroid hormones: understanding free vs. total levels, the limitations of current T3 assays, best practices, and more [36:00]; Genetic and sex-based variability in thyroid hormone regulation and their limited clinical significance [43:45]; Hyperthyroidism: causes, symptoms, diagnosis, and treatment options [46:00]; Hypothyroidism: diagnosis and autoimmune causes of hypothyroidism [56:30]; More on hypothyroidism: diagnostic biomarkers, antibody patterns, and non-autoimmune presentations [1:05:00]; Thyroid hormone replacement therapy [1:15:15]; More on thyroid replacement strategies: exploring the evidence gaps, mortality signals, effects on lipids, and more [1:28:00]; Hypothyroidism basics: causes, antibody implications (including pregnancy), and how to make the diagnosis before choosing therapy [1:35:15]; Thyroid medication: compounded controlled-release T3, brand name versus generic, and what Antonio prescribes to newly diagnosed hypothyroid patients [1:42:45]; Redefining treatment success: why normalizing TSH isn't always enough for patients with hypothyroidism [1:54:45]; Case studies: analysis of two unusual cases of thyroid disease [1:57:00]; Dangers of supplementing with high levels of iodine, and female-specific risk of thyroid disease [2:05:45]; Case study of a patient who presents with elevated TSH but no symptoms [2:09:30]; How future research could reshape treatment, and Antonio's new book called "Rethinking Hypothyroidism" [2:13:15]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#373 – Thyroid function and hypothyroidism: why current diagnosis and treatment fall short for many, and how new approaches are transforming care | Antonio Bianco, M.D., Ph.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter breaks down the science of dietary fiber, moving beyond the blanket advice to "eat more fiber" to uncover what it actually does in the body and where its benefits are truly supported by evidence. He explains how different types of fiber—soluble, insoluble, viscous, and fermentable—affect digestion, satiety, weight management, and glycemic control, and compares their impact to other, more potent metabolic tools. Peter also examines how certain fibers influence lipid metabolism and cardiovascular risk, evaluates the strength of evidence for fiber's role in colorectal cancer prevention, and highlights why some individuals may not tolerate specific fibers well. The discussion concludes with practical guidance on moving past generic fiber targets toward a more strategic and personalized approach that maximizes the true benefits of fiber. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #77 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  Why it's time to re-examine the evidence behind dietary fiber recommendations [2:00]; Why it's hard to isolate fiber's true effects on health: the limits of nutritional epidemiology [5:45]; Defining dietary fiber: what it is, how it's digested, and why different types have different effects [8:15]; Understanding fiber properties: how solubility, viscosity, and fermentability shape its effects in the body [11:15]; Resistant starches explained: types, food sources, and how cooking and cooling influence their benefits [16:30]; A framework for evaluating each of the major health claims linked to fiber [19:15]; How fiber can support weight loss: mechanisms, realistic expectations, and its complementary role to broader dietary strategies [20:30]; How fiber modestly improves glycemic control by reducing glucose spikes and insulin demand [26:15]; How fiber modestly lowers LDL cholesterol and supports cardiovascular health [34:30]; How fiber compares to other available tools and strategies for managing lipids, blood sugar, and weight [42:00]; Fiber's role in colon cancer prevention: mechanisms, evidence, and limitations [45:30]; Is fiber necessary for colon cancer prevention in otherwise healthy individuals? [53:30]; Why some people have adverse reactions to certain types of fiber, and how to manage them [56:00]; A general strategy for dietary fiber: combine multiple fiber types through whole foods and supplements [58:45]; Why total fiber intake is more important than the ratio of soluble-to-insoluble fiber [1:02:45]; The optimal timing and context for consuming fiber to maximize blood sugar control and metabolic benefits [1:05:00]; How food processing affects the functional properties of fiber, the differences between supplement forms and natural sources, and why whole foods generally remain the best option [1:06:45]; Fiber's potential to interfere with medication absorption [1:09:30]; How to safely increase fiber intake: ramp up gradually and stay hydrated [1:12:00]; Final takeaway on fiber: modest benefits, strong rationale, low downside [1:13:00]; Peter's carve-out: lessons and inspiration from the Acquired podcast [1:14:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#372 - AMA #77: Dietary fiber and health outcomes: real benefits, overhyped claims, and practical applications

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Sally Greenwald is an OB-GYN who specializes in women's sexual health from a hormonal and physiologic perspective, with expertise spanning desire, arousal, pelvic floor function, contraception, and menopause care. In this episode, she explains why sexual health is a vital component of overall well-being, exploring topics such as the drivers of desire, the anatomy of sexual function, myths and realities around orgasm, and the role of hormones in perimenopause and menopause. She also covers vaginal and pelvic health, pain with sex, evidence-based therapies for low desire and arousal, how contraception and medications can affect sexual function, and practical strategies for enhancing sexual satisfaction and maintaining intimacy across life stages. This episode offers a comprehensive, evidence-based discussion with immediate real-world relevance for women as well as for men who want to better understand their partners. We discuss:  How sexual health influences physical health, emotional well-being, and relationships [3:15]; Understanding the physiology of the female orgasm, sexual comfort and satisfaction, and the disparity between men and women [12:45]; Foreplay, the science of desire, and methods to help women cultivate arousal and connection [19:00]; The physiology and sources of female lubrication, the role of clitoral nerve anatomy in pleasure, and the use of lubricants and vibrators to enhance comfort and sexual health [23:45]; Understanding female anatomy and what is needed for orgasm [31:15]; Understanding sexual desire, how to cultivate it, the role of hormones, and testosterone therapy in women [41:15]; Personalizing perimenopause care: how desire for ovulation guides the choice between contraception and menopausal hormone therapy [49:30]; Considerations for choosing contraceptives and hormonal therapies during perimenopause [59:45]; Factors negatively affecting desire, and why female libido persists with age and fluctuates across the menstrual cycle [1:11:00]; How sexual trauma and physical pain can affect sexual health, and evidence-based strategies for recovery [1:15:15]; Vaginal care routine: lubricants, moisturizers, topical hormones, and other approaches for vaginal health [1:19:15]; Tips for sexually satisfying your female partner [1:25:45]; The pharmacology of arousal: various treatments for low sexual desire in women [1:30:30]; Sex during and after pregnancy: impact on arousal, safety of sex, and how to manage postpartum recovery and pain [1:37:45]; How Sally would redesign sex education [1:42:15]; Sally's optimism about a new era in women's sexual health [1:49:00]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#371 – Women's sexual health: desire, arousal, and orgasms, navigating perimenopause, and enhancing satisfaction | Sally Greenwald, M.D., M.P.H.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this special episode, Peter provides a comprehensive introduction to longevity, perfect for newcomers or those looking to refresh their knowledge. He lays out the foundational concepts of lifespan, healthspan, and the marginal decade. Additionally, Peter discusses the four main causes of death and their prevention, as well as detailing the five key strategies in his longevity toolkit to improve lifespan and healthspan. Detailed show notes provide links for deeper exploration of these topics, making it an ideal starting point for anyone interested in understanding and improving their longevity. We discuss:  Key points about starting exercise as an older adult [2:45]; Overview of episode topics and structure [1:45]; How Peter defines longevity [3:45]; Why healthspan is a crucial component of longevity [11:15]; The evolution of medicine from medicine 1.0 to 2.0, and the emergence of medicine 3.0 [15:30]; Overview of atherosclerotic diseases: the 3 pathways of ASCVD, preventative measures, and the impact of metabolic health [26:00]; Cancer: genetic and environmental factors, treatment options, and the importance of early and aggressive screening [33:15]; Neurodegenerative diseases: causes, prevention, and the role of genetics and metabolic health [39:30]; The spectrum of metabolic diseases [43:15]; Why it's never too late to start thinking about longevity [44:15]; The 5 components of the longevity toolkit [46:30]; Peter's framework for exercise—The Centenarian Decathlon [47:45]; Peter's nutritional framework: energy balance, protein intake, and more [58:45]; Sleep: the vital role of sleep in longevity, and how to improve sleep habits [1:08:30]; Drugs and supplements: Peter's framework for thinking about drugs and supplements as tools for enhancing longevity [1:13:30]; Why emotional health is a key component of longevity [1:17:00]; Advice for newcomers on where to start on their longevity journey [1:19:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

Longevity 101: a foundational guide to Peter's frameworks for longevity, and understanding CVD, cancer, neurodegenerative disease, nutrition, exercise, sleep, and more (re-broadcast)

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter revisits the "proven, promising, fuzzy, noise, nonsense" scale and applies it to a variety of popular topics. He begins with a refresher on what each category represents before classifying a range of interventions based on the strength of their supporting evidence. The conversation spans three main areas: drugs for geroprotection (including GLP-1 receptor agonists, SGLT2 inhibitors, methylene blue, and telomere-lengthening supplements), the use of low-dose aspirin for cardiovascular disease prevention, and strategies to improve muscle mass through optimal protein intake and follistatin gene therapy. This episode provides a clear, evidence-based overview for listeners seeking to understand where these popular health and longevity interventions stand on the spectrum of scientific credibility. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #76 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  A scale for evaluating scientific claims: proven, promising, fuzzy, noise, or nonsense [1:30]; Strong convictions, loosely held: the mindset that separates great scientists from the rest [7:30]; GLP-1 receptor agonists: are there benefits beyond improving metabolic health and promoting weight loss? [12:45]; GLP-1 drugs and the brain: exploring the potential cognitive benefits [18:45]; GLP-1 drugs and lifespan: examining the evidence for potential geroprotective effects [23:00]; Rapamycin and geroprotection: why it remains in the "promising" category [25:45]; SGLT2 inhibitors and their potential geroprotective effect [27:30]; Methylene blue: examining the evidence of an anti-aging effect [34:45]; Methylene blue's potential neuroprotective effects: limited and inconsistent evidence in humans, and the challenges of dosing and safety [41:15]; Telomeres: what they are, how they relate to aging, and why telomere-lengthening supplements lack credible scientific evidence [43:45]; Does the idea of targeting telomere length to extend lifespan have scientific merit? [50:15]; Low-dose aspirin for cardiovascular disease prevention: weighing its clot-prevention benefits against bleeding risks across different populations [55:00]; Rethinking the protein RDA: why most people need twice the recommended amount for muscle health [1:00:45]; Debunking the protein–cancer myth: why higher protein intake doesn't promote tumor growth [1:06:15]; The biology of follistatin and myostatin, and why follistatin gene therapy has become an emerging topic of interest for muscle growth [1:13:15]; Follistatin gene therapy for muscle growth: state of the evidence in animals and humans, and the technical challenges and regulatory barriers [1:17:00]; Why injectable follistatin is theoretically possible but impractical for real-world use [1:23:15]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#370 - AMA #76: Peter evaluates longevity drugs, aspirin for CVD, and strategies to improve muscle mass — proven, promising, fuzzy, noise, or nonsense?

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Rhonda Patrick is a scientist, health educator, and host of the FoundMyFitness podcast whose work explores the intersection of nutrition, aging, and disease prevention. In this episode, Rhonda joins Peter for part two of his deep dive on protein, continuing last week's discussion with David Allison and expanding the conversation to include creatine supplementation and sauna use. She discusses why the current RDA for protein is insufficient, how much more is needed to maintain muscle mass and prevent frailty, how activity level and aging influence protein requirements through mechanisms such as anabolic resistance, and how to determine optimal protein intake. The conversation also covers creatine's proven effects on strength, endurance, and performance; its overlooked benefits for cognition and brain health; and the optimal dosing for different populations. Rhonda closes with the science behind sauna use, including its cardiovascular and cognitive benefits, the role of heat shock proteins, and practical guidance on temperature and duration. We discuss:  Why the current protein RDA is too low, and why maintaining sufficient amino acid intake is vital for muscle preservation and health [3:30]; The case for raising the protein RDA by at least 50% [9:45]; Anabolic resistance: why inactivity—more than aging—blunts the body's response to protein, and how resistance training restores it [14:00]; How sarcopenia develops, the profound effect of frailty on quality of life, and why it's crucial to build and maintain muscle early [20:00]; Finding the optimal protein dose [25:00]; Why aiming higher is smarter: the case for targeting 2g of protein per kg of body weight in the real world [32:15]; Protein needs for pregnant women and growing adolescents [37:30]; Why higher protein intake is crucial when trying to lose fat while preserving or gaining muscle [39:45]; GLP-1 drugs: protein needs, muscle preservation, dosing strategies, evidence of broader health impacts, and more [43:45]; How overweight individuals should calculate protein needs based on target body weight [50:45]; Unpacking a misunderstood topic: the relationship between protein intake, mTOR activation, and longevity [52:00]; Why it's unclear whether rapamycin is geroprotective in humans, and how misinterpreted animal data have fueled misconceptions about protein or mTOR activation being harmful [1:00:45]; The unmatched longevity benefits of exercise, its synergy with higher protein intake, and Peter's recommended protein intake [1:06:15]; How Rhonda became fascinated with creatine—a well-studied, safe, and effective supplement for improving exercise performance [1:09:00]; Creatine for the brain: how higher doses may enhance cognition under stress and support resilience against aging and disease [1:16:30]; Optimal creatine use: dosing for adults and teens, safe product selection, debunking kidney myths, and more [1:25:45]; Sauna: how deliberate heat exposure mimics exercise, boosts cardiovascular and brain health, and shows promise for improving mood and mental resilience [1:32:15]; The benefits of sauna for reducing risk of dementia, and why hotter may not be better [1:41:15]; The FoundMyFitness podcast [1:45:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#369 ‒ Rethinking protein needs for performance, muscle preservation, and longevity, and the mental and physical benefits of creatine supplementation and sauna use | Rhonda Patrick, Ph.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter David Allison is a world-renowned scientist and award-winning scientific writer who has spent more than two decades at the forefront of obesity research. In this episode, David joins for his third appearance on The Drive to bring clarity to one of the most contentious topics in modern nutrition—protein. He explores the historical pattern of demonizing macronutrients, the origins and limitations of the RDA for protein, and what the evidence really says about higher protein intake, muscle protein synthesis, and whether concerns about harm are supported by actual data. He also discusses the challenges of conducting rigorous nutrition studies, including the limits of epidemiology and crossover designs, as well as conflicts of interest in nutrition science and why transparency around data, methods, and logic matter more than funding sources. The episode closes with a discussion on processed and ultra-processed foods, the public health challenges of tackling obesity, and whether future solutions may depend more on drugs like GLP-1 agonists or broader societal changes. This is part one of a two-part deep dive on protein, setting the stage for next week's conversation with Rhonda Patrick. We discuss:  The cyclical pattern of demonizing different macronutrients in nutrition and why protein has recently become the latest target of controversy [3:15]; The origin and limits of the protein RDA: from survival thresholds to modern optimization [6:30]; Trust vs. trustworthiness: why data, methods, and logic matter more than motives in science [13:30]; The challenges of nutrition science: methodological limits, emotional bias, and the path to honest progress [17:15]; Why the protein RDA is largely inadequate for most people, and the lack of human evidence that high protein intake is harmful [30:30]; Understanding the dose-response curve for muscle protein synthesis as protein intake increases [45:15]; Why nutrition trials are chronically underpowered due to weak economic incentives, and how this skews evidence quality and perceptions of conflict [48:15]; The limitations and biases of nutrition epidemiology, and the potential role of AI-assisted review to improve it [56:15]; The lack of compelling evidence of harm with higher protein intake, and why we should shift away from assuming danger [1:04:15]; Pragmatic targets for protein intake [1:09:30]; Defining processed and ultra-processed foods and whether they are inherently harmful [1:16:15]; The search for a guiding principle of what's healthy to eat: simple heuristics vs. judging foods by their molecular composition [1:25:00]; Why conventional public health interventions for obesity have largely failed [1:38:15]; Two ideas from David for addressing the metabolic health problem in society [1:42:30]; The potential of GLP-1 agonists to play a large role in public health [1:46:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#368 ‒ The protein debate: optimal intake, limitations of the RDA, whether high-protein intake is harmful, and how to think about processed foods | David Allison, Ph.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this special episode of The Drive, Peter addresses the recent headlines linking acetaminophen (Tylenol) use during pregnancy to autism in exposed children. Recognizing the confusion these claims have sparked among patients, listeners, and the broader public, Peter uses this episode to provide a framework for thinking critically about complex conditions and the research related to them. He highlights the dramatic rise in autism diagnoses over recent decades, noting that multifactorial conditions rarely have a single cause, and emphasizes the importance of resisting oversimplified explanations. Peter also stresses that humans are not naturally wired for scientific thinking, making disciplined frameworks like the Bradford Hill criteria essential for evaluating causality in epidemiology. Ultimately, he uses this framework to explore the evidence surrounding acetaminophen use during pregnancy and its potential link to autism. We discuss:  Laying the groundwork for this discussion, the rise in autism rates, and the value in using frameworks [1:00]; The FDA pregnancy drug categories, where Tylenol falls within that framework, and a structured method for evaluating scientific evidence and causality [6:00]; What exactly are the claims being made about acetaminophen and autism? [13:45]; The increase in autism rates and why so many things are being linked to autism: the multiple comparisons problem [15:00]; Evaluating the review paper that triggered the recent concern over acetaminophen and autism [21:45]; Breaking down the largest studies on prenatal Tylenol exposure and autism: is there a causal link? [35:00]; Why observational studies can't prove causality, the role of confounding variables, and the importance of frameworks like the Bradford Hill criteria [43:30]; Applying the Bradford Hill criteria: testing the case for Tylenol and autism [45:45]; Putting it all together to answer the question: Does acetaminophen use during pregnancy increase the risk of autism? [56:15]; If autism risk is overwhelmingly genetic, what explains the dramatic rise in autism diagnoses? [59:15]; Other risk factors for autism: parental age, maternal health, environment, and where Tylenol fits in [1:09:15]; Medication use during pregnancy: balancing risks, benefits, and FDA categories [1:15:15]; Considerations for taking Tylenol during pregnancy [1:19:30]; Final thoughts: critical thinking, balanced risk assessment, and the importance of context when evaluating medications like Tylenol during pregnancy [1:22:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#367 - Tylenol, pregnancy, and autism: What recent studies show and how to interpret the data

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Joe Liemandt is a software entrepreneur turned education reformer who left Stanford in 1989 to found Trilogy, a highly profitable private software company, before pivoting to transforming K-12 learning. In this episode, Joe shares how he transitioned from leading a global software enterprise to becoming principal of Alpha School, where his focus is building a mastery-based, individualized education model that leverages AI as the missing infrastructure for large-scale change. He details the shortcomings of traditional K-12 education, explains how Alpha replaces conventional seat time with focused academics, and outlines the role of AI tutors and human coaches in helping students accelerate through material. Joe also discusses early results, the data-driven systems that track progress, and his ambitious plan to reach a billion children in the next 20 years by combining cutting-edge technology with proven learning science. We discuss:  Joe's early interest in AI and the story of how he quit school to build Trilogy [4:45]; Joe's first encounter with Alpha School and how it sparked his journey into education innovation [8:15]; America's declining K-12 performance and the hidden power of mastering fundamentals [13:00]; How traditional time-based grade progression undermines later learning, and how mastery-focused instruction can transform student achievement [20:30]; Motivation as the key to high-level learning: how Alpha School fosters motivation with its "Timeback" model and leverages AI to accelerate learning [28:45]; Core principles of learning: how high standards, mastery-based instruction, and supportive struggle foster both academic excellence and personal growth [35:45]; Breaking down self-imposed limitations with foundational skills, defined time requirements, and a mastery model [41:15]; Using short-term extrinsic rewards to help students overcome limiting beliefs and ignite lasting intrinsic motivation [46:45]; $100 for 100: a simple but powerful incentive system that helps students fill academic gaps and master fundamentals [53:45]; How AI is the pivotal technology that can finally allow proven learning science to scale and unlock unprecedented student potential [57:45]; The emergence of generative AI that catalyzed Joe's billion-dollar investment in education [1:09:45]; The path and obstacles to integrating Alpha's AI-powered model into mainstream education [1:12:00]; Reimagining schooling from the ground up across five key dimensions [1:22:30]; The potential of this educational approach to reduce inequality in academic success [1:30:00]; Why the biggest challenge to scaling Alpha's AI-driven education is cultural adoption and systemic redesign [1:34:00]; Peter's daughter's experience at Alpha School [1:38:30]; Alpha School's expansion plans and need for people and resources for maximum impact [1:42:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#366 ‒ Transforming education with AI and an individualized, mastery-based education model | Joe Liemandt

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this special episode of The Drive, Peter hosts a strength and conditioning roundtable with three experts in the field—Gabrielle Lyon, Jeff Cavaliere, and Mike Boyle. Together they explore why maintaining muscle mass, strength, and power is essential for healthspan and longevity, and examine how resistance training supports metabolic resilience and injury prevention across the lifespan. The conversation covers practical strategies for getting started and staying consistent, the importance of a protein-centered diet tailored to age and activity level, and approaches to resistance training for peri- and post-menopausal women—including tendon care and optimal programming. They debate single-leg training versus heavy bilateral lifts, share knee-friendly lower-body options, and highlight exercises that belong in the "graveyard" due to poor risk-reward ratios. Finally, the group discusses youth sports specialization, emphasizing the long-term value of variety for developing lifelong athletes. We discuss:  Personal career journeys and philosophies of each guest that shaped their approaches to strength, conditioning, and lifelong health [3:30]; Why so few people engage in resistance training despite its proven health benefits [8:30]; Mike's low-stress, high-consistency method for training beginners to resistance training [18:45]; How resistance training enhances metabolic health and body composition even in lean, highly active endurance athletes [25:30]; The dominant role of nutrition in shaping physique and achieving low body fat, the synergistic effect of resistance training, and the unrealistic expectations about muscle growth and fat loss [28:30]; Why Jeff advocates for five meals a day, and why meal timing matters less than overall protein intake and caloric consistency [38:00]; Optimizing protein for every stage of life: quality, quantity, and guidelines for diverse diets and body types [44:15]; The advantages of unilateral lower-body training over heavy bilateral lifts: impact on strength, athleticism, recovery, and functional movement [51:45]; Rethinking heavy squats and deadlifts: risk-reward, aging bodies, and the case for reverse lunges and other single-leg alternatives [1:01:15]; Adapting with age: Gabrielle on injuries, hip dysplasia, and the shift to smarter training [1:10:15]; Exercises that belong in the "iron graveyard": unnecessarily risky exercises and their safer alternatives [1:19:15]; The downside of early sports specialization in children and the long-term benefits of encouraging kids to play multiple sports [1:25:00]; Advice for preventing an Achilles injury: calf strength, ankle mobility, and listening to pain signals [1:33:15]; Shoulder pain: how to keep training the upper body when shoulder pain limits pressing movements [1:40:45]; Effective strength training strategies for women before, during, and after the menopausal transition [1:43:15]; Best practices for strength training and athletic development in children, and the pitfalls of early sports specialization [1:50:30]; How to foster healthy habits and an interest in fitness beyond playing sports [2:00:00]; Something each guest has changed their mind about in the last five years [2:04:00]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#365 ‒ Training for longevity: A roundtable on building strength, preventing injury, meeting protein needs, guidance for women and youth athletes, and more | Gabrielle Lyon, Mike Boyle, Jeff Cavaliere

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter explores how to determine the right diet for yourself rather than searching for a universal "best" diet. He begins by laying out five non-negotiable criteria that any sustainable eating pattern must meet—energy balance, metabolic health, adequate protein, micronutrient sufficiency, and long-term adherence—before introducing a practical rubric for evaluating different diets. Using this framework, Peter walks through the ketogenic, carnivore, vegan, and Mediterranean diets, highlighting their strengths, ideal candidates for each, and common pitfalls such as micronutrient gaps or adherence challenges. He explains why this guidance is aimed at people who feel overwhelmed by diet choices, not zealots defending a single approach, and provides practical advice on using tools like DEXA scans, lab markers, continuous glucose monitors, and symptom tracking to assess whether a diet is truly working. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #75 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  Peter's family chess battle [3:00]; Framing the diet discussion: moving past tribalism to practical frameworks for evaluating various dietary strategies [5:00]; Peter's high-level nutrition framework [11:00]; Why diet is such a uniquely polarizing subject [14:15]; The five non-negotiables that apply to any diet [17:45]; How to think about energy balance in the context of evaluating a specific diet [20:15]; How diet can address metabolic health [21:45]; Protein as a dietary foundation [23:30]; Micronutrient essentials: avoiding deficiencies in restrictive and processed diets [24:45]; Why adherence and sustainability are essential for diet success [27:15]; Examining the standard American diet through the five non-negotiables [31:00]; The evaluation framework for specific diets [33:30]; The ketogenic diet: defining ketosis, clinical origins, modern uses, and potential health benefits [35:00]; The main strengths and weaknesses of the ketogenic diet [43:00]; How to avoid micronutrient deficiencies while on a ketogenic diet [47:15]; Electrolytes and fiber and the ketogenic diet: preventing magnesium loss and maintaining digestive health [49:15]; Adherence challenges of the ketogenic diet [51:30]; The carnivore diet: definition, motivations, anecdotal benefits, and possible mechanisms [53:15]; The main strengths and weaknesses of the carnivore diet [57:30]; Plant exclusion on the carnivore diet: nutrient gaps, gut changes, and unanswered questions [1:03:15]; Adherence challenges of the carnivore diet [1:04:45]; The vegan diet: definition, core beliefs, and various motivations for this strategy [1:05:45]; The main strengths and weaknesses of the vegan diet [1:09:15]; Adherence to the vegan diet: social acceptance, edge cases, and personal sustainability [1:13:15]; The Mediterranean diet: definitional challenges, traditional patterns, and its relatively strong evidence base [1:15:15]; Limitations of the Mediterranean diet: loose definitions and indulgence risks [1:19:30]; Measuring diet success: why setting clear goals and tracking outcomes matter [1:21:00]; Tracking body composition using DEXA scans [1:22:15]; Tracking metabolic health: key blood tests and advanced glucose monitoring tools [1:22:45]; Using elimination diets to identify food sensitivities that may cause digestive problems, autoimmune symptoms, or low energy [1:23:30]; Evaluating "anti-inflammatory diets": confirming inflammation through symptoms and hs-CRP testing [1:25:15]; Final takeaways: flexibility, structure, and avoiding dogma in dietary choices [1:27:00]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#364 – AMA #75: Diets: how to evaluate and implement any diet including keto, carnivore, vegan, Mediterranean, and more

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Edward Chang is a neurosurgeon, scientist, and a pioneering leader in functional neurosurgery and brain-computer interface technology, whose work spans the operating room, the research lab, and the engineering bench to restore speech and movement for patients who have lost these capabilities. In this episode, Edward explains the evolution of modern neurosurgery and its dramatic reduction in collateral damage, the experience of awake brain surgery, real-time mapping to protect critical functions, and the split-second decisions surgeons make. He also discusses breakthroughs in brain-computer interfaces and functional electrical stimulation systems, strategies for improving outcomes in glioblastoma, and his vision for slimmer, safer implants that could turn devastating conditions like ALS, spinal cord injury, and aggressive brain tumors into more manageable chronic illnesses. We discuss:  The evolution of neurosurgery and the shift toward minimally invasive techniques [2:30]; Glioblastomas: biology, current treatments, and emerging strategies to overcome its challenges [10:45]; How brain mapping has advanced from preserving function during surgery to revealing how neurons encode language and cognition [16:30]; How awake brain surgery is performed [22:00]; How brain redundancy and plasticity allow some regions to be safely resected, the role of the corpus callosum in epilepsy surgery, and the clinical and philosophical implications of disconnecting the hemispheres [26:15]; How neural engineering may restore lost functions in neurodegenerative disease, how thought mapping varies across individuals, and how sensory decline contributes to cognitive aging [39:15]; Brain–computer interfaces explained: EEG vs. ECoG vs. single-cell electrodes and their trade-offs [48:30]; Edward's clinical trial using ECoG to restore speech to a stroke patient [1:01:00]; How a stroke patient regained speech through brain–computer interfaces: training, AI decoding, and the path to scalable technology [1:10:45]; Using brain-computer interfaces to restore breathing, movement, and broader function in ALS patients [1:28:15]; The 2030 outlook for brain–computer interfaces [1:34:00]; The potential of stem cell and cell-based therapies for regenerating lost brain function [1:38:00]; Edward's vision for how neurosurgery and treatments for glioblastoma, Parkinson's disease, and Alzheimer's disease may evolve by 2040 [1:42:15]; The rare but dangerous risk of vertebral artery dissections from chiropractic neck adjustments and high-velocity movements [1:44:45]; How Harvey Cushing might view modern neurosurgery, and how the field has shifted from damage avoidance to unlocking the brain's functions [1:46:15]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#363 ‒ A new frontier in neurosurgery: restoring brain function with brain-computer interfaces, advancing glioblastoma care, and new hope for devastating brain diseases | Edward Chang, M.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Stuart McGill is a distinguished professor emeritus at the University of Waterloo and the chief scientific officer at Backfitpro where he specializes in evaluating complex cases of lower back pain from across the globe. In this episode, Stuart engages in a deep exploration of lower back pain, starting with the anatomy of the lower back, the workings of the spine, the pathophysiology of back pain, and areas of vulnerability. He challenges the concept of nonspecific back pain, emphasizing the importance of finding a causal relationship between injury and pain. Stuart highlights compelling case studies of the successful treatment of complex cases of lower back pain, reinforcing his conviction that nobody needs to suffer endlessly. He also covers the importance of strength and stability, shares his favorite exercises to prescribe to patients, and provides invaluable advice for maintaining a healthy spine. We discuss:  Peter's experience with debilitating back pain [3:00]; Anatomy of the back: spine, discs, facet joints, and common pain points [14:15]; Lower back injuries and pain: acute vs. chronic, impact of disc damage, microfractures, and more [24:30]; Why the majority of back injuries happen around the L4, L5, and S1 joints [30:45]; How the spine responds to forces like bending and loading, and how it adapts to different athletic activities [36:00]; The pathology of bulging discs [43:00]; The pathophysiology of Peter's back pain, injuries from excessive loading, immune response to back injuries, muscle relaxers, and more [45:45]; The three most important exercises Stuart prescribes, how he assesses patients, and the importance of tailored exercises based on individual needs and body types [56:00]; The significance of strength and stability in preventing injuries and preserving longevity [1:08:00]; Stuart's take on squats and deadlifting: potential risks, alternatives, and importance of correct movement patterns [1:19:15]; Helping patients with psychological trauma from lower back pain by empowering them with the understanding of the mechanical aspects of their pain [1:29:45]; Empowering patients through education and understanding of their pain through Stuart's clinic and work through BackFitPro [1:38:30]; When surgical interventions may be appropriate, and "virtual surgery" as an alternative [1:46:30]; Weakness, nerve pain, and stenosis: treatments, surgical considerations, and more [1:55:15]; Tarlov cysts: treatment and surgical considerations [2:00:00]; The evolution of patient assessments and the limitations of MRI [2:02:00]; Pain relief related to stiffness and muscle bulk through training [2:06:45]; Advice for the young person on how to keep a healthy spine [2:14:00]; Resources for individuals dealing with lower back pain [2:25:15]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

Lower back pain: causes, treatment, and prevention of lower back injuries and pain | Stuart McGill, Ph.D. (#287 rebroadcast)

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter explains how to evaluate sugar and its substitutes in the context of health. Peter explores the role of sweeteners in three common use-cases – beverages, protein supplements, and sweet treats – and breaks down how our evolutionary craving for sweetness now clashes with today's food environment. He examines whether sugar is uniquely fattening, the hormonal effects of sugar consumption, and the significance of timing in sugar intake. The episode compares natural versus refined sugars, sugar in beverages versus in solid foods, and the pros and cons of popular sweeteners including saccharin, aspartame, sucralose, allulose, and sugar alcohols like erythritol and xylitol. With a focus on weight management, glycemic impact, gut health, and long-term safety, this episode offers a comprehensive guide to navigating the sweetener landscape with clarity and nuance. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #74 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  A quick tangent on chess and parenting [2:30]; Overview of key scenarios for evaluating sugar and sweeteners [6:15]; Why humans are hardwired to crave sweetness [13:30]; Evaluating whether sugar is uniquely fattening or more harmful than other macronutrients under isocaloric conditions [15:15]; Why sugar drives appetite: low satiety, insulin response, and reward system activation [18:45]; How sugar type, liquid vs. solid form, and processing level influence appetite and metabolic impact [20:15]; Addressing the common belief that natural sugars are healthier than refined sugars [26:00]; How the timing of sugar consumption alters the body's metabolic response [29:15]; How Peter advises patients on sugar intake, factoring in metabolic health, insulin sensitivity, and activity level [34:45]; The most common sugar substitutes, their sweetness relative to sugar, and their caloric content [36:30]; Evaluating the role of sugar substitutes in weight control: efficacy vs. effectiveness and limitations in study design [40:15]; Assessing the real-world impact of sugar substitutes on weight, and the role of sweetness without calories [44:00]; The impact of sugar substitutes on glycemic control [47:30]; Are microbiome changes from artificial sweeteners substantial enough to cause obesity and diabetes? [50:30]; How Peter advises patients on the use of sugar substitutes across different contexts [52:30]; Allulose—a sweetener with unique satiety and glycemic benefits and potential for weight control [57:15]; Emerging evidence that stevia, monk fruit, and sugar alcohols may provide modest metabolic benefits compared to sugar [1:03:00]; Sugar alcohols explained [1:04:15]; Sugar alcohols and GI issues [1:05:00]; Xylitol's dental health benefits and considerations for use [1:06:30]; Artificial sweeteners and cancer risk: evaluating evidence, the aspartame controversy, and the role of dose in toxicology [1:07:15]; Sugar substitutes and cardiovascular disease: assessing flawed studies and the absence of direct risk evidence [1:11:00]; Why artificial sweeteners seem to attract so many negative headlines [1:12:45]; Balancing benefits and risks of sugar substitutes: guidance for desserts, beverages, and protein products [1:14:15]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#361 - AMA #74: Sugar and sugar substitutes: weight control, metabolic effects, and health trade-offs

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Charles Duhigg is a Pulitzer Prize-winning journalist and best-selling author known for distilling complex neuroscience and psychology into practical strategies for behavior change, performance, and decision-making. In this episode, Charles explores the neuroscience behind habit formation, including how cue-routine-reward loops drive nearly half of our daily actions and why positive reinforcement is far more effective than punishment. He explains how institutions like the military and Alcoholics Anonymous engineer environments to change behavior at scale, as well as discussing the limits of willpower and how to preserve it by shaping context. The conversation also covers the real timeline of habit formation, how to teach better habits to kids, the role of failure and self-compassion in lasting change, and the power of social accountability. Charles further discusses how cognitive routines enhance productivity and creativity, how to gamify long-term goals through immediate rewards, why identity and purpose are often the strongest forces behind sustainable behavior change, and the potential of AI to power habit change. We discuss:  How Charles's background in journalism and personal experiences led to his interest in habit formation [3:15]; The science behind reinforcement: why positive rewards outperform punishment in habit formation [10:15]; How the military uses habit science to train soldiers using cues, routines, and rewards [17:15]; Methods for creating good habits and eliminating bad ones: environmental control, small wins, rewards-based motivation, and more [24:00]; How parents can teach kids to build habits and strengthen willpower [32:15]; How adults experience changes in motivation and cue effectiveness over time, and why willpower must be managed like a finite resource [34:30]; Keys to successful habit change: planning for relapse, learning from failure, and leveraging social support [38:00]; Advice for parents: praise effort, model habits, and normalize failure [47:45]; The time required for making or breaking a habit [50:45]; The different strategies for creating new habits vs. changing existing ones, and the crucial role of cues and reward timing [55:15]; How to create habits around long-term goals when the rewards are delayed (like saving money) [1:01:45]; How to stick with good habits that offer no immediate reward: designing reinforcements and identity-based motivation [1:11:15]; The potential for AI to provide social reinforcement [1:16:45]; Mental habits: how thought patterns and contemplative routines shape deep thinking, innovation, and high-stakes performance [1:23:30]; How cognitive routines boost productivity and habit formation but may stifle creativity [1:35:15]; Contemplative routines: using stillness to unlock deeper productivity and creativity [1:40:45]; How habits reduce decision fatigue and enable deep, high-quality productivity [1:44:15]; New research that reveals the power of environment and social feedback in habit formation [1:49:45]; How AI may transform work, identity, and our sense of purpose [1:53:45]; The potential of AI-powered habit change, and the essential—but often lacking—element of motivation [2:02:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#360 ‒ How to change your habits: why they form and how to build or break them | Charles Duhigg, M.B.A

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Eric Verdin is a physician-scientist and the CEO of the Buck Institute for Research on Aging whose career has centered on understanding how epigenetics, metabolism, and the immune system influence the aging process. In this episode, Eric traces his scientific journey from studying viruses and histone deacetylases (HDACs) to leading aging research at the Buck Institute, offering insights into how aging impairs immune and nervous system function—including thymic shrinkage, chronic inflammation, and reduced vaccine response—and how these changes impact lifespan. He explores the metabolic underpinnings of aging, such as oxidative stress and insulin and IGF-1 signaling, and he discusses practical tools like zone 2 cardio, ketogenic diets, and GLP-1 drugs. The conversation also covers declining NAD levels with age, the roles of NAD-consuming enzymes such as sirtuins and CD38, and what current NAD-boosting strategies (like NMN, NR, and IV NAD) can and can't accomplish. Eric weighs in on promising longevity interventions including rapamycin, growth hormone for thymic regeneration, and anti-inflammatory therapies, while also examining the promise and limitations of current biological age tests and the potential of combining epigenetic, proteomic, and organ-specific metrics with wearables to guide personalized longevity care. We discuss:  Eric's scientific journey from virology to the field of geroscience [2:45]; How dysfunction in the immune system and central nervous system can drive aging throughout the body [5:00]; The role of metabolism and oxidative stress in aging, and why antioxidant strategies have failed to deliver clear benefits [8:45]; Other aspects of metabolism linked to aging: mitochondrial efficiency, fuel utilization, and glucose-modulating drugs [16:30]; How inefficient glucose metabolism drives insulin, IGF-1 signaling, and accelerates aging [21:45]; The metabolic effects of GLP-1 agonists, and the need to move beyond crude metrics like BMI in favor of more precise assessments of metabolic health [27:00]; The case for immune health as a "fifth horseman" [36:00]; How the innate and adaptive immune systems work together to build immune memory [39:45]; Why vaccines lose effectiveness with age: shrinking of the thymus gland and diminished T-cell diversity [44:15]; Exploring growth hormone, thymic regeneration, and the role of exercise in slowing immune aging [48:45]; The challenges of identifying reliable biomarkers for immune function, and the potential of rapamycin analogs to enhance vaccine response in older adults [57:45]; How rapamycin's effects on the immune system vary dramatically by dosage and frequency [1:03:30]; The limitations of mouse models in aging research and the need for cautious interpretation of rapamycin's benefits in humans [1:08:15]; NAD, sirtuins, and aging: scientific promise amid commercial hype [1:15:45]; How CD38 drives age-related NAD decline, influences immune function, and may impact longevity [1:23:45]; How NMN and NR supplementation interact with CD38 and NAD metabolism, and potential risks like homocysteine elevation and one-carbon cycle depletion [1:31:00]; Intravenous NAD: limited evidence and serious risks [1:37:00]; Interleukin-11 (IL-11) as a new target in immune aging, the dual role of chronic inflammation in aging, and the need for better biomarkers to guide interventions [1:43:00]; Biological aging clocks: types of clocks, promise, major limitations, and future outlook [1:48:30]; The potential of proteomics-based aging clocks for detecting organ-specific decline and frailty [2:00:45]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#359 ‒ How metabolic and immune system dysfunction drive the aging process, the role of NAD, promising interventions, aging clocks, and more | Eric Verdin, M.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this quarterly podcast summary (QPS) episode, Peter summarizes his biggest takeaways from the last three months of guest interviews on the podcast. Peter shares key insights from his discussions with Paul Turek and Paula Amato on male and female fertility; Rachel Rubin on menopause and hormone replacement therapy; Brian Kennedy on the biology of aging; Tanuj Nakra and Suzan Obagi on facial aging and skin rejuvenation; and BJ Miller and Bridget Sumser on lessons we can learn from the dying about how to live. Peter highlights the most important insights from each episode and any behavioral changes he's made for himself or his patients as a result of these fascinating discussions. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the episode #358 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  Summary of episode topics [1:15]; Episodes on fertility with Paul Turek and Paula Amato: insights on all things male and female fertility [4:45]; How men can optimize fertility [20:15]; How women can optimize fertility [26:00]; Rachel Rubin episode: insights on women's sexual health, menopause, and HRT [31:45]; How women can prepare for menopause: proactive care, evidence-based HRT, and more [41:45]; Brian Kennedy episode: understanding aging, role of inflammation and mTOR, and current limitations of aging clocks and biomarkers [46:30]; Advice from Brian Kennedy on testing longevity interventions [56:45]; Tanuj Nakra/Suzan Obagi episode: causes of facial aging and practical strategies for prevention and treatment [57:30]; Skincare: making sense of the wide range of skin resurfacing treatments [1:06:45]; How to create a realistic, sustainable skincare routine [1:12:30]; The dangers of following unqualified aesthetic advice online and the importance of getting professional medical guidance for cosmetic treatments [1:18:00]; BJ Miller/Bridget Sumser episode: lessons about living from the dying [1:21:45]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#358 ‒ Peter's takeaways on navigating HRT, rejuvenating the face, understanding the biology of aging, optimizing fertility, and learning to live well from the dying | Quarterly Podcast Summary #6

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Brian Kennedy is a renowned biologist, leader in aging research, and director of the Center for Healthy Longevity at the National University of Singapore. In this episode, Brian shares insights from ongoing human aging studies, including clinical trials of rapamycin and how dosing strategies, timing, and exercise may influence outcomes. He presents two key models of aging—one as a linear accumulation of biological decline and the other as an exponential rise in mortality risk—and explains why traditional models of aging fall short. He also explains why most current aging biomarkers lack clinical utility and describes how his team is working to develop a more actionable biological clock. Additional topics include the potential of compounds like alpha-ketoglutarate, urolithin A, and NAD boosters, along with how lifestyle interventions—such as VO2 max training, strength building, and the use of GLP-1 and SGLT2 drugs—may contribute to longer, healthier lives. We discuss:  Brian's journey from the Buck Institute to Singapore, and the global evolution of aging research [2:45]; Rethinking the biology of aging: why models like the hallmarks of aging fall short [9:45]; How inflammation and mTOR signaling may play a central, causal role in aging [14:15]; The biological role of mTOR in aging, and the potential of rapamycin to slow aging and enhance immune resilience [17:30]; Aging as a linear decline in resilience overlaid with non-linear health fluctuations [22:30]; Speculating on the future of longevity: slowing biological aging through noise reduction and reprogramming [33:30]; Evaluating the role of the epigenome in aging, and the limits of methylation clocks [39:00]; Balancing the quest for immortality with the urgent need to improve late-life healthspan [43:00]; Comparing the big 4 chronic diseases: which are the most inevitable and modifiable? [47:15]; Exploring potential benefits of rapamycin: how Brian is testing this and other interventions in humans [51:45]; Testing alpha-ketoglutarate (AKG) for healthspan benefits in aging [1:01:45]; Exploring urolithin A's potential to enhance mitochondrial health, reduce frailty, and slow aging [1:05:30]; The potential of sublingual NAD for longevity, and the combination of NAD and AKG for metabolic and exercise enhancement [1:09:00]; Other interventions that may promote longevity: spermidine, 17𝛼-estradiol, HRT, and more [1:17:00]; Biological aging clocks, clinical biomarkers, and a new path to proactive longevity care [1:23:15]; Evaluating rapamycin, metformin, and GLP-1s for longevity in healthy individuals [1:32:15]; Why muscle, strength, and fitness are the strongest predictors of healthspan [1:37:30]; Why combining too many longevity interventions may backfire [1:39:30]; How increased funding and AI integration could accelerate breakthroughs in aging research [1:41:45]; The research Brian is most excited about, and the need to balance innovation with safety in longevity clinics [1:47:00]; Peter's reflections on emerging interventions and the promise of combining proven aging compounds [1:54:00]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#357 ‒ A new era of longevity science: models of aging, human trials of rapamycin, biological clocks, promising compounds, and lifestyle interventions | Brian Kennedy, Ph.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter addresses frequently requested topics, including brain health, exercise programming, and body composition. He explores the factors that influence dementia risk—including metabolic health, fitness, sleep, hearing, cholesterol levels, and more. He explains how to implement zone 2 training and VO₂ max intervals for cardiovascular fitness and also covers how to combine cardio modalities, how to stay in zone 2, and special considerations for women. Peter highlights the benefits of light movement after meals and offers strength training tips for those managing injuries. Additional insights include how to maintain fat loss, the truth about so-called "slow metabolisms," and how to set appropriate daily protein goals while managing the trade-off between lean mass and body fat over time. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #73 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  Overview of episode topics on brain health, cardiovascular training strategies, and body composition [2:15]; Understanding dementia risk: modifiable vs. non-modifiable contributors to cognitive decline [5:00]; The causality between metabolic health and dementia [9:45]; How diet and exercise influence brain health: energy balance and exercise as key preventative tools [13:30]; Why combining aerobic, resistance, and cognitively engaging activities offers the most comprehensive benefits for preventing cognitive decline [17:00]; Additional lifestyle factors that influence dementia risk: smoking, head trauma, alcohol, and sleep [19:45]; The link between hearing loss and dementia: dose-dependent risk and the case for correction [25:15]; How poor oral hygiene may contribute to neuroinflammation and dementia risk [27:30]; Supplements for brain health: which ones matter and when they're worth considering [28:45]; Low LDL cholesterol and brain health: debunking the myth of cognitive risk [33:45]; How to approach zone 2 training: the importance of staying in zone 2 and tailoring intensity based on your time and goals [38:00]; Lactate testing for zone 2: clinical protocols and at-home approaches [43:00]; Combining modalities in zone 2 training: balancing enjoyment and efficiency [47:00]; Zone 2 training for women: addressing the misconception that zone 2 training is unnecessary or ineffective for postmenopausal women [49:30]; Effective strategies for VO₂ max training: short vs. long intervals [51:45]; The benefits of post-meal walking for glucose management, and why spikes in glucose during exercise aren't harmful [56:45]; The role of stability training in supporting resistance work and healthy aging [1:00:15]; Adapting strength training to manage chronic back injuries and train for longevity [1:02:00]; The role of aerobic exercise (like zone 2) in fat loss, metabolic health, and weight maintenance [1:06:30]; Debunking the "fast vs. slow metabolism" myth: why energy balance and protein matter most for fat loss [1:09:45]; Lean mass vs. body fat: why both matter for health and longevity [1:12:15]; How protein intake impacts muscle mass and why pairing it with resistance training is significantly more effective [1:15:15]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#356 - AMA #73: Preserving brain health, optimizing exercise programming, improving body composition, and more

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this episode from July 2022, Peter dives deep into the topic of bone health and explains why this is an important topic for everyone, from children to the elderly. He begins with an overview of bone mineral density, how it's measured, how it changes over the course of life, and the variability between sexes largely due to changes in estrogen levels. From there he provides insights into ways that one can improve bone health, from exercise to nutrition supplements to drugs. Additionally, Peter discusses what happens when one may be forced to be sedentary (e.g., bedrest) and how you can work to minimize the damage during these periods. While this original episode is an AMA, it is available in full to all listeners as a special rebroadcast. We discuss:  Overview of bone health topics to be discussed [2:30]; Bones 101: bone function, structure, and more [6:15]; Bone mineral density (BMD), minerals in bone, role of osteoblasts and osteoclasts, and more [9:30]; The consequences of poor bone health [14:30]; The devastating nature of hip fractures: morbidity and mortality data [18:00]; Where fractures tend to occur in the body [23:45]; Defining osteopenia and osteoporosis [25:30]; Measuring BMD with DEXA and how to interpret scores [28:00]; Variability in BMD between sexes [35:15]; When should people have their first bone mineral density scan? [37:45]; How BMD changes throughout the life and how it differs between men and women [40:15]; How changes in estrogen levels (e.g., menopause) impact bone health [45:15]; Why HRT is not considered a standard of care for postmenopausal bone loss [49:00]; Factors determining who may be at higher risk of poor bone health [52:00]; Common drugs that can negatively impact BMD [55:45]; How children can optimize bone health and lay the foundation for the future [59:30]; Types of physical activity that can positively impact bone health [1:03:30]; How weight loss can negatively impact bone health and how exercise can counteract those effects [1:12:15]; Nutrition and supplements for bone health [1:16:00]; Pharmaceutical drugs prescribed for those with low BMD [1:18:45]; Impact of extreme sedentary periods (e.g., bedrest) and how to minimize their damage to bone [1:23:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

Navigating bone health: early life influences and advanced strategies for improvement and injury prevention (#214 rebroadcast)

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Tanuj Nakra and Suzan Obagi, two leading experts in aesthetic medicine, join Peter to explore the science of facial aging and skin health as well as the responsibilities physicians face in the world of cosmetic procedures. In this episode, they examine the biological and hormonal drivers of facial aging, the evolutionary and psychological foundations of attractiveness, and the impact of modern media on beauty standards. They discuss the rise in cosmetic procedures among adolescents and the ethical responsibilities of physicians in these cases. The conversation then shifts to a practical, evidence-based guide to skin health—covering the use of mineral sunscreens, retinoids, vitamin C, and tailored skincare routines, as well as the management of acne and the psychology behind aesthetic consultations. The episode culminates in a candid, personal assessment of Peter's own face, offering a revealing look at what aesthetic medicine can achieve and how to think critically about pursuing it. We discuss:  Tanuj's and Suzan's training and expertise, and the evolving field of aesthetic medicine [4:00]; The biology of the aging face [10:45]; Why facial fat atrophies with age while body fat tends to accumulate [17:00]; How chronic stress accelerates facial aging [20:30]; The evolutionary biology of beauty, and how modern lifestyle, culture, and medicine interact with these ancient aesthetic instincts [25:30]; How social media and influencers have rapidly shifted aesthetic trends toward exaggerated features and unrealistic beauty standards [36:45]; The ethical challenges, financial incentives, and social pressures shaping modern aesthetic medicine [42:00]; The concerning trend of teenagers seeking cosmetic enhancements: the ethical and cultural impact of early beauty pressure [51:45]; Protecting the skin: UV damage and sunscreen recommendations [58:15]; Strategies for minimizing skin aging: retinoids, vitamin C, and evidence-based application methods [1:09:00]; Effective daily skincare routine: cleansing, antioxidants, retinoids, moisturization, and more [1:18:45]; The playbook for managing acne [1:31:00]; The 4 changes of aging and the complexities of aesthetic consultations including the anatomical, psychological, and ethical factors physicians must navigate [1:39:00]; The 5 R's of rejuvenation [1:50:15]; A facial aging analysis and cosmetic strategy using Peter's face as a real-time case study [1:53:00]; The decision-making process between fat grafting and dermal fillers for facial rejuvenation [1:56:30]; How self-image, eye aesthetics, and fleeting photos drive the desire for cosmetic enhancement [2:01:45]; Advice for wrinkles, causes of dark circles under the eyes, and the importance of facial symmetry [2:05:45]; Considerations that shape clinical decision making around fat grafting and other procedures to address the eye area [2:11:00]; The evolution of facial cosmetic surgery techniques, the serious risks involved, and how physician skill and procedure selection greatly impact outcomes [2:21:30]; How patients can make informed and safe choices when selecting a cosmetic surgeon [2:27:15]; A comparison of ablative versus non-ablative skin resurfacing treatments, laser vs. peels, and more [2:38:45]; How treatments are chosen and customized based on patient-specific factors [2:48:00]; The lifelong human desire to align physical appearance with self-identity [2:52:45]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#355 – Skincare strategies, the science of facial aging, and cosmetic-intervention guidance | Tanuj Nakra, M.D. & Suzan Obagi, M.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter BJ Miller, a hospice and palliative care physician, and Bridget Sumser, a licensed social worker specializing in serious illness and end-of-life care, join Peter to share insights from their decades of work supporting people at the end of life. In this episode, they explore the emotional and physiological processes of dying, the cultural barriers that prevent meaningful conversations about death, and how early engagement with mortality can lead to greater clarity and connection. The conversation highlights the distinctions between hospice and palliative care, the nature of suffering beyond physical pain, and the transformative role of honesty, forgiveness, and relational awareness in the dying process. Through stories and reflections, BJ and Bridget reveal what truly matters in the end—and how the dying can teach the living not only how to face death but how to live more fully. We discuss:  The personal journeys of BJ and Bridget into end-of-life care, and the connection between living and dying [3:30]; What dying looks like: the physical, cognitive, and emotional realities at the end of life [13:15]; How historical perspectives on death contrast with modern experiences of dying [25:30]; The difference between palliative care and hospice care [30:45]; The systemic challenges surrounding hospice care: why patients often enter it too late to receive its full benefits [35:30]; How delayed hospice referrals and unspoken preferences often prevent patients from dying where and how they truly want [39:30]; The realities of home hospice: challenges, costs, and burdens placed of families [43:45]; How proactively engaging with the reality of death can avoid unnecessary suffering and promote a more peaceful ending [53:30]; How palliative care is misunderstood and underutilized—especially in cancer care [1:02:45]; Palliative care in the case of Alzheimer's disease: emotional support, future planning, and family involvement [1:12:15]; The importance of having an advance directive: defining what matters most before it's too late [1:23:00]; The differences between how young and old individuals experience dying from cancer [1:30:15]; The difference between pain and suffering, role of medicine in pain relief, and why emotional healing is essential at the end of life [1:35:45]; Dying well: the power of self-honesty and human connection at the end of life [1:47:00]; How psychedelics like psilocybin can unlock emotional breakthroughs and deepen connection for patients near the end of life [1:55:15]; Lessons from the dying on how to live well [1:57:30]; The physical process of active dying, and the emotional and practical considerations for loved ones [2:09:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#354 – What the dying can teach us about living well: lessons on life and reflections on mortality | BJ Miller, M.D. and Bridget Sumser, L.C.S.W.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter revisits the topic of fasting, sharing how his thinking has evolved over time. The episode explores fasting-related terminology and common types of fasting, as well as the various reasons individuals might choose to fast. Peter explores potential benefits including improvements in body composition, metabolic health, lifespan extension, cardiovascular disease, cancer prevention and treatment, neurodegenerative conditions such as Alzheimer's and Parkinson's, and autoimmune symptoms like arthritis. He also examines the risks and potential downsides of fasting and offers a practical framework to help assess when and how fasting may be most appropriately applied. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #72 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  Why the topic of fasting is being revisited [1:45]; The importance of being open to changing one's opinion in science and medicine as new evidence emerges [4:15]; Defining fasting and how it fits in the framework of dietary restriction, time-restricted feeding, and calorie restriction [7:30]; The most common types of fasting [11:45]; Why someone might choose fasting over continuous caloric restriction [19:00]; The biochemical effects of fasting: fuel partitioning, autophagy, and more [21:00]; Autophagy: a cellular cleanup process stimulated by fasting and energy depletion [26:00]; Comparing the physiological effects of a ketogenic diet to those of long-term fasting [27:45]; How long fasting takes to induce ketosis and boost autophagy, and how autophagy is measured [29:45]; At-home tests for ketones [33:45]; Reducing senescent ("zombie") cells and inflammation through autophagy [35:00]; Examining the evidence for the long-term health benefits of fasting beyond short-term metabolic effects [37:15]; The common health claims associated with fasting across metabolic, neurological, oncological, autoimmune, and longevity domains [40:30]; The impact of fasting on body weight and body composition [42:00]; Weight regain and potential metabolic consequences of fasting [44:00]; The risk of lean mass loss with fasting and how to mitigate it [47:15]; A practical framework for using fasting as a strategy to improve body composition [52:15]; How extended fasting compares to caloric restriction in improving insulin sensitivity in people with insulin resistance or type 2 diabetes [54:00]; Is there any evidence that fasting can extend lifespan? [55:45]; Examining whether fasting improves cardiovascular disease risk beyond the effects of weight loss and calorie reduction [58:15]; Exploring whether prolonged fasting can reduce cancer risk [59:45]; The potential benefits of fasting or fasting-mimicking diets during cancer treatment: emerging evidence and practical considerations [1:02:15]; Fasting for protection against neurodegenerative diseases: early evidence of therapeutic benefit and open questions [1:10:45]; Various fasting methods for autoimmune diseases: potential symptom relief with cautious application [1:14:00]; Fasting and type 1 diabetes: risks, evidence, and careful dietary alternatives [1:16:45]; Fasting and gut disorders: potential benefits outside of flare-ups [1:18:45]; The primary risks and downsides associated with fasting [1:19:45]; The essential vitamins and minerals to supplement during prolonged fasting [1:21:30]; Who should avoid fasting and why [1:22:15]; Fasting's role in health: where it shows promise and where it likely offers no distinct advantage over caloric restriction [1:23:45]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#353 - AMA #72: Fasting: benefits for body composition and disease prevention, potential risks, and Peter's updated practical framework

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter This is part two of a two-part mini-series on fertility and reproductive health. Paula Amato is a leading expert in female reproductive health and infertility, widely recognized for her contributions to advancing fertility treatment and research. In this episode, which follows last week's conversation on male fertility, Paula explores the biology of female fertility, including how hormonal changes regulate the menstrual cycle and ovulation, what those patterns reveal about fertility potential, and why both partners should be evaluated early in infertility workups. She discusses the role of the fallopian tubes, the causes of miscarriage, the impact of age and lifestyle on fertility, and treatment options for conditions like PCOS—including the emerging use of GLP-1 agonists. The episode also covers the evolution of IVF, advances in pre-implantation genetic testing, egg freezing, and the promise and limitations of next-generation reproductive technologies. We discuss:  The finite nature of a woman's egg reserve, how it changes over time, and the basic process of ovulation and fertilization [3:00]; How hormones influence egg selection, and how and why chromosomal errors lead to most miscarriages [5:30]; The full journey of conception—from hormonal cues triggering ovulation, to fertilization, embryo development, implantation, and early pregnancy risks [16:30]; How infertility is defined and diagnosed, and the broader trends contributing to rising infertility rates [25:15]; Fallopian tube damage: how STDs and scarring impact fertility and raise ectopic pregnancy risk [31:30]; Unexplained infertility: how doctors evaluate ovulation and cycles—and why more research on women's health is needed [41:00]; The defining symptoms of polycystic ovary syndrome (PCOS), its hormonal characteristics, and its relationship with insulin resistance [44:00]; Managing PCOS without pregnancy: cycle regulation, androgen suppression, and insulin resistance treatment [46:00]; The treatment approach for women with PCOS who are trying to conceive: GLP-1 use, ovulation induction, and timing protocols [49:45]; Barriers to getting informed fertility care for PCOS: limited provider knowledge and access, insurance gaps, and next steps when ovulation treatments don't lead to pregnancy [55:45]; Fertility treatment for women with unexplained infertility, risk of multiple pregnancies with superovulation, and more [1:03:00]; Intrauterine insemination (IUI): process, success rates, and when in vitro fertilization (IVF) becomes the better option [1:07:00]; The history of in vitro fertilization (IVF), and how access and acceptance have evolved over time [1:16:45]; The step-by-step process of IVF [1:19:30]; The IVF lab process: egg retrieval, fertilization, embryo culture, and freezing [1:26:30]; Genetic testing and embryo selection in IVF: aneuploidy screening, polygenic traits, and ethical concerns [1:41:15]; Embryo transfer in IVF: timing, uterine preparation, and implantation support [1:47:30]; Egg donation in IVF: indications, donor guidelines, and other considerations [1:50:45]; How to choose the right IVF clinic [1:54:45]; Innovations in fertility on the horizon, advice about freezing eggs, and more [2:02:00]; Optimizing fertility through lifestyle: diet, stress management, sleep, exercise, and supplementation [2:07:45]; Promising areas of fertility research [2:15:45]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#352 ‒ Female fertility: optimizing reproductive health, diagnosing and treating infertility and PCOS, and understanding the IVF process | Paula Amato, M.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter This is part one of a two-part mini-series on fertility and reproductive health, with next week's guest, Dr. Paula Amato, focusing on the female side of the equation. Paul Turek is a world-renowned expert in male fertility and reproductive health, the founder and medical director of the Turek Clinic, and host of the Talk with Turek podcast. In this episode, Paul explores the topic of male fertility, offering a detailed look at the complex and highly coordinated process of conception and the many challenges sperm face on their journey to fertilizing an egg. He shares fascinating insights into how sperm work together to navigate the female reproductive tract, how environmental factors like heat, stress, and toxins impact sperm quality, and what men can do to improve their reproductive health. Paul also dispels common myths about testosterone replacement therapy and its effects on fertility, providing strategies for preserving fertility while on TRT. The episode also highlights cutting-edge advances in reproductive medicine, from genetic testing and sperm sorting to emerging treatments for infertility. We discuss:  The incredibly complex and hostile journey sperm must take to fertilize an egg [3:00]; How sperm are made: meiosis, genetic variation, and the continuous renewal influenced by environmental factors [9:00]; The built-in filter that weeds out genetically abnormal sperm [14:45]; How sperm are finalized in form and function: tail formation, energy storage, and chemical sensing abilities [18:30]; How to optimize conception through the timing of sex, ejaculation frequency, and understanding the sperm lifecycle [26:30]; Male infertility and Paul's diagnostic approach: detailed history, a physical exam, and identifying red flags [33:30]; Viral infections that can affect the testes and potentially lead to sterility [40:30]; Semen analysis: morphology, motility, and hormonal clues to male fertility [45:45]; Effects of medication, microplastics, stress, and exercise on fertility [57:15]; Testosterone replacement therapy (TRT) and male fertility [1:06:00]; Restoring fertility after prolonged use of exogenous testosterone [1:25:00]; Effects of heat and cold exposure on fertility and sperm quality [1:36:00]; How different levels of exercise—especially cycling—affect male fertility [1:41:45]; How alcohol, marijuana, and nicotine affect male fertility [1:46:00]; Why type 2 diabetes is a risk factor for male infertility [1:50:00]; How varicoceles—a common cause of male infertility—are diagnosed and treated [1:51:15]; Genetic factors that affect fertility [1:54:00]; The impact of lifestyle and environmental exposures on fertility [1:56:30]; The evidence (or lack thereof) behind stem cell and PRP therapies for male infertility, and how lifestyle and non-invasive interventions often lead to successful conception [2:00:30]; Considerations for sperm banking, and how paternal age impacts fertility planning and offspring health [2:05:00]; Semen quality as a biomarker: linking male fertility, longevity, and preventative health through Medicine 3.0 and epigenetics [2:14:45]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#351 ‒ Male fertility: optimizing reproductive health, diagnosing and treating infertility, and navigating testosterone replacement therapy | Paul Turek, M.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Kyler Brown is a sports rehab chiropractor who specializes in injury recovery, pre- and post-surgical rehabilitation, and guiding clients from rehab back to peak performance. As co-founder of the private training program 10 Squared alongside Peter, Kyler shares his approach to injury prevention and performance optimization—highlighting how overlooked movement patterns can quietly lead to chronic issues over time. He outlines a practical framework for assessing and treating individuals, highlights the importance of understanding movement dynamics and asymmetries, and discusses personalized rehab strategies through real-world case studies. The conversation also explores the psychological side of recovery, including the role of fear and mental barriers in rehabilitation. Kyler shares actionable tools to evaluate movement patterns and implement training strategies that support long-term strength and health. A companion video series demonstrating exercises for common problem areas—such as the lower back, neck, shoulders, and knees—is available exclusively to subscribers on the show notes page. We discuss:  The personalized rehab strategy for Peter's shoulder surgery that sparked creation of a training program called 10 Squared [3:00]; Training for the marginal decade: why precision and purpose are essential for quality of life [11:00]; The Centenarian Decathlon: how training for long-term capacity enhances both current and future quality of life [18:00]; How the shortcomings of conventional rehab and performance systems led to the creation of 10 Squared, a personalized training model focused on long-term physical capacity and individualized care [23:45]; Case study: how personalized assessment and treatment at 10 Squared helps uncover the root causes of injuries [31:00]; The role of the "core" in movement and injury prevention, and the importance of training stability before strength [40:15]; The layered assessment process used at 10 Squared to determine whether a person is ready to perform dynamic movements [47:45]; Case study: the rehab plan designed to treat a hamstring injury while preserving fitness and preventing reinjury [51:45]; Training approach for clients with minimal training history: risk reduction, habit-building, and long-term consistency [55:30]; How to train foot reactivity, tendon resilience, and explosive capacity in a safe, progressive way [1:00:00]; Peter's foot and ankle pain: how to diagnose, treat, and strengthen the lower extremities [1:04:15]; How fear and perception influence recovery, what drives back pain, and when to choose surgery vs. treatment [1:13:15]; Could AI and app technology eventually deliver an individualized rehab and training experience? [1:22:30]; Kyler's professional evolution from traditional chiropractic care to a degree-agnostic, performance-based rehab philosophy [1:25:00]; How 10 Squared provides precision rehab and training in a remote format [1:30:30]; How Peter resolved a severe back pain flare-up using DNS-guided isometric exercise instead of passive treatments [1:33:15]; How to identify and treat common joint pain (neck, back, knee, shoulder) using a rehab framework that strengthens supporting structures and helps avoid surgery [1:39:00]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#350 ‒ Injury prevention, recovery, and performance optimization for every decade | Kyler Brown, D.C.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter dives deep into the topic of muscle mass and strength, examining their essential roles in both lifespan and healthspan. Drawing from over 30 hours of prior discussions with experts including Layne Norton, Andy Galpin, and Mike Israetel, this episode distills the most important insights into one comprehensive and up-to-date conversation. Peter explores why muscle matters for longevity, metabolic health, and injury prevention, and clarifies the differences between muscle mass and strength, including which is more vital for aging well. He breaks down practical strategies for building muscle safely and effectively, including progressive overload, training intensity, rep ranges, and the importance of explosive power. Peter also covers key nutrition strategies—like protein intake, timing, and creatine supplementation—and offers practical advice for everyone from beginners to seasoned lifters on building and maintaining muscle safely and sustainably. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #71 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  Peter's humorous experience talking nutrition with a second grader [2:30]; Overview of topics, episode structure, and reasoning for focus on muscle mass and strength [6:00]; Defining key terms: muscle mass, strength, hypertrophy, power, and more [8:15]; The importance of muscular strength, muscle mass, and cardiorespiratory fitness for longevity [10:30]; Grip strength as a simple yet powerful predictor of all-cause mortality [16:45]; Is muscle strength causal or just a marker of health? [20:00]; Why VO2 max, strength, and muscle mass are powerful health markers: a reflection of long-term consistent effort [22:30]; How muscle mass and strength enhance healthspan by supporting metabolic health, inflammation control, recovery from illness, mobility, and fall prevention [23:45]; How muscle mass and strength decline with age, and why it's essential to act early to slow decline and preserve function later in life [30:30]; The foundational principles of building muscle strength and size through resistance training [35:30]; How to apply "progressive overload" for long-term strength and muscle gains [39:30]; The difference between concentric and eccentric muscle contractions and how each impacts strength, hypertrophy, and injury prevention [44:45]; The differences between muscle fiber types, and how aging disproportionately affects fast-twitch fibers responsible for power [50:15]; How to effectively train for power [52:00]; Training intensity: the benefits and safety of using the "reps in reserve" method [53:00]; How to balance compound and isolation exercises in a workout routine, and why compound lifts are foundational [55:45]; Can bodyweight exercises build muscle as effectively as weight training? [57:45]; How women can effectively build strength and muscle: key considerations [59:15]; Effective methods for tracking progress in strength [1:01:15]; Effective methods for tracking progress in muscle mass, and how to interpret results from a DEXA scan [1:04:30]; How to balance workout frequency with recovery for optimal results [1:06:45]; How to recognize signs of overtraining and when to consider taking rest days [1:10:15]; Avoiding injury: how beginners or returning lifters can start resistance training safely [1:15:15]; Protein: recommended intake, quality sources, timing of consumption, and more [1:17:30]; How fasting and calorie restriction affect muscle mass and what can be done to minimize muscle loss [1:24:15]; Key nutritional factors beyond protein that support muscle growth: hydration, creatine, and recovery [1:27:45]; The impact of hormones, sleep, stress, and consistency on muscle building and recovery [1:28:45]; How to structure an effective workout routine for a younger person that is new to resistance training [1:31:30]; How to modify beginner resistance training programs for older individuals to prioritize safety and gradual progress [1:35:30]; Should beginners start with machines or free weights when resistance training? [1:36:30]; How experienced lifters should modify their training to support healthspan and performance in later life [1:38:00]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#349 - AMA #71: Building strength and muscle mass: how to optimize training, nutrition, and more for longevity

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Rachel Rubin is a board-certified urologist and one of the nation's foremost experts in sexual health. In this episode, she shares her deep expertise on the often-overlooked topic of women's sexual health, exploring why this area remains so neglected in traditional medicine and highlighting the critical differences in how men and women experience hormonal decline with age. Rachel explains the physiology of the menstrual cycle, the complex hormonal shifts of perimenopause, and the wide-reaching health risks associated with menopause, including osteoporosis, cardiovascular disease, dementia, and recurrent urinary tract infections. She also breaks down the controversy surrounding hormone replacement therapy (HRT), particularly the damaging legacy of the Women's Health Initiative study, and provides guidance on the safe and personalized use of estrogen, progesterone, and testosterone in women. With particular emphasis on local vaginal hormone therapy—a safe, effective, and underused treatment—Rachel offers insights that have the potential to transform quality of life for countless women. We discuss:  Rachel's training in urology and passion for sexual medicine and women's health [3:00]; Hormonal changes during ovulation, perimenopause, and menopause: why they occur and how they impact women's health and quality of life [5:30]; Why women have such varied responses to the sharp drop in progesterone during the luteal phase and after menopause, and the differing responses to progesterone supplementation [14:45]; The physical and cognitive health risks for postmenopausal women who are not on hormone therapy [17:45]; The history of hormone replacement therapy (HRT), and how misinterpretation of the Women's Health Initiative study led to abandonment of HRT [20:15]; The medical system's failure to train doctors in hormone therapy after the WHI study and its lasting impact on menopause care [29:30]; The underappreciated role of testosterone in women's sexual health, and the systemic and regulatory barriers preventing its broader use in female healthcare [35:00]; The bias against HRT—how institutional resistance is preventing meaningful progress in women's health [46:30]; How the medical system's neglect of menopause care has opened the door for unregulated and potentially harmful hormone clinics to take advantage of underserved women [53:30]; The HRT playbook for women part 1: progesterone [57:15]; The HRT playbook for women part 2: estradiol [1:05:00]; Oral formulated estrogen for systemic administration: risks and benefits [1:13:15]; Topical and vaginal estrogen delivery options: benefits and limitations, and how to personalize treatment for each patient [1:17:15]; How to navigate hormone lab testing without getting misled [1:24:15]; The wide-ranging symptoms of menopause—joint pain, brain fog, mood issues, and more [1:31:45]; The evolution of medical terminology and the underrecognized importance of local estrogen therapy for urinary and vaginal health in menopausal women [1:37:45]; The benefits of vaginal estrogen (or DHEA) for preventing UTIs, improving sexual health, and more [1:41:00]; The use of DHEA and testosterone in treating hormone-sensitive genital tissues, and an explanation of what often causes women pain [1:50:15]; Is it too late to start HRT after menopause? [1:56:15]; Should women stop hormone therapy after 10 years? [1:58:15]; How to manage hormone therapy in women with BRCA mutations, DCIS (ductal carcinoma in situ), or a history of breast cancer [2:00:00]; How women can identify good menopause care providers and avoid harmful hormone therapy practices, and why menopause medicine is critical for both women and men [2:06:00]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#348 ‒ Women's sexual health, menopause, and hormone replacement therapy (HRT) | Rachel Rubin, M.D.

View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this quarterly podcast summary (QPS) episode, Peter summarizes his biggest takeaways from the last three months of guest interviews on the podcast. Peter shares key insights from his discussions with Jeff English on the journey to healing from trauma; Ashley Mason on improving sleep and CBT-I; Sanjay Mehta on misconceptions around radiation and its use in cancer therapy and treating inflammatory conditions (such as arthritis and tendonitis); Sean Mackey on understanding and treating acute and chronic pain; and Susan Desmond-Hellmann on insights from her extraordinary career that pertain to the use of AI in medicine, understanding cancer, and the development of cancer therapeutics. Additionally, Peter shares any behavioral changes he's made for himself or his patients as a result of these fascinating discussions. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the episode #347 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  Summary of episode topics [1:45]; Jeff English episode: how trauma shapes behavior and identity, and the value of understanding personal adaptations and working through unresolved emotional wounds [3:45]; Practical behavioral changes and emotional tools Peter has applied since the Jeff English episode [13:00]; Ashley Mason episode: treating insomnia using CBT-I and practical behavioral techniques for improving sleep quality [19:15]; When to seek professional care for sleep issues [30:30]; Sanjay Mehta episode: radiation therapy's evolution, its underused potential in treating inflammatory conditions, and the cultural misconceptions surrounding radiation exposure [33:45]; Peter's predictions and insights for the upcoming Formula 1 season [43:15]; Sean Mackey episode: the neuroscience, classifications, and treatment strategies for chronic pain, and the importance of personalized care [57:45]; Susan Desmond-Hellmann episode: how AI is revolutionizing medicine through advancements in drug development, biomarker discovery, and the potential of training models on private clinical data [1:05:45]; More from Susan Desmond-Hellmann: why cancer is so difficult to treat with drugs, the promise of immunotherapy, and the long-term hope for systemic treatments [1:14:00]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#347 – Peter's takeaways on mastering sleep, dealing with chronic pain, developing breakthrough cancer drugs, transforming healthcare with AI, advancing radiation therapy, and healing trauma | Quarterly Podcast Summary #5

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Susan Desmond-Hellmann is a physician and scientist whose remarkable career has spanned clinical medicine, oncology, biotech innovation, and global health leadership. In this episode, Susan shares insights from her journey training in internal medicine during the early AIDS crisis, treating HIV-related cancers in Uganda, and developing groundbreaking cancer therapies like Herceptin and Avastin. She reflects on her leadership roles at UCSF and the Bill and Melinda Gates Foundation, offering lessons on guiding large-scale health initiatives, navigating uncertainty, and fostering scientific innovation. The conversation explores the promise of precision medicine, the integration of patient care and policy, and the evolving role of artificial intelligence in transforming diagnostics, drug development, and global access to care. We discuss:  Susan's medical training, the start of the AIDS epidemic, and the transformative experiences that shaped her career [3:00]; Susan's experience working on the frontlines of the HIV/AIDS crisis in Uganda [12:30]; Susan's time working in general oncology and her transition to biotech where she helped develop taxol—a top-selling cancer drug [26:30]; Genentech's origins, and its groundbreaking use of recombinant DNA to develop biologic drugs [33:45]; Susan's move to Genentech, and her pivotal role in the development and success of Herceptin as a groundbreaking therapy in targeted oncology [44:00]; The rise of antibody-based cancer therapies: the development of Rituxan and Avastin [52:15]; The step-by-step drug development process and the scientific and strategic challenges involved [1:01:30]; The ethical and economic controversy surrounding Avastin's high cost and limited survival benefit [1:12:30]; Susan's tenure as chancellor at UCSF: leading during a financially strained period, and her strategic approach to fundraising and institutional development [1:14:45]; What Susan learned as CEO of the Bill and Melinda Gates Foundation: strategic processes and decision-making frameworks [1:26:00]; Susan's philosophy of leadership and how she sought to build an empowering, values-driven culture at the Gates Foundation [1:35:15]; The erosion of public trust in science during COVID, the communication failures around controversial treatments like ivermectin, and the need for better public health engagement and transparency [1:39:30]; The role of AI in transforming medicine: from drug development to cancer detection and beyond [1:53:00]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#346 - Scaling biotech and improving global health: lessons from an extraordinary career in medicine | Susan Desmond-Hellmann, M.D., M.P.H.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Sean Mackey is a professor of pain medicine at Stanford University and the director of the Stanford Systems Neuroscience and Pain Lab, where his research explores the neural mechanisms of pain and the development of novel treatments for chronic pain. In this episode, Sean joins Peter for a wide-ranging discussion on the multifaceted nature of pain—as both a sensory and emotional experience—and its evolutionary purpose as a critical survival mechanism. He dives into how pain is transmitted through the nervous system, the different types of pain, and why different individuals perceive pain so differently. Sean shares insights into pain management strategies ranging from medications like NSAIDs and opioids to neuromodulation techniques such as transcutaneous electrical nerve stimulation (TENS). Additionally, this episode explores the interplay between sleep and chronic pain and the psychological and emotional dimensions of pain, and it includes a personal story from Peter about his own experience with pain and how Sean's expertise helped him more than two decades ago. We discuss:  The definition of pain, and how our understanding of pain has evolved from a simplistic body-mind separation to a nuanced biopsychosocial model [2:30]; The biological mechanisms behind how we perceive pain [9:30]; The role of consciousness in the perception of pain, and how nociception functions during unconscious states [14:30]; The four types of pain [22:00]; Using fMRI to identify objective biomarkers of pain in the brain [31:30]; The evolutionary role of pain in human behavior and survival [36:00]; How the brain processes and modulates pain signals, Gate Control Theory, the variability in individuals' pain perception, and effectiveness of neuromodulation techniques like TENS [41:00]; The brain's influence on pain: the role of emotion, beliefs, sleep, and individual differences in perception and tolerance [53:45]; Peter's personal journey with chronic back pain, and how the emotional consequences of pain can be more distressing than the pain itself [1:04:30]; The pharmacology of common pain medications—NSAIDs, COX-2 inhibitors, and acetaminophen [1:09:30]; Muscle relaxants: benefits, drawbacks, and personalized strategies [1:20:30]; The definition of chronic pain [1:29:15]; The role of antidepressants in pain management [1:30:15]; Opioids: their controversial and nuanced role in pain management [1:33:45]; Alternative therapies: acupuncture and cannabis [1:54:15]; Fibromyalgia and chronic pain: clinical features, brain mechanisms, and emerging treatments like low-dose naltrexone [2:01:00]; Possible brain benefits of low-dose naltrexone (LDN) for people with mild cognitive impairment [2:15:00]; Peter's recovery from severe chronic pain—how he went from immobility and high-dose opioids to full functionality [2:20:15]; Breaking the pain cycle: how physical rehabilitation and psychological recovery work together in chronic pain treatment [2:30:45]; Sean's struggle with cluster headaches, and the value of knowledge, preparation, and empathy in both managing chronic pain and caring for patients [2:39:15]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#345 ‒ Chronic pain: pathways, treatment, and the path to physical and psychological recovery | Sean Mackey, M.D., Ph.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter dives deep into nicotine—a topic increasingly debated both scientifically and publicly. He clarifies the critical differences between nicotine and tobacco, highlighting why nicotine alone isn't primarily responsible for smoking's severe health consequences. Peter examines the specific risks associated with nicotine use, including addiction, sleep disruption, cardiovascular concerns, and effects on mood and anxiety. He evaluates various nicotine delivery methods, from traditional cigarettes to gums, pouches, and synthetic alternatives, ranking them according to their relative safety. Additionally, Peter explores nicotine's potential positive and negative impacts on physical performance, cognitive function, fertility, and its interactions with other stimulants like caffeine. Finally, he provides practical guidance for minimizing risks with nicotine use and offers thoughtful strategies for smoking cessation and effective nicotine replacement therapies. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #70 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  Revisiting the previous AMA on microplastics: low-effort, high-impact changes to significantly reduce microplastic exposure [1:45]; Overview of episode topics related to nicotine [3:30]; The current landscape of nicotine research [4:45]; Addressing the common misconception that nicotine itself is the primary cause of tobacco-related health risks [6:45]; Peter's Marlboro-branded apparel is a nostalgic tribute to the Formula One era and not a sign of support for smoking [10:00]; The limitations of current research on the health risks of nicotine itself [12:15]; The most common side effects of nicotine [18:15]; The impact of nicotine on sleep [21:30]; Nicotine and mood: how nicotine can have both anxiety-inducing and calming effects based on genetics and dosage [25:00]; The addictive properties of nicotine: factors influencing addiction risk, and why certain people may struggle more than others [29:15]; The various nicotine products and nicotine delivery methods available: effects, absorption rates, and potential risks [33:45]; The relative risks of various nicotine products: how differences in nicotine concentration, absorption rates, and presence of contaminants impact their safety [37:00]; Potential cognitive benefits of nicotine: short-term benefits and impact of chronic use [44:45]; How nicotine exposure during adolescence can negatively impact brain development [47:45]; Nicotine's potential to prevent or slow neurodegenerative diseases [50:45]; Nicotine's impact on memory, learning, and attention [52:45]; The interaction between nicotine and other stimulants, particularly caffeine [55:15]; Nicotine's potential impact on physical performance [57:15]; The potential effects of nicotine on fertility, and the challenges of distinguishing the impact of nicotine itself from the effects of smoking [58:30]; Considerations for people curious about using nicotine for its cognitive benefits [1:01:30]; How to think about nicotine: weighing cognitive claims, addiction risks, and personal tolerance [1:03:15]; The prevalence of smoking, the health risks it poses, and the substantial long-term benefits of quitting [1:05:45]; Effective strategies for smoking cessation, including the use of nicotine replacement therapies [1:09:00]; The reasons behind weight gain after quitting smoking, the role of nicotine in appetite suppression, and strategies to manage weight [1:15:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#344 - AMA #70: Nicotine: impact on cognitive function, performance, and mood, health risks, delivery modalities, and smoking cessation strategies

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Sanjay Mehta is a radiation oncologist with over 25 years of experience, and is currently the president of Century Cancer Centers in Houston, Texas (drsanjaymehta.com). In this episode, Sanjay explores the rapidly evolving field of radiation oncology, addressing common misconceptions about radiation exposure. He delves into radiation's critical role in modern oncology, examining recent advancements that precisely target tumors while minimizing damage to surrounding healthy tissues and reducing side effects, with specific insights into breast, prostate, and brain cancers. Sanjay discusses fascinating international practices involving low-dose radiation therapy for inflammatory conditions such as arthritis, tendonitis, and sports injuries, highlighting its effectiveness and potential for wider adoption in the United States. Wrapping up on a lighter note, Peter and Sanjay discuss their mutual passion for cars and reveal how this shared interest first brought them together. We discuss:  How radiation oncology became a distinct, rapidly evolving medical specialty [2:45]; Defining radiation, ionizing vs. non-ionizing, and common misconceptions about radiation exposure [5:30]; How radiation doses are measured, real-world examples of radiation exposure, and safety practices [9:00]; Radiation doses from common medical imaging tests, and why benefits of routine imaging outweigh risks [14:15]; Therapeutic radiation oncology: the evolution of breast cancer treatment toward less invasive surgery combined with targeted radiation [23:30]; Modern radiation oncology treatments for breast cancer—minimizing risks and maximizing patient comfort and outcomes [27:15]; How advances in radiation dosing, technology, and treatment precision have significantly reduced side effects [39:45]; How breast implants affect radiation treatment [44:45]; Radiation therapy for prostate cancer: advancements in precision, effectiveness, and patient selection criteria [48:00]; Radiation therapy options for inoperable prostate cancer or those seeking alternatives to surgery, and a remarkable patient case study [55:15]; How patients can effectively evaluate and select a high-quality radiation oncologist [1:05:45]; Radiation therapy for brain cancer: the shift toward precise, targeted techniques that minimize cognitive side effects, and remaining challenges [1:08:30]; The origins of radiophobia and how it influenced perceptions of radiation use in medicine [1:18:00]; Treating chronic inflammatory conditions such as tendinitis, arthritis, and more with very low-dose radiation [1:23:45]; Using low-dose radiation to treat spine injuries, scar tissue, fibrosis, keloids, and more [1:30:00]; The current barriers preventing widespread adoption of low-dose radiation therapy for inflammatory conditions [1:35:45]; The durability and versatility of low-dose radiation therapy in treating chronic inflammatory and arthritic conditions [1:40:45]; Sanjay's talent as a drummer [1:44:45]; Peter and Sanjay's shared passion for cars and racing [1:47:15]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#343 – The evolving role of radiation: advancements in cancer treatment, emerging low-dose treatments for arthritis, tendonitis, and injuries, and addressing misconceptions | Sanjay Mehta, M.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this special episode of The Drive, Peter joins a unique conversation inspired by his daughter's volunteer experience at a senior care center, where she formed meaningful relationships with residents curious about healthspan, lifespan, and strategies for living well as they age. Peter engages directly with the residents, covering critical topics like the profound impact of exercise—particularly strength training— for maintaining mobility, preventing falls, and preserving independence later in life. He also discusses the importance of nutrition, emphasizing adequate protein intake, along with strategies for sleep optimization and preservation of brain health. Peter also underscores the importance of emotional wellness, purpose, and social connections in healthy aging, provides advice on staving off chronic disease, and much more. We discuss:  Peter's definition of longevity [2:30]; Why it's never too late to invest in your longevity [5:30]; The importance of adding "life to years" rather than just "years to life" [7:45]; The "four horsemen"—heart disease, cancer, neurodegenerative diseases, and metabolic conditions [9:15]; Advice for those managing chronic diseases later in life [11:30]; Why balance declines and falls become increasingly common with age, and how to prevent them [13:30]; Why strength training is essential (and effective) for older adults [18:30]; The five tools in Peter's longevity toolkit [21:00]; Practical ways older adults can safely begin exercising despite physical limitations or health issues [23:00]; Principles of good nutrition, and the importance of adequate protein intake [24:00]; The importance of sleep for cognitive health, and effective sleep-improvement strategies for seniors [27:30]; How emotional health, social connections, and a sense of purpose significantly impact quality of life and longevity [32:00]; Why Peter decided to focus his work on longevity [33:45]; Protein intake recommendations should be based on ideal body weight (not current weight) [34:45]; The potential of klotho as a therapy for improving cognitive function and combating aging-related cognitive decline [35:30]; The best types of protein supplements to consider [36:45]; The APOE gene's influence on Alzheimer's disease risk, and why everyone should proactively address brain health, regardless of genetics [38:15]; How falls can accelerate cognitive decline, and the importance of staying physically and mentally active [40:45]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#342 ‒ Aging well: Peter shares strategies for improving longevity with residents at a senior living center

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Ashley Mason is a clinical psychologist and an associate professor at UCSF, where she leads the Sleep, Eating, and Affect (SEA) Laboratory. In this episode, Ashley provides a masterclass on cognitive behavioral therapy for insomnia (CBT-I), detailing techniques like time in bed restriction, stimulus control, and cognitive restructuring to improve sleep. She explains how to manage racing thoughts and anxiety, optimize sleep environments, and use practical tools like sleep diaries to track progress. She also offers detailed guidance on sleep hygiene; explores the impact of temperature regulation, blue light exposure, and bedtime routines; and offers guidance on finding a CBT-I therapist, along with sharing practical steps you can take on your own before seeking professional help. We discuss:  Defining insomnia: diagnosis, prevalence, and misconceptions [3:00]; How insomnia develops, and breaking the cycle with cognitive behavioral therapy for insomnia (CBT-I) [7:45]; The different types of insomnia, and the impact of anxiety, hydration, temperature, and more on sleep [11:45]; The core principles of cognitive behavioral therapy (CBT) and how CBT-I is used to treat insomnia [20:00]; Implementing CBT-I: time in bed restriction, sleep scheduling, and the effect of napping [29:45]; Navigating family and partner sleep schedules, falling asleep on the couch, sleep chronotypes, and more [39:45]; Key aspects of sleep hygiene: temperature, light exposure, and circadian rhythm disruptions [44:45]; Blue light and mental stimulation before bed, and the utility of A-B testing sleep habits [52:45]; Other simple interventions that may improve sleep [57:30]; Ashley's view on relaxation techniques and mindfulness-based practices [1:02:30]; The effectiveness of CBT-I, the role of sleep trackers, and best practices for managing nighttime awakenings [1:04:15]; Guidance on intake of food and alcohol for good sleep [1:16:30]; Reframing thoughts and nighttime anxiety to reduce sleep disruptions [1:18:45]; Ashley's take on sleep supplements like melatonin [1:21:45]; How to safely taper off sleep medications like benzos and Ambien [1:26:00]; Sleep problems that need to be addressed before CBT-I can be implemented [1:38:30]; The importance of prioritizing a consistent wake-up time over a fixed bedtime for better sleep regulation [1:40:15]; Process S and Process C: the science of sleep pressure and circadian rhythms [1:45:15]; How exercise too close to bedtime may impact sleep [1:47:45]; The structure and variability of CBT-I, Ashley's approach, and tips for finding a therapist [1:50:30]; The effect of sauna and cold plunge before bed on sleep quality [1:56:00]; Key takeaways on CBT-I, and why no one should have to suffer from insomnia [1:58:15]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#341 - Overcoming insomnia: improving sleep hygiene and treating disordered sleep with cognitive behavioral therapy for insomnia | Ashley Mason, Ph.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter explores the complex world of supplements by introducing a practical framework for evaluating their effectiveness and relevance to individual health needs. Rather than providing a simple list of recommendations, Peter aims to equip listeners with the tools to critically assess supplements on their own. He then applies this framework to discuss research on several popular supplements, including creatine, fish oil, vitamin D, B vitamins, and ashwagandha. Additionally, he covers key factors in assessing supplement quality, helping listeners develop a deeper understanding of how to make informed decisions based on their personal health goals. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #69 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  Overview of episode topics [1:45]; How Peter evaluates patients' supplement regimens, and common misconceptions about supplements vs. pharmaceuticals [3:00]; A framework for evaluating supplements [6:15]; Evaluating creatine: purpose of supplementation, dosing, and mechanism of action [10:00]; Creatine: proven benefits for muscle performance, potential cognitive benefits, and why women may benefit more [15:15]; Creatine: risk vs. reward, kidney concerns, and choosing the right supplement [18:45]; Evaluating fish oil: its primary purpose as a supplement and how to track levels [20:45]; Fish oil: how omega-3s impact inflammation, heart health, and brain function, and the strengths and limitations of current research [26:30]; Fish oil: the risks of supplementation, guidance on selecting high-quality products, and how to determine whether supplementation is appropriate [37:30]; Evaluating vitamin D: understanding deficiency and optimal levels [45:15]; Vitamin D: role in bone health, immune function, potential longevity impact, and biomarker limitations [51:15]; Vitamin D: efficacy, safety, and balancing risk vs. reward [58:15]; Evaluating B vitamins: function, consequences of deficiency, and key biomarkers to assess whether supplementation is necessary [1:02:15]; B vitamins: risks for CVD and dementia associated with deficiency, and limited evidence for general population supplementation [1:07:15]; Evaluating ashwagandha: background, uses, and mechanism of action [1:15:30]; Ashwagandha: current evidence for its effects on sleep, stress, and anxiety [1:19:15]; Ashwagandha: evaluating supplement quality, safety profile, and the risk-reward balance [1:22:15]; The importance of using a structured evaluation framework to assess any supplement [1:26:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#340 - AMA #69: Scrutinizing supplements: creatine, fish oil, vitamin D, and more—a framework for understanding effectiveness, quality, and individual need

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Jeff English is a trauma-focused clinical counselor with extensive experience working with adults, teens, families, and groups across various settings, including career counseling, life coaching, addiction recovery, professional workshops, and private practice. In this episode, Jeff shares insights from his work as a trauma therapist, exploring how moments of perceived helplessness shape behaviors and how adaptive strategies can become maladaptive over time. He discusses the concept of the "trauma tree," examining its roots (causes) and branches (consequences), and highlights a powerful framework used at the Bridge to Recovery, a residential workshop where Jeff serves as an outreach specialist. Jeff reflects on the transformative power of group therapy, the role of vulnerability in fostering connection, and the challenges of letting go of control. He also offers practical advice on finding a great trauma therapist, balancing personal growth within relationships, and recognizing when it's time to seek help. We discuss:  Defining trauma—a loaded word [3:00]; The therapeutic process at The Bridge to Recovery: confronting discomfort, embracing vulnerability, and reframing one's story [5:45]; The roots of the trauma tree: the foundational wounding experiences that shape adaptive survival behaviors [11:30]; The branches of the trauma tree: how trauma manifests through co-dependency, addictive patterns, insecure attachments, and more [17:30]; The connection between trauma manifestations and underlying wounding experiences, trauma triggers, and the importance of surrender in the healing process [24:00]; How surrendering control, eliminating distractions, and practicing vulnerability are essential components of the healing process [32:45]; How adaptive behaviors developed during childhood in response to trauma can become maladaptive in adulthood [43:30]; The difference between shame and guilt, and recognizing and addressing toxic shame and shame-driven behaviors [49:15]; The unique rules at The Bridge to Recovery that support the healing process [53:15]; Internal resistance to healing due to the fear of losing positive traits associated with trauma [58:15]; The structured storytelling process at The Bridge, and the role of peer feedback in healing [1:05:00]; The differences between immersive residential therapy and individual therapy, and how to determine the right approach for different individuals [1:09:30]; Jeff's personal journey as a client and therapist at The Bridge [1:22:00]; The generational transmission of trauma, and breaking the cycle [1:25:45]; The challenge of addressing socially acceptable maladaptive behaviors like workaholism, perfectionism, and overachievement [1:28:45]; How to determine whether struggles stem from deep-seated trauma or just bad habits, and how rewiring maladaptive behaviors requires addressing the underlying emotional wounds [1:32:30]; Breakthroughs that shatter beliefs and allows change to occur, and the process that creates this opportunity [1:39:15]; Jeff's advice on finding a therapist for trauma work [1:46:45]; The importance of connection and vulnerability [1:52:45]; How to encourage a resistant partner to seek healing [1:57:30]; Jeff's advice for those facing emotional struggles [1:59:15]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#339 - Unpacking trauma: How early wounds shape behavior and the path toward healing | Jeff English

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this quarterly podcast summary (QPS) episode, Peter summarizes his biggest takeaways from the last three months of guest interviews on the podcast. Peter shares key insights from his discussions on diverse topics such as aerobic efficiency and VO2 max with Olav Aleksander Bu; insulin resistance with Ralph DeFronzo; economics of the US healthcare system and cost-saving strategies with Saum Sutaria; diagnosis and treatment of autism, ADHD, and anxiety in children with Trenna Sutcliffe; and strength training with Mike Israetel. Additionally, Peter shares any personal behavioral adjustments or modifications to his patient care practices that have arisen from these fascinating discussions. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the episode #338 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  Overview of topics to be discussed [2:00]; Olav Aleksander Bu Pt.2 episode: metrics to track aerobic efficiency and insights about VO2 max, and the ability of increased carbohydrate consumption to boost performance [4:30]; The best practices for performing a VO2 max test, the differences between VO2 max training and all-out efforts, and the role of energy intake in endurance performance [14:45]; Ralph DeFronzo episode: the pathophysiology of insulin resistance and type 2 diabetes—how they impact different organs, flaws in conventional diabetes treatment, and more [24:30]; Understanding type 2 diabetes beyond the traditional triumvirate of features: the "ominous octet" describes changes in other organs [31:45]; Pharmacological treatments for insulin resistance and type 2 diabetes [41:30]; The importance of early detection and intervention in insulin resistance [50:30]; Saum Sutaria episode: the economic and systemic drivers of high healthcare costs in the U.S. [54:00]; Reducing health care costs: redefining health insurance, lowering drug prices while maintaining innovation, leveraging AI for efficiency, and more [1:07:15]; Trenna Sutcliffe episode: insights on autism, ADHD, and anxiety in children—definitions and diagnosis [1:11:45]; Exploring the rising prevalence of autism spectrum disorder [1:17:15]; Trenna's views on caring for children with autism [1:21:15]; Misconceptions around vaccines and autism [1:26:00]; Mike Israetel episode: insights about strength training, minimum effective dose, troubleshooting plateaus, tips for beginners, and more [1:28:15]; Topics Peter is interested in exploring in future podcasts [1:40:15]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#338 ‒ Peter's takeaways on aerobic exercise and VO2 max, insulin resistance, rising healthcare costs, treating children with autism and ADHD, and strength training | Quarterly Podcast Summary #4

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Ralph DeFronzo is a distinguished diabetes researcher and clinician whose groundbreaking work on insulin resistance has reshaped the understanding and treatment of type 2 diabetes. In this episode, Ralph shares insights from his five decades of research, including his pivotal role in bringing metformin to the U.S. and developing SGLT2 inhibitors. Ralph explores the impacts of insulin resistance on specific organs, the pharmacologic interventions available, and the gold-standard euglycemic clamp method for measuring insulin resistance. This episode is a masterclass in the pathophysiology and treatment of type 2 diabetes, featuring an in-depth discussion of GLP-1 receptor agonists, metformin, and a lesser-known class of drugs that opened Peter's eyes to new possibilities in diabetes care. We discuss:  Metabolic disease as a foundational driver of chronic illness [4:00]; Defining insulin resistance: effects on glucose, fat, and protein metabolism, and how it varies between healthy, obese, and diabetic individuals [8:15]; The historical significance of the development of the euglycemic clamp technique for measuring insulin resistance [11:45]; How insulin affects different tissues: liver, muscle, and fat cells [15:00]; The different ways insulin resistance manifests in various tissues: Alzheimer's disease, cardiovascular disease, and more [25:00]; The dangers of hyperinsulinemia, and the importance of keeping insulin levels within a physiological range [29:00]; The challenges of identifying the genetic basis of insulin resistance and type 2 diabetes [37:00]; The "ominous octet"—a more comprehensive model of type 2 diabetes than the traditional triumvirate [45:45]; The kidneys' unexpected role in worsening diabetes, and how SGLT2 inhibitors were developed to treat diabetes [55:45]; How insulin resistance in the brain and neurocircuitry dysfunction contribute to overeating and metabolic disease [1:04:15]; Lipotoxicity: how overeating fuels insulin resistance and mitochondrial dysfunction [1:07:30]; Pioglitazone: an underappreciated and misunderstood treatment for insulin resistance [1:10:15]; Metformin: debunking the misconception that it is an insulin sensitizer and explaining its true mechanism of action [1:19:15]; Treating diabetes with triple therapy vs. the ADA approach: a better path for diabetes management [1:24:00]; GLP-1 agonists, the Qatar study, and rethinking diabetes treatment [1:31:30]; Using a hyperglycemic clamp to look for genes that cause diabetes [1:45:15]; The superiority of measuring C-peptide instead of insulin to assess beta-cell function [1:46:45]; How GLP-1-induced weight loss affects muscle mass, the benefits and risks of myostatin inhibitors, and the need for better methods of evaluating functional outcomes of increased muscle mass [1:51:30]; The growing crisis of childhood obesity and challenges in treating it [2:02:15]; The environmental and neurological factors driving the obesity epidemic [2:07:30]; The role of genetics, insulin signaling defects, and lipotoxicity in insulin resistance and diabetes treatment challenges [2:11:00]; The oral glucose tolerance test (OGTT): detecting early insulin resistance and beta cell dysfunction [2:18:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#337 - Insulin resistance masterclass: The full body impact of metabolic dysfunction and prevention, diagnosis, and treatment | Ralph DeFronzo, M.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter tackles a diverse set of listener-submitted questions, covering a wide range of health and performance topics. He dives into assessing cardiovascular health, discussing key biomarkers and risk factors, and breaks down various fasting approaches, including time-restricted eating and prolonged fasting. The conversation also explores the impact of alcohol on health and disease risk, fundamental principles of nutrition, and optimal protein intake. Additionally, he examines the pros and cons of ketogenic and low-carb diets, strategies for building effective exercise routines, and the role of wearables in tracking health metrics. The episode concludes with insights on emotional health, making this a well-rounded discussion packed with practical takeaways for anyone looking to optimize their well-being. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #68 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  Episode format: overview of common health topics based on listener questions [1:30]; How to accurately assess your cardiovascular health [3:00]; The impact of fasting, time-restricted eating, and dietary restriction on metabolic health [9:00]; Alcohol: health risks of consumption, limitations of research, and how to weigh the risks against social and personal enjoyment [13:45]; Principles of a well-balanced diet: macronutrients, micronutrients, protein, energy balance, and more [23:45]; The benefits and drawbacks of ketogenic diets: impact on satiety, metabolic health, athletic performance, lipid levels, and more [29:15]; Protein: best sources for muscle growth, total intake, PDCAAS scoring system, and getting adequate amounts on plant-based diets [36:15]; Creating an effective fitness routine that fits into a busy schedule [41:45]; The role of rest and recovery in a workout routine [46:00]; How to track fitness progress beyond just weight on a scale [48:30]; The best low-impact exercises for individuals with joint issues [52:00]; Wearables: insight vs. compliance, and how to use them effectively [54:45]; How to evaluate the risks and benefits of medical interventions: procedural risks, complication rates, and asking informed questions [59:00]; Sleep: impact on metabolic and cognitive health, and tips for improving sleep quality [1:03:45]; How to identify and address emotional health challenges [1:08:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#336 - AMA #68: Fasting, well-balanced diets, alcohol, exercise for busy people, wearables, emotional health, assessing cardiovascular health, and more

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Mike Israetel is a sports physiologist, competitive bodybuilder, and co-founder of Renaissance Periodization, where he coaches athletes and professionals in diet and weight training. In this episode, Mike shares his journey from powerlifting to academia, breaking down the core principles of resistance training, including exercise selection, volume, intensity, and frequency. He debunks common misconceptions about strength training, explains how to structure an effective program for beginners and advanced lifters, and provides candid insights into his experience with anabolic steroids, discussing their effects on muscle growth, performance, and health risks. This conversation offers a deep dive into the science of building muscle, the realities of bodybuilding at the highest levels, and explores the potential of AI-driven breakthroughs to advance human performance and longevity. We discuss:  Mike's academic journey, and early experiences in powerlifting, personal training, and sports physiology [3:30]; Mike's transition from powerlifting to bodybuilding, and his scientific and artistic approach to sculpting muscle and optimizing aesthetics [9:15]; The value of strength training, time efficiency, and how it differs from endurance training [14:45]; Neurological fatigue in strength training: balancing recovery and pushing the limits [26:15]; The relationship between training intensity and volume, why muscle growth is not linear, and how different approaches affect results [35:00]; Sustainable and effective approaches to maximizing muscle growth: training close to failure while minimizing fatigue [40:00]; An efficient and effective resistance training program for beginners with limited time [49:00]; Advice for finding a good trainer [1:06:30]; Troubleshooting training plateaus: optimizing exercise selection, intensity, and recovery for muscle growth [1:13:30]; The impact of genetics, age, and lifestyle on muscle growth [1:27:45]; The importance of nutrition, protein intake, and consistency in both training and diet for muscle growth [1:31:00]; The use of anabolic steroids to boost muscle growth: doses, drug combinations, and side effects [1:35:45]; Long-term impact of steroid use: muscle retention, genetics and individual variability, and impact after discontinuation [1:52:15]; Trade-offs of long-term usage of supraphysiologic doses of testosterone: health, performance, and Mike's future plans [2:00:45]; The potential for AI-driven medical breakthroughs to reverse aging and disease [2:07:30]; The role of AI in accelerating drug development, advancing human longevity, and overcoming biological limitations [2:19:45]; The philosophical implications of simulated reality, the impact of robotics on human labor and economics, and the challenge of predicting the future [2:25:15]; Would having kids change Mike's philosophy around anabolic steroid use? [2:32:15]; The role of GLP-1 agonists in bodybuilding and general weight management, and the moral and philosophical debates surrounding their use [2:35:45]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#335 ‒ The science of resistance training, building muscle, and anabolic steroid use in bodybuilding | Mike Israetel, Ph.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Tom Dayspring is a world-renowned expert in clinical lipidology and a previous guest on The Drive. In this episode, Tom explores the foundations of atherosclerosis and why atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death worldwide for both men and women. He examines how the disease develops from a pathological perspective and discusses key risk factors, including often-overlooked contributors such as insulin resistance and chronic kidney disease. He breaks down the complexities of cholesterol and lipoproteins—including LDL, VLDL, IDL, and HDL—with an in-depth discussion on the critical role of apolipoprotein B (apoB) in the development of atherosclerosis. Additionally, he covers the importance of testing various biomarkers, the impact of nutrition on lipid levels, and the vital role of cholesterol in brain health, including how cholesterol is synthesized and managed in the brain, how it differs from cholesterol regulation in the rest of the body, and how pharmacological interventions can influence brain cholesterol metabolism. We discuss:  Defining atherosclerotic cardiovascular disease (ASCVD): development, risks, and physiological impact [2:45]; The pathogenesis of ASCVD: the silent development over decades, and the importance of early detection for prevention of adverse outcomes [10:45]; Risk factors versus risk markers for ASCVD, and how insulin resistance and chronic kidney disease contribute to atherosclerosis [17:30]; How hyperinsulinemia elevates cardiovascular risk [24:00]; How apoB-containing lipoproteins contribute to atherosclerosis, and why measuring apoB is a superior indicator of cardiovascular risk compared to LDL cholesterol [29:45]; The challenges of detecting early-stage atherosclerosis before calcification appears [46:15]; Lp(a): structure, genetic basis, and significant risks associated with elevated Lp(a) [55:30]; How aging and lifestyle factors contribute to rising apoB and LDL cholesterol levels, and the lifestyle changes that can lower it [59:45]; How elevated triglycerides, driven by insulin resistance, increase apoB particle concentration and promote atherosclerosis [1:08:00]; How LDL particle size, remnant lipoproteins, Lp(a), and non-HDL cholesterol contribute to cardiovascular risk beyond apoB levels [1:21:45]; The limitations of using HDL cholesterol as a marker for heart health [1:29:00]; The critical role of cholesterol in brain function and how the brain manages its cholesterol supply [1:36:30]; The impact of ApoE genotype on brain health and Alzheimer's disease risk [1:46:00]; How the brain manages cholesterol through specialized pathways, and biomarkers to track cholesterol health of the brain [1:50:30]; How statins might affect brain cholesterol synthesis and cognitive function, and alternative lipid-lowering strategies for high-risk individuals [1:57:30]; Exciting advancements in therapeutics, diagnostics, and biomarkers coming in the next few years [2:09:30]; Recent consensus statements on apoB and Lp(a) from the National Lipid Association (NLA) [2:12:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#334 - Cardiovascular disease, the number one killer: development, biomarkers, apoB, cholesterol, brain health, and more | Tom Dayspring, M.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this special episode of The Drive, Peter introduces a brand-new roundtable format. Joined by three renowned experts in longevity science—Steven Austad, Richard Miller, and Matt Kaeberlein—the group explores the rapidly evolving field of geroscience. Together, they dive deep into topics like the relationship between healthspan and lifespan, evaluating interventions like rapamycin and senolytics, the role of epigenetic changes in aging, and whether GLP-1 receptor agonists hold geroprotective potential. They also tackle major challenges in funding and public acceptance of longevity research including how geroprotective interventions might be tested in humans. Packed with nuanced debate, humor, and groundbreaking insights, this episode is a must-listen for anyone fascinated by the science of aging. We discuss:  The recent rise in public interest in longevity, misconceptions, and the link between healthspan and lifespan [3:45]; Redefining healthspan, the US healthcare paradox, and separating longevity science from commercial hype [12:30]; The need to redirect medical research from disease-specific models to aging-focused approaches [21:30]; Proactive healthcare: rethinking health, disease, and the role of aging [30:00]; Biologic age versus chronologic age, and the limitations and potential of epigenetic clocks [35:00]; The utility and drawbacks of the "hallmarks of aging" as a framework for research and funding [49:30]; The role of epigenetic changes in aging and the challenges of proving causality [56:45]; The translational challenges of moving aging research from preclinical studies to human applications [1:03:45]; Distinguishing between a biomarker of aging and aging rate indicators [1:17:15]; The difficulties of translating longevity research in mice to humans, and the difficulties of testing interventions in humans [1:21:15]; Exercise, aging, and healthspan: does exercise slow aging? [1:35:45]; Are GLP-1 receptor agonists geroprotective beyond caloric restriction effects? [1:41:00]; The role of senescent cells in aging, challenges with reproducibility in studies, and differing views on the value of current research approaches [1:46:15]; How funding challenges and leadership in NIH and other institutes impact the advancement of aging-related research [2:00:15]; Metformin: geroprotective potential, mechanisms, and unanswered questions [2:02:30]; Canagliflozin and rapamycin as geroprotective molecules: mechanisms, dosing strategies, and longevity potential [2:10:45]; Resveratrol and NAD precursors—a lack of evidence for anti-aging effects [2:22:45]; The potential of parabiosis and plasmapheresis to slow aging, the challenges in translating mouse studies to humans, and possible design for human studies [2:29:45]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#333 ‒ Longevity roundtable — the science of aging, geroprotective molecules, lifestyle interventions, challenges in research, and more | Steven Austad, Matt Kaeberlein, Richard Miller

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter tackles a topic that's been dominating headlines and sparking widespread concern: microplastics and plastic-associated chemicals, including BPA, PFAS, and phthalates. Peter explores the science behind these substances including how and why they've become so prevalent, the extent of our exposure, and the potential risks to our health. Most importantly, he provides a practical framework for understanding microplastics and plastic-associated chemicals and minimizing exposure while distinguishing genuine risks from exaggerated concerns. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #67 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  The complexity of the topic of microplastics and associated chemicals [1:30]; Definitions: microplastics, BPA, PM2.5, phthalates, and more [6:30]; The reasons behind the increase in microplastics in our environment and the surge in interest in them [12:00]; The various ways that humans are exposed to microplastics and nanoplastics [14:00]; Volume of plastic consumed by humans, and how the body eliminates or absorbs microplastics [16:00]; How microplastics accumulate in the body, the variability in tissue accumulation, and the challenges in studying their long-term health effects [21:30]; Limitations of blood tests for microplastics, and the importance of reliable biomarkers for guiding behavior and interventions [26:30]; The speculative health risks of microplastics, the limitations of current research, and the need for more robust studies [29:15]; The challenges of measuring microplastics in human tissues, the need for better methodologies, and the importance of critically evaluating study relevance and claims [39:45]; If it's unclear whether microplastics actually cause harm, should we still be concerned about exposure? [42:15]; Strategies to minimize microplastic exposure [45:00]; The financial cost and effort involved in various microplastic exposure mitigation strategies [51:00]; The role of airborne microplastics in total exposure and accumulation [1:03:00]; Chemicals associated with plastics, their role as endocrine disruptors, and the challenges in linking exposure to specific health outcomes [1:04:00]; BPAs: role in plastic production, and its potential developmental risks [1:05:45]; BPA's potential health risks: pregnancy, fertility, obesity, and diabetes, and the socioeconomic confounders in the data [1:08:30]; Regulatory limits on BPA exposure, and practical considerations for reducing exposure [1:12:45]; The prevalence of BPA in modern products and how to identify it [1:17:15]; PFAS: chemical structure and purpose in products [1:18:30]; Why PFAS are considered endocrine disruptors [1:19:45]; The main sources of PFAS exposure, and practical steps to reduce exposure [1:21:30]; The potential health risks of PFAS exposure [1:24:00]; Phthalates: role in making plastics flexible and presence in personal care products [1:24:45]; Why phthalates are considered endocrine disruptors [1:25:15]; The main sources of phthalate exposure, and how manufacturing practices are evolving to reduce exposure [1:26:45]; Practical strategies to reduce exposure to phthalates in food, air, water, and personal care products [1:28:30]; Navigating microplastics and associated chemicals: a framework for personalized risk reduction [1:29:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#332 - AMA #67: Microplastics, PFAS, and phthalates: understanding health risks and a framework for minimizing exposure and mitigating risk

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Olav Aleksander Bu is an internationally renowned sports scientist acclaimed for his coaching prowess with elite athletes spanning a diverse range of sports disciplines. In this episode, Olav returns to dive deeper into his groundbreaking work as an endurance coach, exercise scientist, engineer, and physiologist. The discussion explores his data-driven approach to coaching, unpacking key performance metrics like functional threshold power, VO2 max, and lactate threshold, while emphasizing the importance of consistent testing protocols. Olav shares insights on how training methodologies differ across sports, the impact of nutrition on endurance performance, and the evolving strategies for carbohydrate metabolism in fueling athletes for races. Olav concludes with a discussion on the use of artificial intelligence for optimizing training insights and performance. We discuss:  Olav's unique, engineering-driven approach to endurance coaching [2:45]; Definitions and applications of key performance metrics: FTP, power, anaerobic threshold, and lactate threshold [4:45]; Lactate threshold: factors affecting lactate threshold, testing protocols, and how elite athletes' efficiency affects their performance and lactate profiles [14:15] VO2 max: definition, testing, factors affecting its accuracy, and methods for optimizing oxygen utilization in elite athletes [22:15]; Testing VO2 max: common mistakes and key factors to consider—preparation, warm-up, timing, and more [34:00]; VO2 max testing continued: measuring instruments, testing protocols, and advanced insights gained from elite athletes [41:45]; The influence of supplements like beetroot concentrate and adaptogens on VO2 max and performance [49:45]; How respiratory quotient (RQ) reflects metabolic shifts during exercise, the challenges in measuring and interpreting RQ in elite athletes, and the physiological adaptations needed for prolonged endurance events [53:30]; Triathlon training: the challenge of maintaining elite performance across triathlon distances, metabolic efficiency, and swimming challenges [1:03:15]; How reducing drag in swimming could revolutionize performance and the role of biofeedback tools in optimizing efficiency across various endurance sports [1:07:00]; How endurance athletes prioritize effort regulation using RPE, heart rate, and power output, and the role of lactate in cardiac and athletic efficiency [1:20:00]; Lactate's role as a fuel, buffering methods to combat lactic acidosis, and the variability in athlete response to bicarbonate supplementation [1:25:45]; The physiological mechanisms behind differences in performance between two elite athletes: lactate transport, cardiovascular efficiency, and compensatory systems [1:33:00]; Comparing interventions like acetaminophen to enhance performance in high-heat conditions versus natural adaptations to heat [1:37:15]; Advancements in nutrition science, changes in cyclist body composition, and the impact of fueling strategies on athletic performance and growth [1:39:30]; Optimizing endurance performance with utilization of carbohydrates, and the potential role of ketones [1:48:00]; Insights gained from elite performers in the 2020 and 2024 Olympics [1:58:30]; The use of artificial intelligence to optimizing training insights and performance [2:06:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#331 ‒ Optimizing endurance performance: metrics, nutrition, lactate, and more insights from elite performers | Olav Aleksander Bu (Pt. 2)

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Trenna Sutcliffe is a developmental behavioral pediatrician and the founder and medical director of the Sutcliffe Clinic in the San Francisco Bay Area, where she partners with families to provide care for children facing behavioral challenges, developmental differences, and school struggles. In this episode, Trenna shares her journey into developmental and behavioral pediatrics, including her pioneering work at Stanford and her expertise in autism, ADHD, and anxiety—the "three As." She explores the diagnostic processes, the overlap and comorbidities of these conditions, and the importance of personalized treatment plans that address both medical and environmental factors. Trenna offers valuable insights into the changing prevalence of autism, the impact of evolving diagnostic criteria, and the range of therapies and medications available to support children and their families. She also discusses the challenges in accessing care and the critical need for a holistic approach that bridges healthcare and education. We discuss:  Trenna's passion for developmental-behavioral pediatrics (DBP), and the process of diagnosing anxiety, ADHD, and autism [3:15]; Understanding anxiety and ADHD: assessing impairment and self-esteem and identifying anxiety and emotional well-being in young patients [9:45]; The evolving diagnosis of autism: understanding the spectrum and individual needs [16:30]; The dramatic rise in autism spectrum disorder (ASD): genetics, environment, expanded diagnostic criteria, and more [25:45]; Exploring epigenetics and the potential multigenerational impact of environment exposures on susceptibility to certain disorders [37:15]; The evolution of autism classifications, and the particular challenges for children with level 1 (mild) autism due to a lack of support [41:15]; The broadening of the autism spectrum: benefits and risks of expanded diagnostic criteria and the need for future frameworks to focus on better outcomes [48:00]; The overlap between ASD, ADHD, and anxiety [57:15]; Understanding oppositional defiant disorder, and the importance of understanding the "why" behind a behavior when creating treatment plans [1:00:45]; Defining developmental-behavioral pediatrics (DBP), and Trenna's professional journey [1:07:00]; Updated methods of ABA (applied behavioral analysis) therapy: evolution, controversies, challenges of scaling autism care, and the need for tailored interventions [1:13:45]; Advice for parents trying to find and evaluate care for children with autism, ADHD, or anxiety [1:22:45]; Tailored treatments for ADHD: balancing stimulant medications with behavioral training [1:28:30]; The interplay between medication, behavioral therapy, and neuroplasticity in managing ADHD, and the potential to grow out of the need for medication [1:39:45]; Using medication to treat anxiety and other symptoms in kids with autism without ADHD [1:44:45]; FAQs about medicating children with ADHD: benefits, side effects, dosage, and more [1:46:30]; The "superpowers" associated with level 1 autism [1:48:45]; The next steps to increase support for children with ASD, anxiety, and ADHD [1:50:45]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#330 – Autism, ADHD, and Anxiety: Understanding the rise in autism and a multidisciplinary approach to diagnosis and treatment of each condition in children | Trenna Sutcliffe, M.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter James Clear is the author of the New York Times bestseller Atomic Habits. His extensive research into human behavior has helped him identify key components of habit formation and develop the "Four Laws of Behavioral Change." In this episode, James provides insights into how both good and bad habits are formed, including the influence of genetics, environment, social circles, and more. He points to changes one can make to cultivate more perseverance and discipline and describes the profound impact habits can have when tying them into one's self-identity. Finally, James breaks down his "Four Laws of Behavioral Change" and how to use them to create new habits, undo bad habits, and make meaningful changes in one's life. We discuss:  Why James became deeply interested in habits [2:00]; Viewing habits through an evolutionary lens [6:15]; The power of immediate feedback for behavior change, and why we tend to repeat bad habits [9:30]; The role of genetics and innate predispositions in determining one's work ethic and success in a given discipline [14:45]; How finding one's passion can cultivate perseverance and discipline [23:30]; Advantages of creating systems and not just setting goals [29:30]; The power of habits combined with self-identity to induce change [36:45]; How a big environmental change or life event can bring on radical behavioral change [50:45]; The influence of one's social environment on their habits [54:30]; How and why habits are formed [1:00:45]; How to make or break a habit with the "Four Laws of Behavior Change" [1:09:45]; Practical tips for successful behavioral change—the best strategies when starting out [1:16:30]; Self-forgiveness and getting back on track immediately after slipping up [1:30:45]; Law #1: Make it obvious—Strategies for identifying and creating cues to make and break habits [1:40:00]; Law #2: Make it attractive—examples of ways to make a new behavior more attractive [1:48:00]; Law #3: Make it easy—the 2-minute rule [1:59:00]; Law #4: Make it satisfying—rewards and reinforcement [2:03:45]; Advice for helping others to make behavioral changes [2:06:15]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this special episode of The Drive, Peter tackles a wide range of listener questions submitted over the past year. The discussion spans essential topics such as exercise—covering grip strength, traveling workouts, and why Peter doesn't consider exercise an ideal weight-loss strategy—and the top biomarkers everyone should track. He also explores promising new longevity research, his evolving views on longevity, and frameworks like "objective, strategy, tactics" for personalized decision-making. The episode wraps up with insights on building good habits and a glimpse into Peter's recent reading list. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the Special AMA show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  Overview of episode topics (and Peter's car stereo saga) [1:45]; The importance of grip strength and the best methods for training it effectively [3:45]; Exercise while traveling: strategies for staying active and maintaining an exercise routine [14:45]; Why women should prioritize strength training [18:00]; The limited role of exercise in weight loss and its greater importance in improving health, body composition, and insulin sensitivity [19:45]; The "top five most important biomarkers" for assessing health [22:45]; Promising developments in longevity research [28:15]; The development of Klotho as a neuroprotective drug: challenges, timelines of trials, and more [34:00]; Peter's updated view on the potential of epigenome manipulation to restore aged cells to their youthful state [39:45]; How reversing age-related epigenetic changes in immune cells could revolutionize our approach to aging and disease [43:30]; The "objective, strategy, tactics" framework, and the importance prioritizing impactful lifestyle habits over less significant health trends [49:30]; Strategies for building and maintaining good habits [56:45]; How to think about drugs and supplements as part of a longevity toolkit [1:02:00]; Peter's recent reading list [1:05:15]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#329 ‒ Special AMA: Peter on exercise, important labs, building good habits, promising longevity research, and more

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter dives deep into one of the most frequently discussed and often misunderstood topics: nutrition. From weight loss and maintenance to the intricate relationship between nutrition and exercise and body composition, Peter addresses the complexities of nutrition research and explores the perennial question of whether there is a "best diet." He provides practical insights on how to choose the right diet for your unique needs, discusses the role of protein and processed foods, and outlines the key questions to help you optimize your approach to eating. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #66 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  The key nutrition-related topics to be discussed [1:30]; Why Peter is not fond of discussing nutrition: limitations of nutrition research, the pitfalls of extreme certainty in dietary discussions, and the body's adaptability to varied diets [3:30]; Key health metrics to monitor to evaluate the effects of nutrition [9:30]; The relationship between nutrition and exercise as they relate to weight loss, maintenance, and gain [12:30]; How increased muscle mass from resistance training impacts calorie burn, body composition, glucose metabolism, and overall health benefits [19:45]; Comparing the impact of fitness and nutrition on lifespan and healthspan: data showing fitness to be a more significant predictor of mortality than nutrition [23:30]; The myth of a "best diet," factors that determine the effectiveness of a diet, and data suggesting benefits of the Mediterranean diet [39:00]; How long to trial a new diet, the importance of measurable goals, and the appropriate timescales for observing meaningful changes [48:30]; The inherent challenges in nutrition research: variability in dietary exposures, limitations in study design, the body's adaptive nature which dampen the effects, and more [51:15]; Nutritional approaches for chronic diseases like cardiovascular disease and type 2 diabetes [58:45]; Emerging studies on dietary interventions for non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) [1:02:45]; Practical considerations for individuals to identify the best diet for them: protein intake, energy balance, macronutrient adjustments, and micronutrient levels [1:06:00]; Understanding processed vs. ultra-processed foods [1:09:15]; The effects of ultra-processed foods on health [1:12:30]; Questions that someone should ask themselves if they're looking to fine-tune their diet [1:18:15]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#328 - AMA #66: Optimizing nutrition for health and longevity: myth of a "best" diet, complexities of nutrition science, and practical steps for building a sustainable diet

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Dr. Saum Sutaria is the Chairman and CEO of Tenet Healthcare and a former leader in McKinsey & Company's Healthcare and Private Equity Practices, where he spent almost two decades shaping the field. In this episode, Saum unpacks the complexities of the U.S. healthcare system, providing a detailed overview of its structure, financial flows, and historical evolution. They delve into topics such as private insurance, Medicare, Medicaid, employer-sponsored coverage, drug pricing, PBMs and the administrative burdens impacting the system. Saum's insights help connect healthcare spending to broader economic issues while exploring potential reforms and the role of technology in improving efficiency. Saum highlights how choice and innovation distinguish the U.S. healthcare system, explores the reasons behind exorbitant drug prices, and examines the potential solutions, challenges, and trade-offs involved in lowering costs while striving to improve access, quality, and affordability. The opinions expressed by Saum in this episode are his own and do not represent the views of his employer. We discuss:  The US healthcare system: financial scale, integration with economy, and unique challenges [5:00]; Overview of how the US healthcare system currently works and how we got here [9:45]; The huge growth and price impact due to the transition from out-of-pocket payments in the 1950s to the modern, third-party payer model [18:30]; The unique structure and challenges of the US healthcare system compared to other developed nations [22:00]; Overview of Medicare and Medicaid: who they cover, purpose, and impact on healthcare spending [27:45]; Why the US kept a employer-sponsored insurance system rather than pursue universal healthcare [32:00]; The evolution of healthcare insurance: from catastrophic coverage to chronic disease management [36:00]; The challenge of managing healthcare costs while expanding access and meeting increased demand for chronic illness care [44:15]; Balancing cost, choice, and access: how the US healthcare system compares to Canada [48:45]; The role of the US in pharmaceutical innovation, it's impact on drug pricing, and the potential effects of price controls on innovation and healthcare costs [56:15]; How misaligned incentives have driven up drug prices in the US [1:05:00]; The cost of innovation and choice, and the sustainability of the current healthcare cost expenditures in the US in the face of a shrinking workforce and aging population [1:11:30]; Health outcomes: why life expectancy is lower in the US despite excelling at extending lifespan beyond 70 [1:18:45]; Potential solutions and challenges to controlling drugs costs in the US while balancing choice and access and preserving innovation [1:26:15]; Balancing GLP-1 drug innovation with affordability and healthcare spending sustainability [1:40:00]; Reducing healthcare spending: complexities, trade offs, and implications of making needed cuts to healthcare expenditures [1:46:45]; The role of government regulation, opportunities for cost savings, and more [1:56:15]; Hospital billing: costs, charges, complexities, and paths to simplification [2:01:15]; How prioritizing access and choice increased expenditures: reviewing the impact of healthcare exchanges and the Affordable Care Act [2:08:00]; Feasibility of a universal Medicare program, and what a real path to sustainable healthcare looks like [2:15:45]; The challenge of long-term care and the potential of innovation, like device-based therapies and AI, to improve health [2:23:15]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#327 - Choices, costs, and challenges in US healthcare: insurance intricacies, drug pricing, economic impacts, and potential reforms | Saum Sutaria, M.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Bill Perkins is one of the world's most successful hedge fund managers and entrepreneurs, and the author of the bestseller, Die With Zero. In this episode, Bill unpacks the Die With Zero philosophy which challenges conventional thinking related to the balance between health, wealth, and time—the three variables important for fulfillment. Bill makes the case that we should strive for maximum net fulfillment rather than net worth (or even health). He argues that we need to optimize our life to have memorable experiences before it's too late and that most people are over-saving and under-living. Bill also explains how one can apply the principles in Die With Zero to break out of "autopilot" and optimize their life to achieve maximum net fulfillment. We discuss:  Bill's upbringing, background, and first job on Wall Street [2:45]; A missed experience and feeling of regret that shaped Bill's thinking [13:45]; Thinking in terms of time, and the relationship between money, time, and health [16:30]; Solving for net fulfillment and allocating your time based on the seasons of life [26:45]; How Bill thinks about risk, opportunity costs, and the difference between fear and risk tolerance [35:00]; Optimizing for fulfillment, finding purpose outside of work, and more [41:15]; Thinking about the order of experiences you want to have based on seasons of life [49:30]; Bill's unique perspective on philanthropy and a more impactful way to give money away [54:15]; Applying the principles in 'Die With Zero' to maximize fulfillment [1:03:30]; How to break out of living life on autopilot [1:13:45]; When should your net worth peak? [1:17:30]; Taking calculated risks [1:21:00]; Bill shares a lesson from his incredible birthday [1:24:45]; How Bill's philosophy has evolved since writing Die With Zero [1:33:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

Optimizing life for maximum fulfillment | Bill Perkins (#237 rebroadcast)

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter dives into the world of red light therapy in response to frequent questions from listeners. Peter provides a comprehensive exploration, starting with the basics of red light therapy and why it's getting so much attention. The conversation examines the latest data on various applications, including aging, skin health, acne, wound healing, hair loss, eye health, exercise performance, metabolic health, weight loss, inflammation, injury recovery, and menstrual cramps. Peter analyzes the scientific literature on each use case and concludes with a summary table that provides an easy-to-follow breakdown of the potential benefits of red light therapy across these areas. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #65 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  Overview of topics and the motivation behind exploring red light therapy [1:45]; The basic science of red light therapy [3:15]; The unique penetration properties of red light [6:00]; What happens when tissue is exposed to red light [9:30]; Exploring red light therapy's potential to combat aging [11:00]; Red light therapy for treating acne [13:00]; Red light therapy for aiding in wound healing [18:45]; Red light therapy for hair loss: promising benefits and practical advice [24:15]; Analyzing the evidence of a positive or negative effect of red light therapy on the eyes [28:00]; Red light therapy's impact on performance and recovery [30:30]; Red light therapy's impact on metabolic health: analyzing the limited evidence for improved glucose metabolism [32:45]; Red light therapy for weight loss and targeted fat reduction [36:45]; Red light therapy for inflammation, chronic pain, and injury rehabilitation [41:00]; Red light therapy as a treatment for menstrual cramps [43:45]; Summary: promising applications of red light therapy, unsupported claims, and costs to consider [46:45]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#326 - AMA #65: Red light therapy: promising applications, mixed evidence, and impact on health and aging

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this quarterly podcast summary (QPS) episode, Peter summarizes his biggest takeaways from the last three months of guest interviews on the podcast. Peter shares key insights from his discussions on diverse topics such as dopamine and addiction with Anna Lembke, the current state and exciting future of CRISPR-mediated gene editing with Feng Zhang, how to build and maintain strong bones from youth to old age with Belinda Beck, how calorie restriction may influence longevity and metabolic health with Eric Ravussin, and the role of testosterone and TRT in prostate cancer with Ted Schaeffer. Additionally, Peter shares any personal behavioral adjustments or modifications to his patient care practices that have arisen from these engaging discussions. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the episode #325 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  Overview of topics to be covered [1:45]; Anna Lembke episode: addiction, dopamine's role in pleasure and pain, and managing addictive behaviors [4:15]; Follow-up questions about addiction: heritability, cold therapy, exercise, and strategies for breaking addictive behaviors [14:45]; Feng Zhang episode: the potential of gene editing with CRISPR technology for treating diseases, and the challenges ahead [21:00]; Feng Zhang's impactful education experience, and how early exposure and curiosity-driven learning can develop scientific interest for kids [28:30]; The future of CRISPR: weighing the scientific potential to combat complex diseases against ethical considerations around genetic modification [33:45]; Belinda Beck episode: how to build and maintain strong bones from youth to old age [37:30]; How both nutrition and exercise are crucial for bone health at all ages, and why it's never too late to start [54:45]; Eric Ravussin episode: calorie restriction, energy expenditure, exercise for weight maintenance, and more [59:00]; Measuring energy intake and energy expenditure: techniques and challenges [1:09:45]; ed Schaeffer episode: the nuance role of testosterone in prostate cancer, TRT, and the need for better cancer biomarkers [1:14:30]; Peter's favorite bands [1:25:45]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#325 ‒ Peter's key takeaways on bone health, calorie restriction and energy balance, dopamine and addiction, gene editing, and testosterone therapy safety with a prostate cancer diagnosis | Quarterly Podcast Summary #3

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Eric Ravussin is a world-renowned expert on obesity, metabolism, and aging whose pioneering research has shaped much of what we understand today about energy balance and caloric restriction. In this episode, Eric shares insights from his cutting-edge work on energy expenditure—a critical factor in understanding how our bodies regulate weight and appetite. He discusses methods for measuring energy output, energy balance, food intake, and appetite regulation, and explores key studies on macronutrient manipulation. Eric then delves into the CALERIE study on caloric restriction, highlighting insights related to biomarkers of both primary and secondary aging. The conversation also covers the potential of GLP-1 agonists to replicate these effects and looks ahead to how AI and technology could transform metabolic research in the coming years. We discuss:  Eric's background and current work metabolism and measuring energy expenditure [3:00]; The science behind metabolic chambers for measuring energy expenditure, and the complexities of indirect and direct calorimetry [8:00]; The body's regulatory systems for maintaining energy balance and the primary influence of energy intake on body weight [18:30]; The epidemic of obesity and a discussion of resting metabolic rate [24:45]; The impact of exercise, appetite, gut hormones, and eating patterns on weight regulation [28:45]; Experiments looking at how macronutrient composition affects energy expenditure [38:45]; The challenges of studying diet in real-life settings, the potential of personalized nutrition, and how public health policy could play a role in guiding nutritional habits [51:00]; The importance of protein in the diet, the limitations of dietary data collection, and how AI could potentially transform nutrition science [1:08:15]; How Eric's interest in caloric restriction (CR) began with Biosphere 2, metabolic efficiency's role in aging, and goals of the CALERIE study [1:15:15]; The CALERIE study: exploring the real-world impact of caloric restriction [1:28:00]; Notable findings from the CALERIE study after two years: sustained weight loss, participant retention, and more [1:40:00]; The effect of caloric restriction on the hallmarks of aging [1:47:00]; The challenge of applying CR to the general population, the potential of drugs and exercise to mimic the effects of CR [1:55:45]; Upcoming study comparing caloric restriction to time-restricting eating, and Peter's takeaways from the discussion [2:02:45]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#324 ‒ Metabolism, energy balance, and aging: How diet, calorie restriction, and macronutrients influence longevity and metabolic health | Eric Ravussin, Ph.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Feng Zhang, a professor of neuroscience at MIT and a pioneering figure in gene editing, joins Peter to discuss his groundbreaking work in CRISPR technology, as well as his early contributions to optogenetics. In this episode, they explore the origins of CRISPR and the revolutionary advancements that have transformed the field of gene editing. Feng delves into the practical applications of CRISPR for treating genetic diseases, the importance of delivery methods, and the current successes and challenges in targeting cells specific tissues such as those in the liver and eye. He also covers the ethical implications of gene editing, including the debate around germline modification, as well as reflections on Feng's personal journey, the impact of mentorship, and the future potential of genetic medicine. We discuss:  Feng's background, experience in developing optogenetics, and his shift toward improving gene-editing technologies [2:45]; The discovery of CRISPR in bacterial DNA and the realization that these sequences could be harnessed for gene editing [10:45]; How the CRISPR system fights off viral infections and the role of the Cas9 enzyme and PAM sequence [21:00]; The limitations of earlier gene-editing technologies prior to CRISPR [28:15]; How CRISPR revolutionized the field of gene editing, potential applications, and ongoing challenges [36:45]; CRISPR's potential in treating genetic diseases and the challenges of effective delivery [48:00]; How CRISPR is used to treat sickle cell anemia [53:15]; Gene editing with base editing, the role of AI in protein engineering, and challenges of delivery to the right cells [1:00:15]; How CRISPR is advancing scientific research by fast-tracking the development of transgenic mice [1:06:45]; Advantages of Cas13's ability to direct CRISPR to cleave RNA and the advances and remaining challenges of delivery [1:11:00]; CRISPR-Cas9: therapeutic applications in the liver and the eye [1:19:45]; The ethical implications of gene editing, the debate around germline modification, regulation, and more [1:30:45]; Genetic engineering to enhance human traits: challenges, trade-offs, and ethical concerns [1:40:45]; Feng's early life, the influence of the American education system, and the critical role teachers played in shaping his desire to explore gene-editing technology [1:46:00]; Feng's optimism about the trajectory of science [1:58:15]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#323 - CRISPR and the future of gene editing: scientific advances, genetic therapies, disease treatment potential, and ethical considerations | Feng Zhang, Ph.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Belinda Beck, founder of The Bone Clinic and a leading authority on exercise physiology and bone health, delves into the science of osteoporosis, bone density, and the lifelong importance of maintaining skeletal health. In this episode, she explains how the foundation for strong bones is established during childhood, offering valuable advice for parents on optimizing bone health for their kids. She also explores how bone remodeling occurs throughout life, driven by activity, nutrition, and hormones. Belinda highlights the power of resistance training in improving bone strength, even for those at risk of bone loss, and emphasizes the role of essential vitamins and minerals in maintaining bone health. She shares practical strategies, backed by research, for preventing fractures and combating osteoporosis. We discuss:  Belinda's journey into bone health research and training [2:45]; The physiology of bone and how bones adapt to mechanical loading [8:15]; Bone development from birth to adulthood, why early life is a crucial period, the functions of osteoblasts and osteoclasts, and gender differences in BMD [14:00]; How parents can optimize their children's bone health through diet (calcium and vitamin D), sunlight exposure, and physical activity [27:30]; The best sports and activities for promoting bone health, weight training for kids, and advice for parents [36:30]; The impact of corticosteroid use on bone health in children and strategies to minimize negative effects [48:30]; Advice for people in middle age to preserve bone density: physical activity and bone-loading exercises [52:00]; Bone loss during the menopause transition for women: hormone replacement therapy and other strategies to mitigate BMD losses [59:30]; Interpreting the bone mineral density results from a DEXA scan: T-score, Z-score, and more [1:03:00]; The LIFTMOR study: testing the effects of heavy weightlifting on bone health in postmenopausal women with low bone density [1:10:15]; Profound benefits of weight training outside of BMD improvements: exploring the broader impacts on patients in the LIFTMOR study [1:19:30]; Guidance for people wanting to use exercise designed to improve their bone health [1:29:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#322 - Bone health for life: building strong bones, preventing age-related loss, and reversing osteoporosis with evidence-based exercise | Belinda Beck, Ph.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Anna Lembke is the Chief of the Stanford Addiction Medicine Dual Diagnosis Clinic and author of Dopamine Nation: Finding Balance in the Age of Indulgence. In this episode, Anna dives deep into the biochemistry and neurobiology of addiction, exploring the critical role of dopamine and the prefrontal cortex. She shares her framework for diagnosing and treating addiction, providing real-world examples involving alcohol, gambling, cannabis, social media, and more. Anna outlines the risk factors for addiction, including inherited and nurture-based risks, explores the rise of addictions in younger generations, and discusses effective ways to address these issues with children. Additionally, she touches on healthy coping strategies, the evolution of the "marshmallow experiment," and provides insights into GLP-1 agonists as a possible tool for addiction treatment. Finally, she reflects on the value of 12-step programs and how she navigates the emotional challenges of her work. We discuss:  The role of dopamine and the prefrontal cortex in addiction [3:00]; The clinical definition of addiction and the behavioral criteria for diagnosing it [13:00]; Assessing alcohol use: patterns, risks, and addiction diagnosis [17:15]; Applying the addiction diagnosis framework using gambling as an example [21:45]; Exploring addiction variability: how nature, nurture, and access shape individual vulnerability and drug of choice [25:15]; How abstinence from addictive behaviors can help reset the brain's reward system and improve mental health [41:15]; Safely abstaining from addiction substances, drugs needing medical supervision, and other key considerations [51:30]; Transitioning from abstinence to long-term recovery: tools and considerations [59:00]; Exploring behavioral addictions like sex addiction, and the gender differences in addiction patterns [1:08:30]; Factors contributing to the increasing levels of addiction across the world [1:13:45]; How online pornography can affect young boys' developing brains and lead to addictive behaviors, and strategies for parents to address this issue [1:23:30]; The link between social media use and declines in mental health, potential solutions, and protective measures [1:34:45]; How exercise affects brain chemistry, the role of dopamine and endorphins, and how exercise can become addictive [1:44:00]; Cold-water immersion for mood regulation, and other healthy coping strategies [1:47:15]; The "marshmallow experiment": how broken promises affect behavior and trustworthy environments help children develop self-control [1:54:00]; Can GLP-1 agonists be useful in treating addiction? [1:58:30]; The benefits of 12-step programs [2:06:00]; Why understanding a patient's story is essential for meaningful psychiatric care [2:11:45]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#321 – Dopamine and addiction: navigating pleasure, pain, and the path to recovery | Anna Lembke, M.D.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter dives back into the increasingly popular topic of GLP-1 agonists, such as Ozempic and Mounjaro, which have garnered widespread attention for their ability to promote weight loss. Peter covers the latest findings in this rapidly evolving landscape, including new insights into their long-term efficacy, side effects, and what happens when the drug is discontinued. Peter also explores their impact on body composition and how resistance training interacts with these treatments. Additionally, he compares different GLP-1 receptor agonists and discusses promising new drugs in the pipeline. Finally, Peter addresses questions about the role of compounding pharmacies in the GLP-1 agonist market, compares oral vs. injectable options, and provides key considerations for anyone deciding whether to use a GLP-1 agonist for weight loss. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #64 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  The rapidly evolving landscape of GLP-1 agonists [2:15]; The mechanism of GLP-1 agonists, their origin as diabetes treatments, and how they evolved into weight-loss drugs [6:45]; Overview of new data and open questions related to the benefits and risks of GLP-1 agonists [10:30]; New insights into the long-term safety of GLP-1 agonists, side effects, and more [16:45]; The long-term efficacy of GLP-1 agonists, financial barriers, and more [19:45]; The mechanisms behind GLP-1 agonists' ability to promote weight loss [22:00]; New data on body weight changes after discontinuing the drug [26:00]; Effects of GLP-1 agonists on lean mass and body composition, and the role of protein and resistance training in preserving muscle [31:30]; Semaglutide vs. tirzepatide: comparing benefits and side effects [36:30]; How compounding pharmacies affect availability of GLP-1 drugs and the types of formulations that are available [39:15]; How do oral formulations of GLP-1 drugs compare to injectable formulations? [44:15]; How do sublingual (under tongue) formulations of GLP-1 drugs compare to injectable formulations? [46:15]; Guidance for using compounding pharmacies to purchase GLP-1 agonists [47:15]; Data on retatrutide—a promising new triple receptor agonist in the pipeline [50:15]; Can GLP-1 agonists be beneficial for sleep apnea and immune function? [57:00]; Potential neuroprotective benefits of GLP-1 agonists: impact on dementia risk [1:00:45]; Exploring why GLP-1 agonists may reduce the risk of cancer, kidney disease, and cardiovascular disease [1:04:00]; How GLP-1 agonists might boost fertility in women [1:10:15]; Early indications that GLP-1 agonists may help treat substance abuse disorders [1:12:00]; Potential health risks of GLP-1 agonists: addressing thyroid cancer concerns and the unknowns due to lack of data [1:14:00]; Examining the potential link between GLP-1 agonists and increased depression or suicidal ideation [1:16:00]; Major remaining questions: the effects of cyclic use, rebound appetite, impact on adolescents' development, and more [1:19:30]; Key considerations when deciding whether to use a GLP-1 agonist for weight loss [1:23:45]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#320 – AMA 64: New insights on GLP-1 agonists (Ozempic, Wegovy, Mounjaro) - efficacy, benefits, risks, and considerations in the rapidly evolving weight-loss drug landscape

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this quarterly podcast summary (QPS) episode, Peter summarizes his biggest takeaways from the last three months of guest interviews on the podcast. Peter shares key insights from each episode, covering diverse topics such as liver health with Julia Wattacheril, heart rate variability with Joel Jamieson, artificial intelligence with Zak Kohane, klotho for brain health with Dena Dubal, and lactate and lactate metabolism with George Brooks. Additionally, Peter shares any personal behavioral adjustments or modifications to his patient care practices that have arisen from these engaging discussions. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the episode #319 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  Overview of topics, and the positive feedback on the quarterly podcast summary format [2:00]; Julia Wattacheril episode: liver health and disease [4:00]; Noninvasive methods to diagnose liver conditions, and how to manage and improve liver health [16:00]; Joel Jamieson episode: heart rate variability (HRV) for training and health [27:15]; Practical tools for measuring HRV and how it informs training and recovery decisions [37:00]; Zak Kohane episode: artificial intelligence and medicine [47:15]; The current role of AI in medicine and how it could revolutionize medicine in the future [53:45]; The limitations and concerns pertaining to AI [1:00:15]; Dena Dubal episode: the potential benefits of klotho for brain health [1:05:00]; Animal studies on klotho and brain health [1:11:00]; Genetics-based variations in klotho levels in humans and their impact on cognition, disease risk, and longevity [1:14:15]; Testing klotho levels, the significance of the KL-VS variant, the role of exercise in increasing klotho, and more [1:17:30]; The potential of klotho as a treatment for cognitive decline and Alzheimer's disease [1:23:15]; George Brooks episode: a new paradigm to think about lactate and lactate metabolism [1:27:45]; The potential for lactate infusions to aid in brain recovery following a head injury [1:34:00]; The relationship between lactate and cancer, and the impact of exercise on lactate levels and cancer risk [1:36:30]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#319 ‒ Peter's key takeaways on liver health, heart rate variability, AI in medicine, klotho, and lactate metabolism | Quarterly Podcast Summary #2

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Tadej Pogačar is a three-time Tour de France champion and one of the most dominant cyclists of his generation. In this episode, he shares insights into his 2020 Tour de France victory, his historic 2024 season winning both the Giro d'Italia and Tour de France, and the struggles he faced in 2022 and 2023. He also dives into his training regimen, nutrition, and the key metrics he tracks, like power, VAM, and heart rate variability. Tadej offers a glimpse into his goals for the future and what it takes to stay at the top of the sport. We discuss:  2020 Tour de France win [4:30]; Learning from previous mistakes [8:45]; Training: simulating steep climbs and other challenging race conditions [10:30]; Tadej's historic 2024 season and what contributed to his success [12:30]; Nutrition for optimal performance: offseason diet and carbohydrate intake during intense training sessions [15:30]; Training metrics: heart rate, power output, VAM, and HRV, and his approach to zone 2 training [18:15]; Epic climbs in the Tour de France, mindset after challenging stages, and rebuilding confidence after the 2023 Tour [25:45]; Racing dynamics, media criticism, and Tadej's reflections on racing records [32:15]; Training in the off-season [39:00]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#318 ‒ Cycling phenom and Tour de France champion Tadej Pogačar reveals his training strategies, on-bike nutrition, and future aspirations

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter Marty Makary, a Johns Hopkins surgeon and New York Times bestselling author, returns to The Drive to discuss his latest book, Blind Spots: When Medicine Gets It Wrong, and What It Means for Our Health. In this episode, Marty explores how a new generation of doctors is challenging long-held medical practices by asking critical new questions. He discusses the major problems of groupthink and cognitive dissonance in the medical community and delves into several of the "blind spots" raised in the book, including treatments for appendicitis, the peanut allergy epidemic, misunderstandings about HRT and breast cancer, antibiotic use, and the evolution of childbirth. He explains the urgent need for reform in medical education and the major barriers standing in the way of innovative medical research. Throughout the conversation, Marty offers insightful reflections on where medicine has succeeded and where there's still room to challenge historic practices and embrace new approaches. We discuss:  The issue of groupthink and cognitive dissonance in science and medicine [2:30]; How a non-operative treatment for appendicitis sheds light on cognitive dissonance [7:00]; How cognitive dissonance and effort justification shape beliefs and actions [13:15]; How misguided peanut allergy recommendations created an epidemic [17:45]; The enduring impact of misinformation and fear-based messaging around hormone replacement therapy allegedly causing breast cancer [25:15]; The dangers of extreme skepticism and blind faith in science, and the importance of understanding uncertainty and probability [28:00]; The overuse of antibiotics and the rise of antibiotic resistant infections and poor gut health [33:45]; The potential correlations between early antibiotic use and chronic diseases [40:45]; The historical and evolving trends in childbirth and C-section rates [50:15]; Rethinking ovarian cancer: recent data challenging decades of medical practice and leading to new preventive measures [1:05:30]; Navigating uncertainty as a physician [1:19:30]; The urgent need for reform in medical education [1:21:45]; The major barriers to innovative medical research [1:27:30]; The dogmatic culture of academic medicine: why humility and challenging established norms are key for progress [1:38:15]; The major successes and ongoing challenges of modern medicine [1:51:00]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube

#317 ‒ Reforming medicine: uncovering blind spots, challenging the norm, and embracing innovation | Marty Makary, M.D., M.P.H.

 View the Show Notes Page for This Episode  Become a Member to Receive Exclusive Content  Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter dives deep into the topic of hair loss, exploring its relationship with aging and its impact on quality of life. The conversation focuses on androgenic alopecia, the most common form of hair loss in both men and women, and covers the differences in patterns and causes between the sexes. Peter delves into the right timing for treatment, breaking down various options such as minoxidil and finasteride, low-level laser therapy, platelet-rich plasma injections, and more. Additionally, Peter outlines the pros and cons of the two primary hair transplantation methods and concludes with practical advice on selecting the right specialist or treatment team for those facing hair loss. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #63 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss:  The impact of hair loss on emotional health [2:15]; The prevalence, patterns, and causes of hair loss in men and women [5:15]; The genetic and hormonal causes of hair loss, and the role of dihydrotestosterone (DHT) in androgenic alopecia [8:45]; The visual differences in hair loss patterns between men and women, and the importance of consulting a specialist to rule out non-genetic causes of hair loss [13:30]; How genetic predisposition influences the risk of androgenic alopecia, and how early detection through diagnostic tools and blood tests can help manage risk more effectively [16:45]; Ideal timing for starting treatment: why early treatment is crucial for effectively managing hair loss [19:30]; The various FDA-approved treatments for androgenic alopecia, their mechanisms, and additional off-label treatments commonly used to manage hair loss [24:30]; Topical minoxidil—the most commonly recommended starting treatment for hair loss [30:15]; Oral vs. topical minoxidil: efficacy, ease of use, and potential side effects that must be considered [33:45]; Finasteride for treating hair loss: efficacy, potential side effects on libido, and the need for careful PSA monitoring in men to avoid missing early signs of prostate cancer [37:15]; Other effective hair loss treatments for women: boosting hair density with spironolactone gel and ketoconazole shampoo as part of a comprehensive strategy [41:30]; Low-level laser therapy: effectiveness, costs, practicality, and a comparison of in-office treatments with at-home devices [49:00]; Platelet-rich plasma (PRP) as a treatment for hair loss: potential effectiveness, varying protocols, and significant costs [53:45]; Hair transplant for advanced hair loss: criteria and considerations [58:00]; Types of hair transplants: follicular unit transplantation (FUT) vs. follicular unit extraction (FUE) [1:02:00]; The financial cost of hair transplant surgery, and what to consider when seeking affordable options [1:06:15]; The potential risks and downsides of the various hair transplant procedures [1:09:30]; Post-procedure care for hair transplants and whether the procedure must be repeated periodically [1:16:30]; Combining different hair loss treatments: benefits, risks, and considerations [1:18:30]; Emerging hair loss treatments with limited data [1:21:00]; Key considerations for selecting the right treatment plan for hair loss [1:22:00]; A summary of the different considerations for men and women facing hair loss [1:24:30]; Practical advice on selecting the right specialist or treatment team [1:26:15]; and More.  Connect With Peter on Twitter, Instagram, Facebook and YouTube